0001213900-23-038626.txt : 20230512 0001213900-23-038626.hdr.sgml : 20230512 20230511175207 ACCESSION NUMBER: 0001213900-23-038626 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US NUCLEAR CORP. CENTRAL INDEX KEY: 0001543623 STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829] IRS NUMBER: 454535739 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54617 FILM NUMBER: 23912503 BUSINESS ADDRESS: STREET 1: 7051 ETON AVENUE CITY: CANOGA PARK STATE: CA ZIP: 91303 BUSINESS PHONE: 818-883-7043 MAIL ADDRESS: STREET 1: 7051 ETON AVENUE CITY: CANOGA PARK STATE: CA ZIP: 91303 FORMER COMPANY: FORMER CONFORMED NAME: APEX 3, INC. DATE OF NAME CHANGE: 20120301 10-K 1 f10k2022_usnuclearcorp.htm 10-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-K

 

(Mark One)

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to ______________

 

Commission file number 000-54617

 

US NUCLEAR CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   45-4535739
State or other jurisdiction of
Incorporation or organization
  (I.R.S. Employer
Identification No.)

 

c/o Robert I. Goldstein

7051 Eton Avenue

Canoga Park, CA 91303

(Address of principal executive offices)

 

(818) 883-7043

(Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Exchange Act:

None.

 

Securities registered under Section 12(g) of the Exchange Act:

 

Common Stock, $0.0001 par value per share

(Title of Class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes  ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark if disclosure of delinquent filers in response to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer 
Non-accelerated filer Smaller reporting company
Emerging growth company   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If the securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No

  

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrants most recently completed second fiscal quarter. $2,938,723 as of June 30, 2022.

 

The number of shares of the Registrant’s common stock outstanding as of May 10, 2023, was 35,798,087.

 

 

 

 

 

 

US NUCLEAR CORP.

FORM 10-K

TABLE OF CONTENTS

 

      Page
  PART I    
       
Item 1. Business   1
Item 1A. Risk Factors   6
Item 1B. Unresolved Staff Comments   17
Item 2. Properties   17
Item 3. Legal Proceedings   17
Item 4. Mine Safety Disclosures   17
       
  PART II    
       
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities   18
Item 6. [ReseRved]   20
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations   20
Item 7A. Quantitative and Qualitative Disclosures About Market Risk   23
Item 8. Financial Statements and Supplementary Data   23
Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure   23
Item 9A. Controls and Procedures   23
Item 9B. Other Information   24
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections   24
       
  PART III    
       
Item 10. Directors, Executive Officers and Corporate Governance   25
Item 11. Executive Compensation   28
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters   30
Item 13. Certain Relationships and Related Transactions, and Director Independence   31
Item 14. Principal Accountant Fees and Services   31
       
  PART IV    
       
Item 15. Exhibits, Financial Statement Schedules   F-1
  SIGNATURES   33

 

i

 

 

PART I

 

Special Note Regarding Forward-Looking Statements

 

Information included or incorporated by reference in this Annual Report on Form 10-K contains forward-looking statements. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Forward-looking statements may contain the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “forecasts,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, and are subject to numerous known and unknown risks and uncertainties. Additionally, statements relating to implementation of business strategy, future financial performance, acquisition strategies, capital raising transactions, performance of contractual obligations, and similar statements may contain forward-looking statements.  In evaluating such statements, prospective investors and shareholders should carefully review various risks and uncertainties identified in this Report, including the matters set forth under the captions “Risk Factors” and in the Company’s other SEC filings. These risks and uncertainties could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements. The Company disclaims any obligation to update or publicly announce revisions to any forward-looking statements to reflect future events or developments.

 

Although forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading “Risk Factors Related to Our Business” below, as well as those discussed elsewhere in this Annual Report on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K. We file reports with the Securities and Exchange Commission (“SEC”). You can read and copy any materials we file with the SEC at the SEC’s Public Reference Room, 100 F. Street, NE, Washington, D.C. 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

 

We disclaim any obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report on Form 10-K. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

 

ITEM 1. BUSINESS

 

Corporate History

 

US Nuclear Corp f/k/a APEX 3 Inc., was incorporated in the State of Delaware on February 14, 2012, and has since amended its name to US Nuclear Corp., (“US Nuclear”) on May 4, 2012 with the State of Delaware. US Nuclear Corp was formed as a vehicle to pursue a business combination with an operating company that would have perceived benefits of becoming a publicly traded corporation. Optron Scientific was incorporated in the State of California in 1971 and is the operating company of US Nuclear Corp with two divisions, Optron Scientific Company, Inc., doing business as (“DBA”) Technical Associates and Overhoff Technology Corporation, both of which design, manufacture and market detection and monitor systems that are used to detect and identify radioactive material, leaks, waste, contamination, biohazards, nuclear material, as well as products used in airports, cargo, screening as ports and borders, government buildings, hospitals, and other critical infrastructure, as well as by the military and emergency responder services The company uses a wide range of technologies including x-ray, trace detection, millimeter-wave, infra-red, tritium detection, and diagnostics in its product applications.

 

1

 

 

US Nuclear Corp is a smaller reporting company under SEC Rule 405 because it has a public float of less than $250 million and has annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available.  As a smaller reporting company, pursuant to Rule 8-01 of Regulation S-X, the Company is only required to produce financial statements as follows: (a) audited balance sheet as of the end of each of the most recent two fiscal years, or as of a date within 135 days if the issuer has existed for a period of less than one fiscal year, (b) audited statements of income, cash flows and changes in stockholders’ equity for each of the two fiscal years preceding the date of the most recent audited balance sheet (or such shorter period as the registrant has been in business), and (c) interim reviewed financial statements for the current period if the filing is more than 135 days after the end of your fiscal year.  Any and all amendments shall include updated interim or audited financial statements if the financial statements in the prior filing are more than 135 days old.

 

On October 15, 2013, US Nuclear Corp f/k/a APEX 3 Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger between the Company, Robert I. Goldstein, US Nuclear Acquisition Corp (“Merger Sub”), a California corporation and Optron Scientific Company, Inc. dba Technical Associates, (“Optron Scientific”) a California corporation and the parent company of Overhoff Technology Corp. The Agreement and Plan of Merger provided for the acquisition by the Company of all of the outstanding shares of Optron Scientific through a reverse merger of Merger Sub into Optron Scientific, the surviving corporation. We have filed the Agreement and Plan of Merger as Exhibits 3.4 and 2.1 with this statement and with the State of California.

 

As part of the Agreement and Plan of Merger with Optron Scientific the parties agreed to an exchange of shares, in which all of the 98,372 issued and outstanding shares of Optron Scientific were exchanged for 9,150,000 shares of the Company.

 

Prior to the share exchange, Mr. Goldstein was the sole owner of 98,372 shares of Optron Scientific Company, Inc., which represented all of the outstanding shares of Optron Scientific Company, Inc. Mr. Goldstein was the owner of 9,150,000 shares of US Nuclear Corp prior to the merger, and 9,150,000 shares of US Nuclear Corp were issued to him as a result of the merger in exchange for 98,372 shares of Optron Scientific Company, Inc.

 

In conjunction with the Agreement and Plan of Merger, US Nuclear Corp, Optron Scientific and Robert I. Goldstein entered into a Cancellation Agreement which provided for the cancellation of 9,150,000 shares of US Nuclear Corp held by Robert I. Goldstein, in consideration of his entering into the Agreement and Plan of Merger, which provided for his right to acquire 9,150,000 shares of US Nuclear Corp after it had the value of the ownership of Optron Scientific. As part of the consideration for the merger transaction, the share value of Mr. Goldstein’s shares of the Company prior to the merger was estimated at the par value of the shares, or 9,150,000 times the par value of .0001 per share. After the merger, the newly issued 9,150,000 shares of the Company held by Mr. Goldstein had a value of 85.51 percent of the total value of the outstanding stock of the Company after its acquisition of all of the stock of Optron Scientific. The Agreement and Plan of Merger was signed by Mr. Goldstein in his individual capacity and as President and Chief Executive Officer of the Company and as President and Chief Executive Officer of Optron Scientific, and of Merger Sub. The Cancellation Agreement was signed by Mr. Goldstein in his individual capacity and as President, and Chief Executive Officer of the Company and of Optron Scientific. The Corporate Secretary of each of the companies, Darian B. Andersen, also signed on behalf of each of the companies. The remaining 1,550,000 outstanding shares of US Nuclear Corp, which are held by Richard Chiang, were unaffected by the Cancellation Agreement. 

 

2

 

 

Following the merger, we began to provide a full line of radiation detection equipment and services to clients’ industries that range from nuclear reactor plants, universities, local and state hospitals, government agencies, and emergency medical technicians or EMT/first responders. The Company’s nuclear radiation safety detection equipment company has its roots from the famous Manhattan Project of the 1940s. In 1971, Allen Goldstein, the father to our current President and CEO, Robert Goldstein, acquired the assets of Technical Associates and incorporated the company. The Company designed and built the first industrial grade radiation monitors and continues to innovate its legacy with new product engineering for radiation measurement and safety instruments. The Company designs and manufactures nuclear radiation detection and safety equipment, survey meters, air and water monitors, port security equipment and tritium air monitors. The Company’s customers are diverse groups such as Homeland Security, Lawrence Livermore Labs, Los Alamos National Labs, Department of Defense, FBI, CIA, US Navy, Chevron Corporation, Bechtel Corporation, Biotechnology Laboratories, Hospitals, Universities, and Civil Emergency Management departments such as Fire, Paramedics and Law Enforcement. The Company is headquartered in Canoga Park, California and the Company can be accessed through its websites on the Internet at usnuclearcorp.com, tech-associates.com and overhoff.com.

 

The Company’s four divisions consisting of Optron Scientific Company Inc., DBA Technical Associates, Overhoff Technology Corporation, Electronic Control Concepts, and Cali From Above, offer over 200 products that service and address the nuclear power industry, domestically and internationally. Technical Associates specializes in the design and manufacture of radiation detection equipment monitors and hand-held devices. Overhoff Technology Corporation specializes in the design and manufacture of tritium air monitors and water monitors. Electronic Control Concepts specializes in test and maintenance meters for x-ray machines for both medical and industrial users. Cali From Above offers specialized inspection services from height and difficult-to-access locations with the use of unmanned aerial vehicles (UAVs).

 

Technology and Products

 

The Company designs and develops both technologies in-house by its CEO, Robert I. Goldstein as well as offers products from other manufacturers. Mr. Goldstein’s extensive experience of over forty years in the field of nuclear radiation detection has allowed the Company to achieve significant recognition that has been approved by US Federal standards set by the Environmental Protection Agency (EPA), Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC). The Company has complete ownership of all of its technology and there are no licenses held by any outside party. No persons, company, vendor, distributor or contractor holds any title or claim to any of the Company’s work or technology. The Company believes that its technology and business is defensible due to the fact that the barriers of entry are high and technically complex. The Company has sought out niche markets in its business by becoming a leading category player in devices such as Tritium equipment. The Company’s products consist of radiation water monitors, tritium monitors, air and water monitors, nano-second x-ray monitors, and vehicle, personnel, exit and room monitors. The Company also offers handheld survey meters/dosimeters, and port security equipment, along with supporting software and services.

 

Radiation Water Monitors

 

US Nuclear Corp’s radiation water monitors allow detection of radioactive materials in drinking water, ground water, rainfall, rivers, and lakes. In order to detect radioactive materials, the emitted radiation must travel from the radiation emitter to the detector. Alpha, Beta, Gamma, and Neutron radiation moves well through air, but poorly through water. The complexity of detecting radiation in water and developing an efficient monitor has given the Company’s monitors a reasonable edge against competitors, and for this reason, has limited competition in the water monitor business. The Company has invested more than ten years developing highly sensitive detectors for this market, giving it a clear advantage over competitors. The Company’s radiation water monitors are used to check for radioactive materials being released as liquid effluent in drain pipes by universities, hospitals, pharmaceutical companies, oil and gas extraction facilities, industrial chemical plants, and nuclear reactor plants.

 

Tritium Monitors

 

US Nuclear Corp is one of very few companies that currently operate within the tritium space. The Company’s Overhoff Technology Corp unit is a leading manufacturer of tritium detection and monitors. The demand for tritium detection and monitors are steadily increasing as countries develop solutions to their energy needs.  In addition to CANDU reactors (Canada Deuterium Uranium), the next generation of nuclear reactors called Molten Salt Reactors, (MSR) and Liquid-Fluoride Thorium Reactors (LFTR) utilize fuels other than traditional uranium and plutonium sources. Thorium, which is more significantly abundant than uranium, is very difficult to use to create nuclear weapons, is favored by many governments, and as a source of conventional energy it has been proven to be highly effective. By way of energy production, MSR and LFTRs produce high amounts of tritium which need to be constantly monitored for detection. Additionally, the waste products of LFTR reactors are less hazardous than the current light-water uranium-plutonium reactors, and thus, LFTR reactors provide higher level of safety and security against terrorist threats. The Company expects that a significant portion of its future sales and business strategy is tied to the growth of MSR and LFTRs, as well as from CANDU reactors.

 

3

 

 

Tritium is produced naturally in the upper atmosphere when cosmic rays strike nitrogen molecules in the air. More commonly, tritium is produced during nuclear weapons explosions, and as a byproduct in reactors producing electricity.  Generally, tritium has several important uses; its most significant contribution is its use as a component in the triggering mechanism in thermonuclear weapons. Very large quantities of required for the maintenance of nuclear weapons capabilities. Tritium is also produced commercially in nuclear reactors, as well as used in various self-luminescent devices, such as exit signs in buildings, aircraft dials, gauges, luminous paints, and wristwatches. In the mid-1950s and early 1960s, tritium was widely dispersed during above-ground testing of nuclear weapons. Today, sources of tritium come from commercial nuclear reactors, research reactors, and government weapons production plants. Tritium may also be released as steam from these facilities or may leak into the underlying soil and ground water. Additionally, self-luminescent devices illegally disposed in municipal landfills come into contact with water which pass through water ways, carrying dangerous levels of tritium. Tritium holds a very dangerous health risk and high levels of exposure to tritium increases risk of developing cancer. To combat tritium leaks and to maintain acceptable levels, the Company has developed several tritium monitors to gauge tritium in water and in the air. 

 

Alpha, Beta, Gamma and Tritium Monitors

 

US Nuclear Corp’s radiation water monitors allow detection of radioactive materials in drinking water, ground water, rainfall, rivers, and lakes. In order to detect radioactive materials, the emitted radiation must travel from the radiation emitter to the detector. Alpha, Beta, Gamma, and Neutron radiation moves well through air, but poorly through water. The complexity of detecting radiation in water and developing an efficient monitor has given the Company’s monitors a reasonable edge against competitors, and for this reason, has limited competition in the water monitor business. The Company has invested more than ten years developing highly sensitive detectors for this market, giving it a clear advantage over competitors. The Company’s radiation water monitors are used to check for radioactive materials being released as liquid effluent in drain pipes by universities, hospitals, pharmaceutical companies, oil and gas extraction facilities, industrial chemical plants, and nuclear reactor plants.

 

For the past 20 years, Overhoff Technology has been devoted exclusively to the design, manufacturing and servicing of Tritium monitors. Overhoff Technology has leading control over market share in the Tritium monitor space as the top maker of Tritium monitors. Tritium monitors are a highly delicate process and are particularly dependent on the selection of the finest materials such as Teflon for low leakage insulators and nafion membranes for separation of noble gas from Tritium. The Company’s Overhoff DC amplifiers called “electrometers” are stable with the ability to register small currents down to the femto-ampere level, 10-13 to 10-15ampre range. The Overhoff electrometer also has the unique ability to reject false counts from Radon gas. Because Tritium is a radioactive material, the Nuclear Regulatory Commission (“NRC”) regulations and state health agencies require Tritium to be measured at every nuclear power plant, all national laboratories, in the nuclear-powered Navies of the United States, France and the United Kingdom, at weapons facilities, at pharmaceutical and pesticide research facilities, and at Fusion Power research sites.

 

DroneRAD Aerial Radiation Detection

 

US Nuclear Corp has partnered with FlyCam UAV (a drone manufacturer). The two companies have married their two technologies with the NEO, an all-weather UAV octocopter capable of carrying a number of radiation and chemical detection sensors. With the advent of merging FlyCam UAV’s NEO and US Nuclear Corp sensor technology aerial radiation and chemical detection is now a reality. The DroneSensor system (the first of its kind) uses state-of-the-art industrial grade drones carrying radiation & chemical sensors. Wireless transmission to ground station provides real-time data. Having these UAV mounted sensors quickly and efficiently surveying large areas for contamination eliminates risk to human life.

 

4

 

 

Air and Water Monitors

 

The Company’s Overhoff Air Monitors come in both hand-held portables and mid-to large-sized air and stack monitors. These are classified as Dual Ion Chamber style detectors or Dual Proportional Detectors. The sample flows into one chamber where ionization current is measured, and at the same time a sealed background detector of the same volume measures the ionization current due to any external gamma emitters plus the addition of background from radioactive minerals in the soil with cosmic rays. The current from the background chamber is subtracted from the current in the main sample chamber to give the net tritium level without distortion from radon or gamma in the background. In nuclear power plants, radioactive noble gases are also in the air stream in small or large quantities. Overhoff combats this problem using Dow Chemical Nafion® tubing which physically separates the noble gases from the tritium oxide prior to measurement. The Company is currently expecting a large number of its users and larger numbers of its competitor’s customers will need to replace or supplement their current air and stack monitors to combat the two biggest pollution nuclides now coming out of nuclear power plants, tritium and C-14. As of today, only US Nuclear Corp offers these full-service monitors.

 

Vehicle Monitors, Personnel Monitors, Exit Monitors and Room Monitors

 

The Company’s suite of radiation monitors can be used in various scenarios where humans may come into contact with radiation contamination. The Company’s Vehicle Monitors, Personnel Monitors, Exit Monitors and Room Monitors are effective tools in detection of radiation in hospitals where radioactivity is used in many departments such as nuclear medicine, oncology, blood labs, and imaging. Since radiation is also used in diagnosing and treating cancer, and since some cancers can develop in any organ, each department in a hospital becomes involved, from ophthalmology to thoracic medicine. Additionally, the Company’s monitors are used to check hospital laundry to detect any radiation on clothes as well as in trash bins before they are picked up by the applicable waste management team. Lastly, the Company’s monitors can be placed in the entrance of hospitals in case there is an incident at a nearby nuclear power plant. These monitors are the first line of defense against further contamination, by providing early warning detection; doctors can provide treatment without placing other patients and staff in direct contact with patients who are contaminated with radiation.

 

Radon Air Monitors and Radon Switch Products

 

The Company produces a full line of radon air monitors and switches that are used to determine the radon content in the air in basements, mills, mines, buildings, or anywhere that radon concentration is a concern. The radon switch products activate and controls radon mitigation fans. These switches have a built-in computer storage with data storage. The Company also makes a radon tritium monitor that is a portable instrument used for detection and measurement of airborne Vadose zone, between the top of the ground surface to the water table.

 

Handheld Survey Meters and Personal Dosimeters, Pocket Micro-R Meters

 

The Company’s survey meters are light-weight, hand-held radiation detectors. They function as general-purpose radiation survey meters, but also serve as special purpose survey meters. For example, the Company’s radon monitors are used in mines where workers are at risk for breathing radon gas along with air. The Company’s surface monitors are used in hospitals, research labs, even in high school chemistry and physics labs to check for radioactive contamination on lab benches. Friskers are used to check if worker’s hands or shoe bottoms have picked up any radiation contamination and the Company’s Gamma survey meter check packages at post offices or airports for radiation, along with scrap metals at collection points and again before it is accepted for processing. 

 

Port Security Equipment

 

Due to increased terror threats from IED (Improvised Explosive Devices), dirty bombs and potential radioactive materials following 9/11 at shipping ports, we began utilizing passive detectors to review radiation emanating from inside containers. While other port security scanners generally use radioactive materials or x-ray generating machines to check everything from shipping containers, Federal Express, USPS (United States Postal Service) packages, and luggage for contraband, our scanner solutions do not use radiation, allowing for safe usage by investigators. We were approached by the FDA after the events of 9/11, and we designed our P-8Neon Quick-Scan X-ray detector to provide complete scanning without releasing any harmful radiation in the process. Our RAD-CANSCAN machines can measure which shipping containers hold radioactive materials by mapping inside the container so that TSA personnel will know the results without having to open each container. Additionally, our TBM-6SPE is a multi-detector system that lets an investigator check specifically for each of the four main emissions of radiation, Alpha, Beta, Gamma and Neutrons.

 

5

 

 

Software

 

The Company’s Overhoff Overview software program provides centralized radiation and environmental monitoring for entire facilities within one building or several square miles allowing monitoring of a nuclear power plant or subway station. Overview accepts data from networked radiation detectors, environmental monitors and webcams, and allows the user to view and generate reports on the data, as well as track maintenance due on instruments. Additionally, Overview lets the user see real-time monitoring for differential pressure on containment boxes or rooms. Our software measures gamma and neutron radiation levels, airborne radioactivity levels, temperature and humidity in the facility, status of security doors, wind speed and direction, and barometric pressure.

 

Risk Factors

 

Risks Related to Our Business and Industry

 

Our business is intensely competitive and our revenues are unpredictable as a small company.

 

We compete with a formidable group of competitors in our business, many of which have greater resources and capabilities than our company. There are numerous companies that have established businesses and command larger market share such as Thermo Fisher Scientific, Canberra Industries, and Mirion Technologies, Ludlum Measurements, Smiths Detection and Lab Impex Systems Ltd. Many of these companies have products and services that compete directly with ours and many of them are supported with larger marketing budgets and sales staff that can provide stronger sales coverage and support to customers than our capabilities. Furthermore, competitors may have technological advantages and may be able to implement new technologies more rapidly than our Company. Additionally, to the extent of our bookings, we cannot accurately predict to a large degree of certainty what annual revenues and income outlook may be. Due to our relatively small size, many factors may contribute to differences in the future and therefore cannot be assured in any manner. The market for nuclear radiation safety equipment is dependent upon a number of factors beyond the Company’s control, which cannot be accurately predicted. Some of these factors include pricing, competition from new entrants, newer technologies, market regulation and government policy, as well as overall market demand. Other factors include fossil fuel energy prices that may have an effect upon nuclear energy demand. Lower oil, natural gas, and coal prices may result in less favorable decisions to pursue nuclear energy as a source of energy.  

 

We rely heavily on our international customers for business and expect to continue to rely on international customers in the future.

 

Our international revenues were 26.57% of our total revenue in 2022. This was a decrease of 2.03% from 2021 and was a result of management’s inability to field new orders and inquires and engage new customers overseas due to political and economic reasons. We believe that South Korea and China will likely be larger contributors to revenue within the next few years. While we maintain steady growth domestically, the international side of our business may be a larger component as nuclear technology and rapid development for clean energy grows abroad. There can be no assurances as to our growth projections and our risk profile as we depend upon increased foreign customers for business.

 

Government Regulation

 

Although the sales of our equipment are not generally regulated by any local or federal government agency, the nuclear power industry itself is highly regulated by the Nuclear Regulatory Commission. As an independent agency of the United States government, the NRC is responsible for overseeing reactor safety, security, reactor licensing, renewal, radioactive material safety, and spent fuel disposal. The effects of the NRC’s policies therefore have an effect on our business. The impact of any negative decision in the nuclear power industry will ultimately affect us. We may also be affected by foreign government policy and regulation not covered by the NRC.

 

Nuclear Power, Fossil Fuel and Renewal Energy

 

While the nuclear power industry is a key component in the context of energy supply in the world today there are other competing energy sources that carry less potential risk hazards. Competing energy sources such as fossil fuels, solar, wind and water are strong threats to nuclear power. Each one has its benefits and conversely a negative side. The current landscape of nuclear power according to the Nuclear Regulatory Commission, or NRC, states that as of May 2022, there were 30 countries worldwide operating 439 nuclear reactors in operation in the world, with 53 new reactors under construction in 17 countries. Within the United States, there are 92 nuclear power plants providing 20% of the country’s total electric energy generation. Additionally, 28 of the 50 US states generate electricity from nuclear power plants, and four states, New Hampshire, South Carolina, Connecticut, and Illinois rely on nuclear power for more than 50 percent of their electricity. The United States produced approximately 30% of the world’s gross nuclear-generated electricity in 2022 with France at 14%, China 14%, Russia 8%, South Korea 5%, and the rest of the world at 29%. Nuclear energy is responsible for 8% of all US energy consumption. However, only one conventional nuclear power plant is now under construction, the Vogtie Plant, in eastern Georgia. China ranked first with 15 units, followed by India with 8 reactors under construction. In the 2021, 10 nuclear reactors were permanently shut down worldwide. In July 2022, the European Parliament endorsed labeling all nuclear energy projects “green”, allowing them access to loans and subsidies. In the context of emissions, nuclear power is considered to be clean. It produces zero carbon emissions and does not produce other noxious greenhouse gases. It is difficult to predict if these plans domestically and internationally will materialize or be postponed indefinitely if negative market forces develop. 

 

6

 

 

Opponents to Nuclear Energy are formidable due to concerns over safety.

 

Maintaining the demand for our products and future growth in demand will depend in part upon continued acceptance of nuclear technology as a means of generating electricity. In many cases, countries have embraced nuclear technology because alternate means of energy have either been at a high cost with heavy pollution, or other means have not been practical. However, incidents involving nuclear energy production, such as overheating reactors, radiation leaks and reactor melt-downs, can cause a significant decrease in public acceptance of nuclear technology. Events at the Fukushima Daiichi nuclear complex in Japan on March 11, 2011 may have adverse long-term effects in some countries decision to either continue using nuclear power or suspend its nuclear power program. While the long-term impact is unclear, several countries have suspended operations at existing nuclear power plants. Specifically, on May 30, 2011, Germany announced that in addition to the permanent closure of eight reactors and with only three nuclear power plants left with a license to operate at full capacity, the nuclear phase out in Germany is almost complete. Switzerland has made a policy decision to phase out of their 5 reactors by 2034. Italy, while not having any operating reactors, has implemented a moratorium on nuclear power. The ultimate results of these safety reviews and/or public resistance to nuclear technology may lead to suspension or cancellation of permitting and development activities, license extensions of existing nuclear facilities, and possibly even the closure of operating nuclear facilities by one or more countries. Lack of public acceptance of nuclear technology would adversely affect the demand for nuclear power and therefore demand for radiation detection equipment. 

 

Continued growth of CANDU reactors and rapid development of next generation Molten Salt (MSR) and Liquid-Fluoride Thorium Reactors (LFTR).

 

The Company relies on continued growth and orders from CANDU reactors (Canada Deuterium Uranium), and rapid development of the next generation of nuclear reactors called Molten Salt Reactors, (MSR) and Liquid-Fluoride Thorium Reactors (LFTR), for its tritium-based equipment. MSR and LFTR are new types of reactors that utilize thorium as a fuel rather than traditional uranium or plutonium. Thorium is a more abundant element than uranium. Many countries with heavy energy needs such as China have begun to adopt MSR and LFTR programs. However, the numbers of these types of reactors are still small in numbers and there can be no assurances that they will ever reach large numbers capable of sustaining rapid growth and development for nuclear-radiation safety products such as our tritium equipment. If CANDU reactors experience adverse events such as long-term inactivity due to political or environmental concerns, or economic issues, and if MSR and LFTR reactors fail to develop beyond its current growth forecasts worldwide, the Company will experience lower demand for its products which would have an adverse effect on the Company’s sales and profitability.

 

Failure to make accretive acquisitions and successfully integrate them could adversely affect our future financial results.

 

As part of our growth strategy, we plan to seek, when management deems advantageous to the Company, to acquire complementary (including competitive) businesses, facilities or technologies and enter into joint ventures.  Our goal is to make such acquisitions, integrate these acquired assets into our operations and reduce operating expenses.  The process of integrating these acquired assets into our operations may result in unforeseen operating difficulties and expenditures and may absorb significant management attention that would otherwise be available for the ongoing development of our business.  We cannot assure you that the anticipated benefits of any acquisitions will be realized.  In addition, future acquisitions by us could result in potentially dilutive issuances of equity securities, the incurrence of debt and contingent liabilities and amortization expenses related to goodwill and other intangible assets, any of which can materially and adversely affect our operating results and financial position.  Acquisitions also involve other risks, including entering geographic markets in which we have no or limited prior experience and the potential loss of key employees.

 

7

 

 

We have filed a provisional patent for our product based on our tritium products but hold no current patents on our products, and our business employs proprietary technology and information which may be difficult to protect and may infringe on the intellectual property rights of third parties.

 

In general, we rely primarily on a combination of trade secrets, copyright and trademark laws, and confidentiality procedures to protect our technology. Due to the technological change that characterizes our business, we believe that the improvement of existing products, reliance upon trade secrets and unpatented proprietary know-how and the development of new products are generally as important as patent protection in establishing and maintaining a competitive advantage.

 

We have currently filed a provisional utility-type patent on our tritium products to protect our intellectual property, but currently rely on trade secrets, proprietary know-how and technology that we seek to protect, in part, by confidentiality agreements with prospective joint venture partners, employees and consultants.  We cannot assure you that these agreements will not be breached, that we will have adequate remedies for any breach, or that our trade secrets and proprietary know-how will not otherwise become known or be independently discovered by others. Other than the provisional patent, we currently do not hold patents from the United States Patent and Trademark Office on any of our products we manufacture. Our success depends, in part, on our ability to keep competitors from reverse engineering our products, maintain trade secrecy and operate without infringing on the proprietary rights of third parties.  We cannot assure you that the patents of others will not have an adverse effect on our ability to conduct our business, that any of our trade secrets and applications will be protected, that we will develop additional proprietary technology that is defensible against theft or will provide us with competitive advantages or will not be challenged by third parties.  Further, we cannot assure you that others will not independently develop similar or superior technologies, duplicate elements of our technology or design around it.

 

It is possible that we may need to acquire licenses to, or to contest the validity of, issued or pending patents or claims of third parties.  We cannot assure you that any license acquired under such patents would be made available to us on acceptable terms, if at all, or that we would prevail in any such contest.  In addition, we could incur substantial costs in defending ourselves in suits brought against us for alleged infringement of another party’s patents or in defending the validity or enforceability of any patents we may seek in the future, or in bringing patent infringement suits against other parties.

 

In December, 2013, we were granted a registered trademark of the US Nuclear Corp name and logo from the United States Patent and Trademark Office and consider it important to the protection of our US Nuclear Corp brands. We have not been nor are we currently involved in or aware of any litigation regarding any of our intellectual property.

 

Our failure to obtain capital may significantly restrict our proposed operations.

 

We will need to raise more capital to expand our business. It is anticipated that we will require an additional capital raise of $5 million dollars over the next twelve months to fund our business plans. Future sources of capital may not be available to us when we need it or may be available only on unacceptable terms. 

 

We are subject to the risk that certain key personnel, including key employees named below, on whom we depend, in part, for our operations, will cease to be involved with us.  The loss of any these individuals would adversely affect our financial condition and the results of our operations.

 

We are dependent on the experience, knowledge, skill and expertise of our President and CEO Robert I. Goldstein. We are also in large part dependent on current CFO, Richard Landry. The loss of any of the key personnel listed above could materially and adversely affect our future business efforts. Our success depends in substantial part upon the services, efforts and abilities of Robert I. Goldstein, our Chairman and Chief Executive Officer, due to his experience, history and knowledge of the nuclear radiation industry and his overall insight into our business direction. The loss or our failure to retain Mr. Goldstein, or to attract and retain additional qualified personnel, could adversely affect our operations.  We do not currently carry key-man life insurance on Mr. Goldstein or any of our officers and have no present plans to obtain this insurance.  See “Management.” 

 

The loss of any of our executive officers could adversely affect our business.

 

We depend to a large extent on the efforts and continued employment of our executive officers. The loss of any executive officer could adversely disrupt our operations.

 

8

 

 

Competition from other radiation detection or related companies could result in a decrease of our business and a decrease in our financial performance.

 

We operate in a highly competitive industry. Many of our current and potential competitors, including larger multinational companies, domestic manufacturing companies with multiple product lines in radiation detection products have existed longer and have larger customer bases, greater brand recognition and significantly greater financial, marketing, personnel, technical and other resources than US Nuclear Corp. In addition, many of these competitors may be able to devote significantly greater resources to:

 

  research and development of new products

 

  attracting and retaining key employees;

 

  maintaining a large budget for marketing and promotional expenses

 

  providing more favorable credit terms to suppliers and channel distributors

 

Regulations, including those contained in and issued under the Sarbanes-Oxley Act of 2002 (“SOX”) and the Dodd–Frank Wall Street Reform and Consumer Protection Act of 2010 (“Dodd-Frank”), increase the cost of doing business and may make it difficult for us to retain or attract qualified officers and directors, which could adversely affect the management of our business and our ability to obtain or retain listing of our Common Stock.

 

We are a public company.  The current regulatory climate for public companies, even smaller reporting companies such as ours, may make it difficult or prohibitively expensive to attract and retain qualified officers, directors and members of board committees required to provide for our effective management in compliance with the rules and regulations which govern publicly-held companies, including, but not limited to, certifications from executive officers and requirements for financial experts on boards of directors. The perceived increased personal risk associated with these changes may deter qualified individuals from accepting these roles.  For example, the enactment of the Sarbanes-Oxley Act of 2002 has resulted in the issuance of a series of rules and regulations and the strengthening of existing rules and regulations by the SEC.  Further, proposed regulations under Dodd-Frank heighten the requirements for board or committee membership, particularly with respect to an individual’s independence from the corporation and level of experience in finance and accounting matters.  We may have difficulty attracting and retaining directors with the requisite qualifications. If we are unable to attract and retain qualified officers and directors, the management of our business could be adversely affected.

 

Limitations on director and officer liability and our indemnification of our officers and directors may discourage stockholders from bringing suit against a director.  

 

Our Certificate of Incorporation and By-Laws provide, with certain exceptions as permitted by Delaware corporation law, that a director or officer shall not be personally liable to us or our stockholders for breach of fiduciary duty as a director, except for acts or omissions which involve intentional misconduct, fraud or knowing violation of law, or unlawful payments of dividends. These provisions may discourage stockholders from bringing suit against a director for breach of fiduciary duty and may reduce the likelihood of derivative litigation brought by stockholders on our behalf against a director. In addition, our Certificate of Incorporation and By-Laws provide for mandatory indemnification of directors and officers to the fullest extent permitted by governing state law.   

 

9

 

 

We may incur a variety of costs to engage in future acquisitions of companies, products or technologies, to grow our business, to expand into new markets, or to provide new services.  As such, the anticipated benefits of those acquisitions may never be realized.

 

It is management’s intention to acquire other businesses to grow our customer base, to expand into new markets, and to provide new product lines.  We may make acquisitions of, or significant investments in, complementary companies, products or technologies, although no additional material acquisitions or investments are currently pending.  Acquisitions may be accompanied by risks such as: 

 

  difficulties in assimilating the operations and employees of acquired companies;

 

  diversion of our management’s attention from ongoing business concerns;

 

  our potential inability to maximize our financial and strategic position through the successful incorporation of acquired technology and rights into our products and services;

 

  additional expense associated with amortization of acquired assets;

 

  additional expense associated with understanding and development of acquired business;

 

  maintenance and implementation of uniform standards, controls, procedures and policies; and

 

  impairment of existing relationships with employees, suppliers and customers as a result of the integration of new management employees.

  

We must attract and retain skilled personnel.  If we are unable to hire and retain technical, sales and marketing, and operational employees, our business could be harmed.

 

Our revenues are generated by the sales of our radiation detection products from our direct sales, sales to catalogs, distributors and to a lesser extent, our website.  Our ability to manage our growth will be particularly dependent on our ability to develop and retain an effective sales force and qualified technical and managerial personnel. We intend to hire additional employees, including engineers, sales and marketing employees and operational employees.  The competition for engineers, qualified sales, technical, and managerial personnel in the technology and manufacturing community, is intense, and we may not be able to hire and retain sufficient qualified personnel.  In addition, we may not be able to maintain the quality of our operations, control our costs, maintain compliance with all applicable regulations, and expand our internal management, technical, information and accounting systems in order to support our desired growth, which could have an adverse impact on our operations. 

 

10

 

   

Our failure to manage growth effectively could harm our ability to attract and retain key personnel and adversely impact our operating results.

 

There can be no assurance that we will be able to manage our expansion through acquisitions effectively. Our current and planned personnel, systems, procedures and controls may not be adequate to support and effectively manage our future operations, especially as we employ personnel in multiple geographic locations. We may not be able to hire, train, retain, motivate and manage required personnel, which may limit our growth, damage our reputation and negatively affect our financial performance and harm our business. 

 

If we obtain financing, existing shareholder interests may be diluted.

 

If we raise additional funds by issuing equity or convertible debt securities, the percentage ownership of our shareholders will be diluted. In addition, any new securities could have rights, preferences and privileges senior to those of our common stock. Furthermore, we cannot assure you that additional financing will be available when and to the extent we require or that, if available, it will be on acceptable terms.

 

Risks Related to Our Common Stock

 

Our stock price may be volatile or may decline regardless of our operating performance, and the price of our common stock may fluctuate significantly.

 

The market price of our common stock may fluctuate significantly in response to a number of factors, most of which we cannot control, including:

 

  competition from other radiation detection companies or related businesses;

 

  changes in government regulations, general economic or market conditions or trends in our industry or the economy as a whole and, in particular, in the nuclear power industry;

 

  changes in key personnel;

 

  entry into new geographic markets;

 

  actions and announcements by us or our competitors or significant acquisitions, divestitures, strategic partnerships, joint ventures or capital commitments;

 

  changes in operating performance and stock market valuations of other radiation detection and related companies;

 

  investors’ perceptions of our prospects and the prospects of the nuclear power industry;

 

  fluctuations in quarterly operating results, as well as differences between our actual financial and operating results and those expected by investors;

 

  the public’s response to press releases or other public announcements by us or third parties, including our filings with the SEC;

 

  announcements relating to litigation;

 

11

 

 

  financial guidance, if any, that we provide to the public, any changes in this guidance or our failure to meet this guidance;

 

  changes in financial estimates or ratings by any securities analysts who follow our common stock, our failure to meet these estimates or failure of those analysts to initiate or maintain coverage of our common stock;

 

  the development and sustainability of an active trading market for our common stock;

 

  future sales of our common stock by our officers, directors and significant stockholders; and

 

  changes in accounting principles affecting our financial reporting.

 

These and other factors may lower the market price of our common stock, regardless of our actual operating performance.

 

The stock markets and trading facilities, including the OTC Bulletin Board, have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities in many companies. In the past, stockholders of some companies have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs and our resources and the attention of management could be diverted from our business.

 

Our Common Stock is subject to risks arising from restrictions on reliance on Rule 144 by shell companies or former shell companies.

 

Under a regulation of the SEC known as “Rule 144,” a person who has beneficially owned restricted securities of an issuer and who is not an affiliate of that issuer may sell them without registration under the Securities Act provided that certain conditions have been met. One of these conditions is that such person has held the restricted securities for a prescribed period, which will be 6 months or 1 year, depending on various factors. The holding period for our common stock would be 1 year if our common stock could be sold under Rule 144. However, Rule 144 is unavailable for the resale of securities issued by an issuer that is a shell company (other than a business combination related shell company) or that has been at any time previously a shell company. The SEC defines a shell company as a company that has (a) no or nominal operations and (b) either (i) no or nominal assets, (ii) assets consisting solely of cash and cash equivalents; or (iii) assets consisting of any amount of cash and cash equivalents and nominal other assets. Until the merger, we were a shell company.

 

The SEC has provided an exception to this unavailability if and for as long as the following conditions are met:

 

  The issuer of the securities that was formerly a shell company has ceased to be a shell company,

  

  The issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act,

 

  The issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form 8-K; and

 

  At least one year has elapsed from the time that the issuer filed current comprehensive disclosure with the SEC reflecting its status as an entity that is not a shell company known as “Form 10 Information.”

 

12

 

 

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

 

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our common stock would be negatively impacted. If we obtain securities or industry analyst coverage and if one or more of the analysts who cover us downgrades our common stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could cause our stock price and trading volume to decline.

 

Our management and other affiliates have significant control of our Common Stock and could control our actions in a manner that conflicts with the interests of other stockholders.

 

Our executive officers, directors and their affiliated entities together will beneficially own approximately 37.3% of our Common Stock. As a result, these stockholders, acting together, will be able to exercise considerable influence over matters requiring approval by our stockholders, including the election of directors, and may not always act in the best interests of other stockholders. Such a concentration of ownership may have the effect of delaying or preventing a change in our control, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices.

 

Penny Stock Considerations

 

Our shares likely will be “penny stocks” as that term is generally defined in the Securities Exchange Act of 1934 to mean equity securities with a price of less than $5.00. Our shares thus will be subject to rules that impose sales practice and disclosure requirements on broker-dealers who engage in certain transactions involving a penny stock.

 

13

 

 

Under the penny stock regulations, a broker-dealer selling a penny stock to anyone other than an established customer or accredited investor must make a special suitability determination regarding the purchaser and must receive the purchaser’s written consent to the transaction prior to the sale. Generally, an individual with a net worth in excess of $1,000,000 or annual income exceeding $200,000 individually or $300,000 together with his or her spouse is considered an accredited investor. In addition, under the penny stock regulations the broker-dealer is required to:

 

  Deliver, prior to any transaction involving a penny stock, a disclosure schedule prepared by the Securities and Exchange Commission relating to the penny stock market, unless the broker-dealer or the transaction is otherwise exempt;

 

  Disclose commissions payable to the broker-dealer and our registered representatives and current bid and offer quotations for the securities;

 

  Send monthly statements disclosing recent price information pertaining to the penny stock held in a customer’s account, the account’s value and information regarding the limited market in penny stocks; and

 

  Make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction, prior to conducting any penny stock transaction in the customer’s account.

 

Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and operating results. In addition, current and potential stockholders could lose confidence in our financial reporting, which could have an adverse effect on our stock price.

 

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud.  If we cannot provide reliable financial reports or prevent fraud, our operating results could be harmed.

 

During the course of our testing, we may identify deficiencies which we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404.  In addition, if we fail to maintain the adequacy of our internal accounting controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404.  Failure to achieve and maintain an effective internal control environment could cause us to face regulatory action and also cause investors to lose confidence in our reported financial information, either of which could have an adverse effect on our stock price.

 

We do not expect to pay any cash dividends for the foreseeable future.

 

The continued operation and growth of our business will require substantial cash. Accordingly, we do not anticipate that we will pay any cash dividends on shares of our Common Stock for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our Board of Directors and will depend upon our results of operations, financial condition, contractual restrictions relating to indebtedness we may incur, restrictions imposed by applicable law and other factors our Board of Directors deems relevant. Accordingly, if you purchase shares in this offering, realization of a gain on your investment will depend on the appreciation of the price of our Common Stock, which may never occur. Investors seeking cash dividends in the foreseeable future should not purchase our Common Stock.

 

14

 

 

OTC Bulletin Board Qualification for Quotation

 

On February 6, 2015, we were issued our ticker symbol, UCLE on the OTC Bulletin Board from FINRA. On March 20, 2015, we were approved for DTC eligibility by the Depository Trust and Clearing Corporation,) (“DTCC”).

 

Holders

 

As of the date of this 10-K, we had 52 holders of record of our Common Stock.

 

Quantitative and Qualitative Disclosures about Market Risk

 

We have entered into derivative financial instruments such as futures contracts, options and swaps, forward foreign exchange contracts or interest rate swaps and futures. In 2022, we entered into two convertible debt instruments that included stock purchase warrants. Though there were no derivatives associated with the Notes, the instruments are affected by changes in market interest rates. We believe that adequate controls are in place to monitor any hedging activities. While we do have significant sales outside the United States, all of our sales are settled with US currency, and we do not currently own assets and operate facilities in countries outside the United States and, consequently, we are not affected by foreign currency fluctuations or exchange rate changes.  Overall, we believe that our exposure to interest rate risk and foreign currency exchange rate changes is not material to our financial condition or results of operations.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Critical Accounting Policies

 

On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for qualifying public companies. As a “smaller reporting company,” we have the option to delay adoption of new or revised accounting standards until those standards would otherwise apply to private companies, until the earlier of the date that (i) we are no longer a smaller reporting company or (ii) we affirmatively and irrevocably opt out of the extended transition period for complying with such new or revised accounting standards. We have elected to opt out of this extended transition period. As noted, this election is irrevocable.  

 

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“US GAAP”). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

 

We suggest that our significant accounting policies, as described in our financial statements in the Summary of Significant Accounting Policies, be read in conjunction with this Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

15

 

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes.” ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.

 

Recent Accounting Pronouncements

   

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 was issued to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard represents significant changes to accounting for credit losses.  Full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope.  The current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold.  The expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts.  This ASU as amended by ASU 2019-10, is effective for fiscal years beginning after December 15, 2022.  The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures.

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes which amends ASC 740 Income Taxes (ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021.  The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted.  The adoption had no effect on the Company’s consolidated financial statements and related disclosures.

 

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 also removes certain conditions that should be considered in the derivatives scope exception evaluation under Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and clarify the scope and certain requirements under Subtopic 815-40. In addition, ASU 2020-06 improves the guidance related to the disclosures and earnings-per-share (EPS) for convertible instruments and contract in entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluation the impact this ASU will have on its consolidated financial statements.

 

16

 

 

Authorization of Preferred Stock

 

Our Certificate of Incorporation authorizes the issuance of up to 5,000,000 shares of preferred stock with designations, rights and preferences determined from time to time by its Board of Directors. Accordingly, our Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting, or other rights which could adversely affect the voting power or other rights of the holders of the common stock. In the event of issuance, the preferred stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of the Company. Although we have no present intention to issue any shares of its authorized preferred stock, there can be no assurance that we will not do so in the future.

 

Control by Management

 

As of December 31, 2022, management currently owns 37.3% of all the issued and outstanding capital stock of the Company. Consequently, management has the ability to control the operations of the Company and will have the ability to control substantially all matters submitted to stockholders for approval, including:

 

  Election of the board of directors;

 

  Removal of any directors;

 

  Amendment of the Company’s certificate of incorporation or bylaws; and

 

  Adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination.

 

This Report Contains Forward-Looking Statements and Information Relating to Us, Our Industry and To Other Businesses.

 

ITEM 1B- UNRESOLVED STAFF COMMENTS.

 

Not applicable.

 

ITEM 2. PROPERTIES

 

US Nuclear Corp is headquartered in Canoga Park, CA, and occupies a 6,000-square foot leased facility and 8,000 square foot leased facility in Milford, Ohio. The office is divided among the Company’s various disciplines: management, finance, sales, marketing and customer service, with 25% of the available space dedicated to inventory. Each location has a bookkeeper, production manager, assembly supervisor, production workers, and customer service staff.

 

The Company’s executive offices are located in Canoga Park, CA, at 7051 Eton Avenue, Canoga Park, California 91303. Per the Company’s lease agreement, the lease payment increased to $7,000 on August 1, 2016. Robert I. Goldstein, our President, Chief Executive Officer and Chairman of the Board of Directors also maintains a position as President of Gold Team Inc., a Delaware company that invests in industrial real estate properties for investment purposes. He holds an 8% interest in Gold Team Inc. The Company leases its current facilities from Gold Team Inc. which owns both the Canoga Park, CA and Milford, Ohio properties. The following table lists the locations of all its current locations.

 

Location  Address  Size
Canoga Park, California  7051 Eton Avenue  6,000 square feet
   Canoga Park, CA 91303   
       
Milford, Ohio  1160 U.S. Route 50  8,000 square feet
   Milford, OH 45150   

 

ITEM 3. LEGAL PROCEEDINGS.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

17

 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS

 

Market Information

 

We have already been approved by FINRA for the Over-the-Counter Bulletin Board (“OTCBB”) trading and additionally have also been approved with the Depository Trust and Clearing Corporation or (“DTCC”) for DTC eligibility. Our stock ticker symbol is UCLE on the Over-the-Counter Bulletin Board. For information on shareholders who owns 5% or more of our common stock, as well as the ownership of our officers and directors, please see “Security Ownership of Certain Beneficial Owners and Management”.

 

Authorized Capital Stock

 

The authorized capital stock of the Company consists of 100,000,000 shares of Common Stock, par value $0.0001 per share, (the “Common Stock”) and 5,000,000 shares of Preferred Stock, (the “Preferred Stock”) par value $0.0001 per share, of which none have been designated or issued. As of December 31, 2022 we had (i) 31,621,242 shares of common stock outstanding, held of record by 53 shareholders, and (ii) no shares of preferred stock outstanding. As of May 10, 2023 there are 35,798,087 shares of common stock outstanding, held of record by 52 shareholders.

 

Description of Capital Stock

 

The following is a summary of the rights of our capital stock and certain provisions of our articles of organization, as amended, and by-laws.  For more detailed information, please see our articles of organization, as amended, and by-laws filed as exhibits to this Current Report on Form 10-K. Each holder of the Company’s Common Stock is entitled to one vote for each share held on all matters submitted to a vote of shareholders and do not have cumulative voting rights.  An election of directors by our shareholders shall be determined by a plurality of the votes cast by the shareholders entitled to vote on the election.  The holders of Common Stock are entitled to receive pro rata dividends, when and as declared by the Board of Directors in its discretion, out of funds legally available therefore, but only if all dividends on the Preferred Stock have been paid in accordance with the terms of such Preferred Stock and there exists no deficiency in any sinking fund for the Preferred Stock.

 

Dividends on the Common Stock are declared by the Board of Directors. The payment of dividends on the Common Stock in the future, if any, will be subordinate to the Preferred Stock and will be determined by the Board of Directors. In addition, the payment of such dividends will depend on the Company’s financial condition, results of operations, capital requirements and such other factors as the Board of Directors deems relevant.  The Company has heretofore never paid any dividends and the Board has no plans for the payment of future dividends.  The Board presently plans for any future surplus income to be reinvested into growing the Company through additional investment.

 

Preferred Stock

 

The Board of Directors is authorized to provide for the issuance of shares of preferred stock in series and, by filing a certificate pursuant to the applicable law of Delaware, to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof without any further vote or action by the shareholders. Any shares of preferred stock so issued would have priority over the common stock with respect to dividend or liquidation rights. Any future issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of our Company without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. At present, we have no plans to neither issue any preferred stock nor adopt any series, preferences or other classification of preferred stock.

 

18

 

 

The issuance of shares of preferred stock, or the issuance of rights to purchase such shares, could be used to discourage an unsolicited acquisition proposal. For instance, the issuance of a series of preferred stock might impede a business combination by including class voting rights that would enable the holder to block such a transaction, or facilitate a business combination by including voting rights that would provide a required percentage vote of the stockholders. In addition, under certain circumstances, the issuance of preferred stock could adversely affect the voting power of the holders of the common stock. Although the Board of Directors is required to make any determination to issue such stock based on its judgment as to the best interests of our stockholders, the Board of Directors could act in a manner that would discourage an acquisition attempt or other transaction that some, or a majority, of the stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock over the then market price of such stock. The Board of Directors does not at present intend to seek stockholder approval prior to any issuance of currently authorized stock, unless otherwise required by law or stock exchange rules. We have no present plans to issue any preferred stock.

 

The description of certain matters relating to the securities of the Company is a summary and is qualified in its entirety by the provisions of the Company’s Certificate of Incorporation and By-Laws, copies of which have been filed as exhibits to the Company’s Form 10 filed with the Securities Exchange Commission on March 2, 2012, as updated by the Company’s Form 8-K filed with the Securities Exchange Commission on October 15, 2013.

 

Dividends

 

We have not paid any dividends on our common stock and do not presently intend to pay cash dividends prior to the consummation of a business combination. The payment of cash dividends in the future, if any, will be contingent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to consummation of a business combination, if any. The payment of any dividends subsequent to a business combination, if any, will be within the discretion of our then existing board of directors. It is the present intention of our board of directors to retain all earnings, if any, for use in our business operations and, accordingly, the board of directors does not anticipate paying any cash dividends in the foreseeable future. 

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The Company does not have any equity compensation plans or any individual compensation arrangements with respect to its common stock or preferred stock. The issuance of any of our common or preferred stock is within the discretion of our Board of Directors, which has the power to issue any or all of our authorized but unissued shares without stockholder approval.

 

Recent Sales of Unregistered Securities

 

During the year ending December 31, 2022, the Company issued 400,000 shares of common stock to Prashant Mehta in connection with the consulting services agreement entered into, by and between US Nuclear Corp and Prashant Mehta.

 

During the year ending December 31, 2022, the Company issued 625,000 shares of common stock in in relation to debt that was obtained.

 

During the year ending December 31, 2022, the Company issued 1,600,000 shares of common stock in satisfaction of principle, interest, and fees on a Convertible Note held by a third party.

 

During the year ending December 31, 2022, the Company issued 203,027 shares of common stock to Carter Terry & Co. in connection with investor relations services provided by the consultant.

 

During the year ending December 31, 2022, the Company issued 40,000 shares of common stock to Richard Cavalli in connection with investor relations services provided by the consultant.

 

During the year ending December 31, 2022, the Company issued 200,000 shares of common stock to Howard Isaacs in connection with investor relations services provided by the consultant.

 

Issuer Purchases of Equity Securities

 

None.

 

19

 

 

ITEM 6. [Reserved]

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Overview

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand US Nuclear Corp, our operations and our present business environment. MD&A is provided as a supplement to—and should be read in conjunction with—our consolidated financial statements and the accompanying notes thereto contained in “Item 8. Financial Statements and Supplementary Data” of this report on Form 10-K. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results may differ materially from those anticipated in these forward-looking statements.

 

We were incorporated in Delaware on February 14, 2012, and on March 2, 2012, we filed a registration statement on Form 10 to register with the U.S. Securities and Exchange Commission as a public company.  We were originally organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation.

 

On April 18, 2012, Richard Chiang, then our sole director and shareholder, entered into a Stock Purchase Agreement whereby Mr. Goldstein of US Nuclear Corp purchased 10,000,000 shares of our common stock from Mr. Chiang, which constituted 100% of our issued and outstanding shares of common stock. Mr. Chiang then resigned from all positions. Subsequently, on May 18, 2012, the Registrant appointed Mr. Chiang to serve as a member of the Board of Directors. He resigned from this position on March 31, 2013.

 

Since our acquisition of Overhoff Technology in 2006, we have had discussions with other companies in our industry for an acquisition. While we targeted Overhoff due to its unique position in the tritium market, we had not commenced an acquisition since our Overhoff Technology acquisition; we believe in part the reason was due to lack of additional capital, our status as a privately-held entity at the time, and focus on developing our own products. We will seek out companies whom our management believes will provide value to our customers and will complement our business. We will focus on diversifying our product line into a larger range so that our customers and vendors may have a more expansive experience in type, choice, options, price and selection. We also believe that with a more diverse product line we will become more competitive as our industry is intensely competitive.

 

Generally, our product concentration places a heavy reliance on our Overhoff Technology division. In 2022, we derived 55.9% of our total revenues from sales made by Overhoff to two customers. We expect to encounter a continuation of this trend unless we are successful in diversifying our client base, executing our acquisition strategy and experience increases in business from our Technical Associates division.

 

Our international revenues were 26.57% of our total revenue in 2022. We expect this to increase over time as we continue to field new orders inquires and engage new customers overseas and recover post-pandemic. We believe that South Korea and China will likely be a larger contributor to revenue within the next few years. While we maintain steady growth domestically, the international side of our business may be a larger component as nuclear technology and rapid development for clean energy grows abroad. Additionally, the Company relies on continued growth and orders from CANDU reactors (Canada Deuterium Uranium), and rapid development of the next generation of nuclear reactors called Molten Salt Reactors, (MSR) and Liquid-Fluoride Thorium Reactors (LFTR), all of which purchase tritium detection and monitor products. There can be no assurances as to our growth projections and our risk profile as we depend upon increased foreign customers for business.

 

20

 

 

Robert I. Goldstein, our President, Chief Executive Officer and Chairman of the Board of Directors also maintains a position as President of Gold Team Inc., a Delaware company that invests in industrial real estate properties for investment purposes. He holds an 8% interest in Gold Team Inc. and spends approximately 5 hours per week with affairs related to Gold Team Inc. The Company leases its current facilities from Gold Team Inc. which owns both the Canoga Park, CA and Milford, Ohio properties at an expense of $7,000 for each facility per month. 

 

On May 31, 2016, we entered into an Asset Purchase Agreement with Electronic Control Concepts (“ECC”) whereby the Company purchased certain tangible and intangible assets of ECC. ECC a small manufacturer of test and maintenance meters for x-ray machines both medical and industrial. We acquired ECC to give a boost to our current x-ray related product and hospital/medical product sales. 

 

Cali From Above (“CFA”) is a US Nuclear Corp subsidiary which was formed and began operations on January 28, 2021. CFA is a commercially recognized aerial mapping, aerial surveying, and airborne inspections company. CFA was formed to expand the Company’s presence in the Unmanned Aerial Vehicle market. The Company believes this market is rapidly growing and changing and feel it is an important growth opportunity. Incorporating as its own subsidiary provides the opportunity to specialize specifically in UAVs and UAV services.

 

Results of Operations

 

For the year ended December 31, 2022 compared to the year ended December 31, 2021

 

   Year Ended December 31,   Change 
   2022   2021   $   % 
                 
Sales  $2,091,366   $2,137,607   $(46,241)   -2.21%
Cost of goods sold   1,303,298    760,955    542,343    41,61%
Gross profit   788,068    1,376,652    (588,584)   -74.69%
Selling, general and administrative expenses   2,284,099    2,738,841    (454,742)   -19.91%
Loss from operations   (1,496,031)   (1,362,189)   (133,842)   8.95%
                     
Other expense   (546,764)   (514,495)   (32,269)   5.90%
Loss before provision for income taxes   (2,042,795)   (1,876,684)   (166,111)   8.13%
                     
Provision for income taxes                
Net income (loss)  $(2,042,795)  $(1,876,684)  $(166,111)   8.13%

 

21

 

 

Revenue for the year ended December 31, 2022, was $2,091,366 compared to $2,137,607 for the year ended December 31, 2021. The decrease of $46,241 or 2.21% is considered by management to be indicative of economic conditions as revenue across all subsidiaries post-Coronavirus pandemic remains constant, however growth was slowed in 2022 due to political and economic uncertainties. The revenue breakdown for the year ended December 31, 2022, is as follows:

 

North America 73.43%

Asia (including Japan) 25.03%

Other 1.54%

 

Our gross margin for the year ended December 31, 2022 was 37.68% as compared to 64.4% for the year ended December 31, 2021. The decrease in gross margin is due to a slight decrease in sales and an increase to cost of goods sold.

 

Selling and general and administrative expenses for the year ended December 31, 2022, decreased by $454,742 or 19.91% to $2,284,099; down from $2,738,841 for the year ended December 31, 2021. The decrease is largely attributed to a reduction in payroll costs.

 

Other expense for the year ended December 31, 2022, was $546,764, an increase of $32,269 from $514,495 for 2021. Other expense in 2022 consists of interest expense and amortization of debt discount. In 2021, other expense consisted of interest expense, write down of investments, interest expense, and equity loss in investment offset by a gain on forgiveness of debt.

 

Net loss for the year ended December 31, 2022, was $2,042,795 compared to net loss of $1,876,684 for the year ended December 31, 2021.

 

Liquidity and Capital Resources

 

Our operations have historically been financed by our majority stockholder. As funds were needed for working capital purposes, our majority stockholder would loan us the needed funds. During the year ended December 31, 2022, the Company’s majority shareholder paid expenses on behalf of the Company of $6,214 and loaned an additional $304,633 to the Company. We anticipate the growth of our business through the sale of our common stock and loans from our majority stockholder, if necessary.

 

At December 31, 2022, total assets increased by $257,551 or 8.28% from $2,851,186 at December 31, 2021 due to an increase in accounts receivable and inventory.

 

At December 31, 2022, total liabilities increased by 30.29% to $3,457,041 from $2,409,917 at December 31, 2021 due to an increase in accrued liabilities, accounts payable, accrued compensation paid to officers, convertible notes, note payable to shareholder, and an increase in our line of credit balances.

 

Critical Accounting Policies

 

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“US GAAP”). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

 

22

 

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes.” ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Contractual Obligations

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

Please see the financial statements beginning on page F-1 located elsewhere in this annual report on Form 10-K and incorporated herein by reference.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this report. The disclosure controls and procedures ensure that all information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rule and forms; and (ii) accumulated and communicated to our management, including our Chief Executive Officer as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2022, these disclosure controls and procedures were ineffective.

 

23

 

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible to establish and maintain adequate internal control over financial reporting. Our Officers are responsible to design or supervise a process that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The policies and procedures include:

 

  maintenance of records in reasonable detail to accurately and fairly reflect the transactions and dispositions of assets,

 

  reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors, and

 

  reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting as of the end of the period December 31, 2022. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control – Integrated Framework. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the fiscal year December 31, 2022, our internal controls over financial reporting were not effective due to the following.

 

  Lack of proper segregation of duties.

 

  No formal documentation of our internal controls

 

  Lack of multiple levels of supervision and review

 

Changes in Internal Controls over Financial Reporting

 

Our management has determined that there were no changes made in the implementation of our internal controls over financial reporting during the fourth quarter of the year ended December 31, 2022.

 

Attestation Report of Independent Public Accounting Firm

 

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting because as a smaller reporting company we are not subject to attestation by our independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

 

ITEM 9B. OTHER INFORMATION

 

Not applicable

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable

 

24

 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 

 

On June 30, 2022, US Nuclear Corp, a Delaware corporation (the “Company”) received notice of resignation by its Chief Financial Officer, Rachel Boulds. Ms. Boulds’ resignation did not result from any disagreement with the Company.

 

On the same day, the Company appointed its Chief Operating Officer, Richard Landry, to serve as the Chief Financial Officer of the Company effective as of June 30, 2022. Mr. Landry’s compensation will not be altered as a result of his appointment to CFO.

 

The following table contains information concerning our directors and executive officers through the date of filing of this report.

 

Name  Age  Position
       
Robert I. Goldstein  74  President, Chief Executive Officer, and Chairman of the Board of Directors
       
Richard Landry  27  Chief Financial Officer
       
Michael Hastings  80  Member of the Board of Directors
       
Dell Williamson  66  Member of the Board of Directors

 

Officers and Directors

 

Robert I. Goldstein –President, Chief Executive Officer and Chairman of the Board of Directors: Mr. Goldstein entered the radiation detection industry in 1972 as an applications engineer, production manager, and then general manager for Optron Scientific Company, Inc. DBA, Technical AssociatesMr. Goldstein is a physicist and an award- winning specialist in the nuclear radiation detection industry and has more than 30 years of experience in the field. He has authored more than 20 white papers and abstract presentations on industrial research use of radiation measurement equipment and instruments. His work has been approved by US Federal standards set by the EPA (Environmental Protection Agency), FDA (Food and Drug Administration), and NRC (Nuclear Regulatory Commission). Mr. Goldstein has also worked closely with and continues ongoing joint development programs with Los Alamos National Lab and Jefferson National Lab. He was instrumental in the acquisition of Overhoff Technology Corp, at the time, the world’s only tritium detection company, in 2006. His experience in the field of radiation detection ranges from development of instrumentation to design and development for air, water and surface applications. He is also an accomplished inventor having invented miniature radiation detectors for use during surgery. Mr. Goldstein graduated from MIT with a BS in Physics and from Stanford University with an MS in Mechanical Engineering. Mr. Goldstein is affiliated with the following scientific groups: Health Physics Society, American Nuclear Society, DOE (US Department of Energy) Tritium Focus Group, Air Monitoring User’s Group and Health Physics Instrument Committee.

 

25

 

 

Richard Landry – Chief Financial Officer, Director of Investor Relations and Business Development Consultant: Mr. Landry began his career in the financial world as a proprietary trader while in college; majoring in Mathematics and Applied Physics. Through an investment banking internship, Mr. Landry furthered his experience in Finance, which eventually lead him to Source 1 Capital, where he spear-headed the business development, marketing and assisted in structuring capital for public and private companies. This included advising, marketing, sourcing, evaluating, and conducting due diligence on new opportunities. Mr. Landry has been instrumental in assisting in raising/structuring almost $1.5B worth in new capital & deal flow. He has built-out and devised algorithms/trading strategies for top hedge funds, implemented CRMs for emerging tech companies, established sales growth strategies while maintaining regulatory requirements, worked with some of the largest asset management firms in the world such as; Fosun International and CIM, and was the Chief Compliance Officer of a Chinese tech firm where he assisted in their $150 million capital raise, as well as maintaining their compliance with China’s One Belt One Road Initiative. His responsibilities at US Nuclear Corp include marketing, research on new technologies, oversight of day-to-day activities, raising capital, procuring new contracts, and evaluating/structuring new acquisitions for the company.

 

Michael Hastings– Member of the Board of Directors: Mr. Hastings has been a corporate finance officer for over thirty years in the medical device industry with C.R. Bard, Inc. (predecessor to Becton Dickinson), and in the industrial battery industry with EnerSys, Inc. (NYSE: ENS). Mr. Hastings retired from EnerSys in 2011 as its Vice President and Treasurer with company revenue of $2 billion and operations in all parts of the world. His responsibilities included global treasury operations including debt and capital transactions; corporate tax; hedging of currencies, interest rate exposures and the price of raw materials; credit management; pension plan investments; and investor relations. He participated fully in due diligence, valuation and negotiation of numerous acquisitions. Mr. Hastings was also a member of the Board of Directors and Chief Financial Officer of MegaGraphite, Inc. - a private graphite exploration company in Canada between 2011 and when it was sold in 2014. Mr. Hastings was a member of the Board of Directors of Organic Transit, Inc., a private solar electric vehicle company in the United States, from 2018 until the company was sold in 2020. Mr. Hastings has no prior business relationship with the Company. 

 

Dell Williamson– Member of the Board of Directors: Mr. Williamson began his career at Overhoff Technology Corporation (“Overhoff”) in 1982. As set forth in prior disclosures, Overhoff is an operating division of the Company, and thus an affiliate or related party of the Company. Mr. Williamson is currently the Vice President for production at Overhoff Technology Corporation. His duties include design, engineering and calibration as well as managing production. Mr. Williamson graduated from Cincinnati Technical College with a degree in electronics technology. He furthered his education and attended the University of Cincinnati where he majored in industrial management and mechanical engineering. Mr. Williamson has become an expert in the use, design and construction of Tritium measurement systems. He serves as the technical interface between the user/scientist and the Overhoff factory. He is a member of the following scientific groups: Health Physics Society, American Nuclear Society, DOE (US Department of Energy) Tritium Focus Group, DOE (US Department of Energy) Air Monitoring User’s Group, DOE (US Department of Energy) Health Physics Instrument Committee. Mr. Williamson has no prior experience in serving as a director of a publicly reporting company.

 

In particular,

 

  With respect to Mr. Goldstein, the board considered his perspective and experience with our ongoing strategy and operations that he has obtained through his service to the Company and his ability to evaluate and assist with potential acquisitions and business opportunities.

 

  With respect to Mr. Hastings, the board considered his extensive managerial and financial expertise, as well as his experience in the medical device industry and his previous experience serving on a board of directors.

 

  With respect to Mr. Williamson, the board considered his long tenure as Vice President of Overhoff Technology Corporation, as well as his technical and engineering expertise and knowledge he has obtained through his service to the Company.

 

26

 

 

The Board of Directors and Committees

 

As of the date of this Report, we had one independent director.  We anticipate appointing additional independent directors as required in the future.  

 

Audit Committee

 

As of the date of this Report, we did not have a standing Audit Committee.  We intend to establish an Audit Committee of the Board of Directors, which will consist of independent directors, of which at least one director will qualify as a qualified financial expert as defined in the regulations of the SEC.  The Audit Committee’s duties would be to recommend to our Board of Directors the engagement of independent auditors to audit our consolidated financial statements and to review our accounting and auditing principles.  The Audit Committee would review the scope, timing and fees for the annual audit and the results of audit examinations performed by the internal auditors, if any, and independent public accountants, including their recommendations to improve the system of accounting and internal control.  The Audit Committee would at all times be composed exclusively of directors who are, in the opinion of our Board of Directors, free from any relationship that would interfere with the exercise of independent judgment as a committee member and who possess an understanding of financial statements and generally accepted accounting principles.  As of the date of this Report, we did not have an audit committee financial expert, in light of our size, although we intend to review this issue as the Company grows, especially as the Company implements a standing Audit Committee.

 

Compensation Committee

 

As of the date of this Report, we did not have a standing Compensation Committee.  We intend to establish a Compensation Committee of the Board of Directors.  The Compensation Committee would review and approve our salary and benefits policies, including compensation of executive officers.  The Compensation Committee would also administer any stock option plans that we may adopt and recommend and approve grants of stock options under such plans.

 

Nominating and Corporate Governance Committee 

 

As of the date of this Report, we did not have a standing Nominating and Corporate Governance Committee.  We intend to establish a Nominating and Corporate Governance Committee of the Board of Directors to assist in the selection of director nominees, approve director nominations to be presented for stockholder approval at our annual meeting of stockholders and fill any vacancies on our Board of Directors, consider any nominations of director candidates validly made by stockholders, and review and consider developments in corporate governance practices.

 

Compliance with Section 16(A) of the Securities Exchange Act Of 1934

 

Section 16(a) of the Securities Exchange Act of 1934, as amended (“Section 16(a)”), requires our Directors and executive officers, and persons who beneficially own more than ten percent of a registered class of our equity securities (collectively, “Section 16 reporting persons”), to file with the SEC initial reports of ownership and reports of changes in ownership of our Common Stock and other equity securities. Section 16 reporting persons are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file.

 

To our knowledge, based solely on a review of the copies of any such reports furnished to us, none of the Section 16 reporting persons failed to file on a timely basis reports required by Section 16(a) of the Exchange Act with respect to our most recent fiscal year ended December 31, 2022.

 

Code of Ethics

 

As of the date of this Report, we had not adopted a formal, written code of conduct (“Code of Ethics”) within the specific guidelines promulgated by the SEC, although we intend to adopt a Code of Ethics. 

 

27

 

 

ITEM 11. EXECUTIVE COMPENSATION

 

Executive Compensation

 

Our President, CEO and Chairman of the Board of Directors, Robert I. Goldstein and our Chief Financial Officer, Richard Landry are compensated for their services to the Company; no other officer receives compensation from the Company. Until the Company acquires additional capital, it is not anticipated that any other officer other than these three individuals will receive compensation from the Company other than reimbursement for out-of-pocket expenses incurred on behalf of the Company.

 

The Company has no stock option, retirement, pension, or profit-sharing programs for the benefit of directors, officers or other employees, but our officers and directors may recommend adoption of one or more such programs in the future.

 

Employment Agreements and Compensation

 

On November 4, 2014, we entered into a five-year Employment Agreement with our President, Chief Executive Officer and Chairman of the Board of Directors, Robert I. Goldstein. The Agreement calls for a salary of $100,000 per year, with his compensation beginning in fiscal 2015 and payable in January 2016. Mr. Goldstein later agreed to temporarily reduce his compensation to $50,000 for 2015. Compensation for 2016 increased to $100,000 as authorized by the Board of Directors and has remained $100,000 through December 31, 2022.

 

On February 27, 2019, we entered into an employment agreement with Richard Landry, our COO. Mr. Landry is entitled to receive monthly compensation of $10,000. During 2022, Mr. Landry became our CFO and his monthly compensation has remained the same.

 

Summary Compensation Table

 

The following table provides information regarding the compensation of our named executive officers for the years ended December 31, 2022 and 2021. 

 

Name and Principal Position  Year   Salary   Stock
Awards
   Option
Awards
   Non-Equity
Incentive
Plan
Compensation
   Other
Compensation
   Total 
Robert I. Goldstein President,   2022   $100,000   $              -0-   $            -0-   $                -0-   $               -0-   $100,000 
Chief Executive Officer, and Chairman of the Board of Directors (1)   2021   $100,000   $-0-   $-0-   $-0-   $-0-   $100,000 
                                    
Richard Landry,   2022   $120,000   $-0-   $-0-   $-0-   $-0-   $120,000 
Chief Financial Officer (2)   2021   $100,000   $-0-   $-0-   $-0-   $-0-   $100,000 

 

(1) Mr. Goldstein has accrued unpaid salary.

 

(2) Mr. Landry has accrued unpaid salary.

 

28

 

 

Equity Incentive Plan

 

As of the date of this Report, the Registrant has not entered into any Equity Incentive Plans.

 

Option Grants in the Last Fiscal Year

 

No Stock Appreciation Rights (“SARs”) or options to purchase our stock were granted to the Named Executive Officers during fiscal year ended December 31, 2022.

 

Retirement Plan

 

We do not currently have any retirement plan, but we expect to adopt one in the near term.

 

Director Compensation

 

The following table provides information concerning the compensation of the directors of the Company for the past fiscal year:

 

Name  Fees Earned or
Paid in Cash
   Stock
Awards
   All Other
Compensation
   Total 
Robert I. Goldstein  $          0   $          0   $          0   $          0 
Michael Hastings  $0   $0   $0   $0 
Dell Williamson  $0   $0   $0   $0 

 

Audit Committee Financial Expert

 


The Company does not have an audit committee financial expert. 

 

29

 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

As of the date of this Report, there were 35,798,087 shares of common stock issued and outstanding. The following table sets forth certain information regarding the beneficial ownership of the outstanding shares as of the date of this Report, (i) each of our executive officers and directors; and (ii) all of our executive officers and directors as a group.

 

Except as otherwise indicated, each such person has investment and voting power with respect to such shares, subject to community property laws where applicable. The address for all individuals for whom an address is not otherwise indicated is 7051 Eton Avenue, Canoga Park, CA 91303.

 

Name of Beneficial Owner  Amount  and
Nature of
Beneficial
Ownership
   Percent (%) of
Common
Stock
 
         
Robert I. Goldstein, President & CEO, Chairman   10,850,000    34.3%
           
Richard Landry, CFO   242,823    * 
           
Michael Hastings, Board Member   639,051    2.0%
           
Dell Williamson, Board Member   60,000    * 
           
All Directors and Officers as a Group (5 persons)   11,791,874    37.3%

 

*indicates less than 1%

 

Significant Employees

 

We are dependent on the experience, knowledge, skill and expertise of our President and CEO Robert I. Goldstein. We are also in large part dependent on Dell Williamson, Manager of the Overhoff Division, and Ivan Mitev, our Chief Engineer at the Overhoff Division, Ian Embry in sales, and Rowena Paredes in accounting. The loss of any of the key personnel listed above could materially and adversely affect our future business efforts. Our success depends in substantial part upon the services, efforts and abilities of Robert I. Goldstein, our Chairman and Chief Executive Officer, due to his experience, history and knowledge of the nuclear radiation industry and his overall insight into our business direction. The loss or our failure to retain Mr. Goldstein, or to attract and retain additional qualified personnel, could adversely affect our operations.  We do not currently carry key-man life insurance on Mr. Goldstein or any of our officers and have no present plans to obtain this insurance.

 

Family Relationships

 

There are no family relationships among directors, executive officers, or persons nominated or chosen by the issuer to become directors or executive officers.

 

Involvement in Certain Legal Proceedings

 

There have been no events under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any director, executive officer, promoter or control person of Registrant during the past five years.

 

30

 

 

Meetings of the Board of Directors

 

Mr. Goldstein was elected director by the former sole stockholder of the Company in April 18, 2012.  On March 28, 2014, Dr. Gerald Entine was elected to serve on the Board of Directors. On May 22, 2018, Gerald Entine died, leaving a vacancy on the Board of Directors for the Company. In order to fill the vacancy resulting from Mr. Entine’s death, the Board of Directors consented in lieu of a meeting to nominate Dell Williamson for appointment to the Board of Directors following receipt and review from Mr. Williamson his Confidential Bad Actor Disqualifying Event Statement confirming no “disqualifying event,” as defined under Rule 506(e) of Regulation D under the 1933 Securities Act and confirmation of receipt of the Company’s Insider Trading Policy and related memorandum regarding the same (as disclosed in prior filings). In addition, pursuant to Article IV of the Company’s Bylaws, as amended, the Board of Directors nominated Michael G. Hastings to serve as a director on the Board of Directors following receipt and review of the same disclosures and documents produced by Mr. Williamson, as identified herein. By signing the consent resolution, Mr. Williamson and Mr. Hastings accepted appointment as directors on the Board of Directors. The Board establishes policy and provides strategic direction, oversight, and control of the Company.  As of the date of this Form 10-K, the Board of Directors had no standing audit, compensation, nominating or other committees, although the Board intends to establish such committees in the future.  

 

Nominating Committee

 

We have not adopted any procedures by which security holders may recommend nominees to our Board of Directors.

 

Retirement Plan

 

We do not currently have any retirement plan, but we expect to adopt one in the near term.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

As stated in our Item 2, Properties disclosure on this Form 10-K, the Company’s executive offices are located in Canoga Park, CA, at 7051 Eton Avenue, Canoga Park, California 91303. The lease payment for each facility was $6,000, paid monthly through July 31, 2016. Per the Company’s lease agreement, the lease payment increased to $7,000 on August 1, 2016. Robert I. Goldstein, our President, Chief Executive Officer and Chairman of the Board of Directors also maintains a position as President of Gold Team Inc., a Delaware company that invests in industrial real estate properties for investment purposes. Mr. Goldstein holds an 8% interest in Gold Team Inc. The Company leases its current facilities from Gold Team Inc. which owns both the Canoga Park, CA and Milford, Ohio properties.

 

During the year ended December 31, 2022, the Company’s majority shareholder paid expenses on behalf of the Company of $6,214 and loaned an additional $304,633. The amounts due to Mr. Goldstein are $874,679 and $576,260 as of December 31, 2022 and 2021, respectively.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Audit Fees 

 

The aggregate fees billed by the Company’s current auditor Fruci & Associates II, PLLC, for professional services rendered for the audit of our annual financial statements, review of our quarterly financial statements or services that are normally provided in connection with statutory and regulatory filings were $83,958 and $82,500 for the years ended December 31, 2022 and 2021, respectively.

 

Audit Related Fees

 

There were no fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements for the year ended December 31, 2022 or 2021.

 

Tax Fees

 

There were no fees billed for professional services for tax compliance, tax advice, tax planning for the year December 31, 2022 or 2021.

 

All Other Fees

 

There were no fees billed for other products and services for the year ended December 31, 2022 or 2021.

 

31

 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

15(a)(1). Financial Statements

 

The following consolidated financial statements, and related notes and Report of Independent Registered Public Accounting Firm are filed as part of this Annual Report:

 

US Nuclear Corp. and Subsidiaries

Consolidated Financial Statements

For The Years Ended December 31, 2022 and 2021

 

Contents

 

    Page
Reports of Independent Registered Public Accounting Firms (PCAOB ID: 05525)   F-2
     
Report of Fruci & Associates II, PLLC   F-2
     
Consolidated Financial Statements:    
     
Consolidated Balance Sheets as of December 31, 2022 and 2021   F-4
     
Consolidated Statements of Operations for the years ended December 31, 2022 and 2021   F-5
     
Consolidated Statement of Changes in Shareholders’ Equity for the years ended December 31, 2022 and 2021   F-6
     
Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021   F-7
     
Notes to Consolidated Financial Statements   F-8

 

F-1

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of US Nuclear Corp.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of US Nuclear Corp. and Subsidiaries (“the Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations, changes in shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021 and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has an accumulated deficit and net losses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

F-2

 

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Valuation of Goodwill

 

Description of the Critical Audit Matter

 

As discussed in Note 2 to the consolidated financial statements, the Company has goodwill with a carrying value of $570,176 and is tested for impairment annually, or more frequently if impairment indicators arise. During the year ended December 31, 2022, the Company recorded no impairment charge.

 

Auditing management’s goodwill impairment test was complex and highly judgmental due to the significant estimation required to determine the fair value of the goodwill and underlying business unit. In particular, the fair value estimate was sensitive to significant assumptions, such as the Company’s financial forecast, discount rate, and operating costs, which are impacted by expectations about future market and economic conditions.

 

How the Critical Audit Matter Was Addressed in the Audit

 

To test the estimated fair value of the Company’s goodwill and underlying business unit, we performed audit procedures that included, among other things:

 

Developed an independent expectation and performed independent assessment of balance.

 

Reviewed current financial forecast in light of management’s current plans, and the historical basis of management’s estimates based on its current operating results that would result from changes in the assumptions.

 

 

We have served as the Company’s auditor since 2019.

 

Spokane, Washington

May 11, 2023  

  

F-3

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2022 AND 2021

 

   2022   2021 
ASSETS        
CURRENT ASSETS        
Cash  $126,109   $246,317 
Accounts receivable, net   329,858    163,577 
Inventories   2,024,664    1,792,312 
Prepaid expenses and other current assets   26,370    44,026 
TOTAL CURRENT ASSETS   2,507,001    2,246,232 
           
Property and equipment, net   6,501    9,719 
Investments   10,059    10,059 
Acquisition deposit   15,000    15,000 
Goodwill   570,176    570,176 
TOTAL ASSETS  $3,108,737   $2,851,186 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable  $100,398   $91,859 
Accounts payable - related party   280,000    128,500 
Accrued liabilities   688,422    587,941 
Accrued compensation - officers   695,000    590,000 
Customer deposit   88,694    101,342 
Notes payable   9,574    48,541 
Convertible notes payable, net of debt discount   412,953    
-
 
Note payable to shareholder   874,679    576,260 
Line of credit   307,321    285,474 
TOTAL CURRENT LIABILITIES   3,457,041    2,409,917 
           
Note payable, net of current portion   
-
    
-
 
TOTAL LIABILITIES   3,457,041    2,409,917 
           
COMMITMENTS & CONTINGENCIES   
-
    
-
 
           
SHAREHOLDERS’ EQUITY:          
           
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; none issued and outstanding   
-
    
-
 
Common stock, $0.0001 par value; 100,000,000 shares authorized, 31,621,242 and 28,353,215 shares issued and outstanding   3,162    2,836 
Common shares to be issued   39,000    
-
 
Additional paid in capital   14,740,401    13,508,581 
Accumulated deficit   (15,130,867)   (13,070,148)
TOTAL SHAREHOLDERS’ EQUITY   (348,304)   441,269 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $3,108,737   $2,851,186 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

 

   2022   2021 
Sales  $2,091,366   $2,137,607 
Cost of sales   1,303,298    760,955 
Gross profit   788,068    1,376,652 
           
Operating expenses          
Consulting expense   
-
    592,659 
Professional fees   326,118    171,024 
Officer compensation   170,000    372,978 
Payroll and related expense   957,954    939,061 
Selling, general and administrative expenses   830,027    663,119 
Total operating expenses   2,284,099    2,738,841 
           
Loss from operations   (1,496,031)   (1,362,189)
           
Other income (expense)          
Interest expense   (63,912)   (11,001)
Other income   
-
    2,950 
Amortization of debt discount   (482,852)   
-
 
Gain on forgiveness of debt   
-
    329,018 
Equity loss in investment   
-
    (835,462)
Total other income (expense)   (546,764)   (514,495)
           
Loss before provision for income taxes   (2,042,795)   (1,876,684)
           
Provision for income taxes   
-
    
-
 
           
Net loss  $(2,042,795)  $(1,876,684)
           
Deemed dividend for down-round provision in warrants   (17,924)   (52,861)
           
Net loss attributed to common stockholders  $(2,060,719)  $(1,929,545)
           
Weighted average shares outstanding - basic and diluted
   29,504,433    27,375,508 
           
Loss per share – basic and diluted
  $(0.07)  $(0.07)

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-5

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

 

   Common Stock   Common
Shares to be
   Additional
Paid in
   Accumulated   Total
Shareholders’
 
   Shares   Amount   Issued   Capital   Deficit   Equity 
Balance, December 31, 2020   25,724,844   $2,572   $-   $11,985,191   $(11,140,603)  $847,160 
Issuance of common stock for services   1,257,300    126    -    737,262    
-
    737,388 
Issuance of common stock for conversion of convertible debenture and accrued interest   250,000    25    -    99,975    
-
    100,000 
Issuance of common stock for investment   1,121,071    112    -    633,293    
-
    633,405 
Deemed dividend for down round provision in warrants   -    
-
    -    52,861    (52,861)   
-
 
Net loss   -    
-
    -    
-
    (1,876,684)   (1,876,684)
Balance, December 31, 2021   28,353,215   $2,835   $-   $13,508,582   $(13,070,148)  $441,269 
                               
Issuance of common stock for services   1,043,027    105    -    197,865    
-
    197,970 
Issuance of common stock for loan incentive   625,000    62    -    99,957    
-
    100,019 
Issuance of common stock for conversion of debt and accrued interest   1,600,000    160    -    259,840    
-
    260,000 
Debt discount on issuance of convertible debt   -    
-
    -    656,233    
-
    656,233 
Deemed dividend for down-round provision in warrants   -    
-
    -    17,924    (17,924)   
-
 
Common stock to be issued for services   -    
-
    39,000    
-
    
-
    39,000 
Net loss   -    
-
    -    
-
    (2,042,795)   (2,042,795)
Balance, December 31, 2022   31,621,242   $3,162   $39,000   $14,740,401   $(15,130,867)  $(348,304)

  

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6

 

  

US NUCLEAR CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

 

   2022   2021 
         
OPERATING ACTIVITIES        
Net loss  $(2,042,795)  $(1,876,684)
Adjustment to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   3,218    2,571 
Bad debt expense   
-
    11,000 
Issuance of common stock for services   267,246    673,617 
Expenses paid directly by majority shareholder   
-
    87,410 
Operating lease expense   
-
    55,079 
Amortization of debt discounts   482,852    
-
 
Forgiveness of PPP Loan   
-
    (329,018)
Finance costs   8,750    
-
 
Equity loss in investment   
-
    835,462 
Write-down of investments   
-
    
-
 
Changes in operating assets and liabilities:          
Accounts receivable   (166,281)   80,625 
Inventories   (232,352)   (474,625)
Prepaid expenses and other current assets   (12,620)   
-
 
Accounts payable   8,539    30,882 
Accounts payable - related parties   151,500    128,500 
Accrued liabilities   115,532    322,203 
Accrued compensation - officers   105,000    160,000 
Customer deposits   (12,648)   (92,969)
Operating lease liability   
-
    (55,079)
Net cash used in operating activities   (1,324,059)   (441,026)
           
INVESTING ACTIVITIES          
Purchase of property and equipment   
-
    (6,446)
Payment of acquisition deposit   
-
    (15,000)
Cash paid for investment   
-
    
-
 
Net cash used in investing activities   
-
    (21,446)
           
FINANCING ACTIVITIES          
Net borrowings (repayments) under lines of credit   26,149    119,600 
Proceeds from sale of common stock   
-
    100,000 
Proceeds from notes payable   
-
    221,431 
Repayments for notes payable   (37,217)   (4,546)
Proceeds from convertible notes payable   916,500    
-
 
Proceeds from note payable to shareholder   304,633    608,010 
Repayments for note payable to shareholder   (6,214)   (563,010)
           
Net cash provided by (used in) financing activities   1,203,851    481,485 
           
NET INCREASE (DECREASE) IN CASH   (120,208)   19,013 
           
CASH          
Beginning of period   246,317    227,304 
End of period  $126,109   $246,317 
           
Supplemental disclosures of cash flow information          
Taxes paid  $
-
   $
-
 
Interest paid  $11,973   $11,001 
Non-Cash investing and financing activities          
Beneficial conversion feature on down-round provision  $239,044   $
-
 
Common shares issued for future services  $39,000    135,859 
Deemed dividend on down round provision  $17,924   $52,861 
Common stock issued for conversion of convertible debt and accrued interest  $260,000   $
-
 
Original issue debt discount  $751,026   $
-
 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-7

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Note 1 – Organization and Basis of Presentation

 

Organization and Line of Business

  

US Nuclear Corp., formerly known as APEX 3, Inc., (the “Company” or “US Nuclear”) was incorporated under the laws of the State of Delaware on February 14, 2012.

 

On May 31, 2016, the Company entered into an Asset Purchase Agreement with Electronic Control Concepts (“ECC”) whereby the Company purchased certain tangible and intangible assets of ECC.

 

The Company is engaged in developing, manufacturing and selling radiation detection and measuring equipment. The Company markets and sells its products to consumers throughout the world.

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company recorded a net loss of $2,042,795 for the year ended December 31, 2022 and had an accumulated deficit of $15,130,867 as of December 31, 2022, which raises substantial doubt about its ability to continue as a going concern. 

 

The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through some private placement offerings of debt and equity securities. These plans, if successful, will mitigate the factors which raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. 

 

Note 2 – Summary of Significant Accounting Policies

 

Principles of Consolidation 

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Cali From Above, LLC, and Optron and its wholly-owned subsidiary, Overhoff Technology Corporation (“Overhoff”), and its wholly-owned subsidiary, Electronic Control Concepts (“ECC”), have been prepared in conformity with accounting principles generally accepted in the United States of America. All significant intercompany transactions and balances have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.

 

F-8

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash on hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. There were no cash equivalents as of December 31, 2022 and 2021.

 

Concentration of Credit Risk

 

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company places its cash with high quality financial institutions and at times may exceed the FDIC insurance limit. The Company has not and does not anticipate incurring any losses related to this credit risk. 

 

Accounts Receivable

 

The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves.  Reserves are recorded based on the Company’s historical collection history. Allowance for doubtful accounts as of December 31, 2022 and 2021 were $5,000 and $16,000, respectively.

 

Inventories

 

Inventories are valued at the lower of cost (determined primarily by the average cost method) or net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. As of December 31, 2022 and 2021, there was no allowance for slow moving or obsolete inventory. The Company periodically assessed its inventory for slow moving and/or obsolete items. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired.

 

F-9

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Property and Equipment

 

Property and Equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:

 

Furniture and fixtures 5 years
Leasehold improvement Lesser of lease life or economic life
Equipment 5 years
Computers and software 5 years

 

Long-Lived Assets

 

The Company applies the provisions of Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at December 31, 2022 and 2021, the Company believes there was no impairment of its long-lived assets.

 

Goodwill

 

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. The entire goodwill balance in the accompanying financial statements resulted from the Company’s acquisition of Overhoff Technology Corporation in 2006. The Company complies with ASC 350, Goodwill and Other Indefinite Lived Intangible Assets, requiring that a test for impairment be performed at least annually. As of December 31, 2022 and 2021 the Company performed the required impairment analysis which resulted in no impairment adjustments. Although the Company experienced a significant decline in revenue due to the effects of COVID-19, management expects that it is more likely than not that its revenue and cost of goods sold will be more in-line with pre-COVID-19 levels in upcoming periods. Significant estimates used in the goodwill impairment analysis may change in the upcoming year if revenues do not rebound and cost of materials continue to increase.

 

Derivative Financial Instruments

 

The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. During the years ended December 31, 2022 and 2021, there were no derivative liabilities associated with our convertible notes payable.

 

F-10

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Investments

 

The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, the Company measures the equity security at fair value as of the date that the observable transaction occurred (“the measurement alternative”) in accordance with ASC 321. The Company accounts for investments for which it owns 20% or more, but less than 50% on the equity method in accordance with ASC 323. 

 

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities, customer deposits, and line of credit, the carrying amounts approximate their fair values due to their short maturities. In addition, the Company has a note payable to shareholder that the carrying amount also approximates fair value.

 

Revenue Recognition

 

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on January 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from the sale of products to customers, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

 

Revenue from the product sales is recognized under Topic 606 in a manner that reasonably reflects the delivery of its products to customers in return for expected consideration and includes the following elements:

 

  executed contracts with the Company’s customers that it believes are legally enforceable;

 

  identification of performance obligations in the respective contract;

 

  determination of the transaction price for each performance obligation in the respective contract;

 

  allocation the transaction price to each performance obligation; and

 

  recognition of revenue only when the Company satisfies each performance obligation.

 

These five elements, as applied to each of the Company’s revenue category, is summarized below:

 

  Product sales - revenue is recognized when the Company performs its obligations under the contracts it has with its customers to deliver products at an agreed upon price and it is generally when the control of the product has been transferred to the customer.

 

Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits.

 

F-11

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Sales returns and allowances was $0 and $0 for the years ended December 31, 2022 and 2021, respectively. The Company provides a one-year warranty on all sales. Warranty expense for the years ended December 31, 2022 and 2021 was insignificant. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.

 

See Notes 11 and 12 for disclosures of revenue disaggregated by geographical area and product line.

 

Customer Deposits

 

Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718,” Compensation – Stock Compensation.” FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

 

F-12

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Basic and Diluted Earnings Per Share

 

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. As of December 31, 2022 and 2021 there were 2,500,000 and 333,333 warrants outstanding, respectively, to purchase shares of common stock. Basic and diluted earnings per share are the same during the years ended December 31, 2022 and 2021 due to the net loss incurred. As of December 31, 2022, the number of potentially dilutive shares issuable on our convertible notes and accrued interest was 6,430,544.

 

Segment Reporting

 

FASB ASC Topic 280, Segment Reporting, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments. See Note 11. 

 

Related Parties

 

The Company accounts for related party transactions in accordance with ASC 850, Related Party Disclosures. A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

 

Reclassifications

 

Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.

 

Recent Accounting Pronouncements    

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 was issued to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard represents significant changes to accounting for credit losses.  Full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope.  The current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold.  The expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts.  This ASU as amended by ASU 2019-10, is effective for fiscal years beginning after December 15, 2022.  The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures.

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes which amends ASC 740 Income Taxes (ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021.  The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted.  The adoption had no effect on the Company’s consolidated financial statements and related disclosures.

 

F-13

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 also removes certain conditions that should be considered in the derivatives scope exception evaluation under Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and clarify the scope and certain requirements under Subtopic 815-40. In addition, ASU 2020-06 improves the guidance related to the disclosures and earnings-per-share (EPS) for convertible instruments and contract in entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluation the impact this ASU will have on its consolidated financial statements.

 

Note 3 – Inventories

 

Inventory at December 31, 2022 and 2021 consisted of the following:

 

   2022   2021 
Raw materials  $1,244,880   $972,759 
Work in Progress   409,637    157,024 
Finished goods   370,127    662,529 
Total inventories  $2,024,664   $1,792,312 

 

At December 31, 2022 and 2021 the inventory reserve was $0.

 

Note 4 – Property and Equipment

 

The following are the details of property and equipment at December 31, 2022 and 2021:

 

   2022   2021 
Furniture and fixtures  $148,033   $148,033 
Leasehold Improvements   50,091    50,091 
Equipment   237,418    237,418 
Computers and software   39,482    39,482 
    475,024    475,024 
Less accumulated depreciation   (468,523)   (465,305)
Property and equipment, net  $6,501   $9,719 

 

Depreciation expense for the years ended December 31, 2022 and 2021 was $3,218 and $2,571, respectively. At December 31, 2022 and 2021, the Company had $440,628 of fully depreciated property and equipment that is still in use.

 

F-14

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Note 5 – Investments

 

MIFTEC

 

On August 3, 2018, the Company closed an agreement by and among, MIFTEC Laboratories, Inc. (“MIFTEC”), a licensee of Magneto-Inertial Fusion Technologies, Inc., (“MIFTI”), and the Company. MIFTEC is a licensee of MIFTI radionuclide technology. MIFTEC will engage the Company to manufacture equipment pursuant to MIFTEC’s specifications and designs and have the Company as a sales representative for the manufactured equipment. The Company will be the exclusive manufacturer and supplier to MIFTEC of equipment in North America and Asia. In addition, the Company received a 10% ownership interest in MIFTEC. The consideration for the exclusive manufacturing rights and a 10% ownership interest in MIFTEC was $500,000 and 300,000 shares of the Company’s common stock valued at $594,000. The fair value was determined based on the Company’s stock price on August 3, 2018. The Company recorded the value of the 10% interest in MIFTEC at $10,000 and recorded $1,084,000 as the acquisition of manufacturing and supply rights in the accompanying consolidated statement of operations during the year ended December 31, 2018. The Company evaluated this investment for impairment and determined that an impairment of $9,000 was necessary during the year ended December 31, 2019. The carrying value of this investment at December 31, 2022 and 2021 was $1,000 and $1,000, respectively.

 

MIFTI

 

In April 2019, the Company also entered into a Cooperative Agreement with MIFTI whereby the Company acquired certain exclusive manufacturing and supply rights, including thermonuclear fusion-powered reactor for production of electricity per MIFTI designs in return for $500,000, of which $100,000 is payable upon signing, $200,000 within four months of the agreement and $200,000 within nine months of the agreement. The $500,000 is an option to buy a 10% interest in MIFTI for $2,700,000, if completed with 24 months of the agreement date. If the option expires, MIFTI shall issue the Company 500,000 shares of common stock and rescind all other exclusive rights contained in the agreement. The option was rescinded and the Company received 500,000 shares of MIFTI common stock which represents an ownership of approximately 0.56% for its $500,000 investment. The Company evaluated this investment for impairment and determined that an impairment of $499,000 was necessary during the year ended December 31, 2019. The carrying value of this investment at December 31, 2022 and 2021 was $1,000 and $1,000, respectively.

 

Grapheton

 

On February 5, 2020, the Company entered into a Stock Purchase Agreement (“SPA”) with Grapheton, Inc., a California corporation (“Grapheton”). The transaction was closed on March 12, 2020. Grapheton is a start-up company that focuses on building energy storage devises, known as supercapacitors, from a new material system. The technology utilized by Grapheton has been proven to provide a compelling advantage in microelectrode arrays with superior electrical and electrochemical properties.

 

Pursuant to the terms of the SPA, the Corporation will acquire a total of 2,552 shares of Grapheton’s common stock over a two-year period. At closing, the Company was issued at total of 1,452 shares of Grapheton’s common stock for $235,000 and 858,896 shares of the Company’s common stock valued at $601,227.

 

In connection with the SPA, during the second quarter of 2021 the Company received an additional 1,100 shares of Grapheton’s common stock in exchange for the Company’s issuing an additional 1,121,071 shares of common stock valued at $633,405. In addition, Grapheton fulfilled its requirements under the earn out provision and the Company is obligated to make the first earn out payment of $192,500. This amount is recorded as accrued expense in the accompanying consolidated balance sheet.

 

An additional “true up” issuance of the Company’s common stock to Grapheton may be made on the second anniversary of the closing of the SPA, based on the valuation of the Company’s common stock on that date by a third-party valuator.

 

The Company currently owns 35.8% of Grapheton and accounts for its investment in Grapheton using the equity method of accounting is in accordance with ASC 323.

 

F-15

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Information regarding Grapheton as of and for the year ended December 31, 2022 is below:

 

Current assets  $17,396 
Total assets   25,691 
Current liabilities   593,333 
Total liabilities   593,333 
Total stockholders’ equity   (567,642)
      
Revenue  $- 
Operating expenses   (760,257)
Other expenses   (246,154)
Net loss   (1,006,411)

 

The Company evaluated this investment and recorded a loss attributed to equity investment of $0 during the year ended December 31, 2022. The carrying value of this investment at December 31, 2022 was $8,059

 

Note 6 – Notes Payable

 

In connection with the acquisition of assets from ECC the Company issued a note payable to the owner of ECC. The note accrued interest at 5% per annum, requires quarterly principal and interest payments of $4,518 and is due on April 15, 2021. At December 31, 2022 and 2021, the amount outstanding under this note payable was $5,272 and $5,272, respectively.   The Company was in default on payment of the note payable as of December 31, 2022. The Company has communicated with the debt holder, and the amount is considered payable on demand as of December 31, 2022.

 

In June 2020 the Company received a loan under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act for $107,587.  The loan has terms of 24 months and accrues interest at 1% per annum. In February of 2021, the Company received two additional loans totaling $221,431 under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. As of December 31, 2021, the Company has had these loans forgiven in the amount of $329,018 as provided by the CARES Act. 

 

On December 26, 2020, a line of credit held by the company had matured, and based on the terms of the line of credit agreement was converted to a note payable upon demand. The obligation accrues interest at the rate of $10.89 per day until the bank receives full payment. As of December 31, 2022, the balance owed by the Company was $4,302.

 

On May 5, 2022, the Company received a loan in connection with the issuance of stock warrants in the amount of $750,000. The loan has terms of 12 months and accrues interest at 5% per annum. As part of the issuance of the loan, the company identified debt discounts related to the warrants issued, the incentive shares issued as discussed at Note 10, the beneficial conversion feature of the debt, and the expenses paid as part of the issuance. The total debt discounts recorded as of the date of the note was $550,538. At December 31, 2022 and pursuant to the down-round provision of the note and associated warrants, the Company reevaluated the beneficial conversion feature which resulted in additional debt discount recorded of $183,422.

 

On October 10, 2022, the Company received a loan in connection with the issuance of stock warrants in the amount of $375,000. The loan has terms of 12 months and accrues interest at 5% per annum. As part of the issuance of the loan, the company identified debt discounts related to the warrants issued, the beneficial conversion feature of the debt, and the expenses paid as part of the issuance. The total debt discounts recorded as of the date of the note was $200,488. At December 31, 2022 and pursuant to the down-round provision of the note and associated warrants, the Company reevaluated the beneficial conversion feature recorded which resulted in additional debt discount recorded of $30,304.

 

The total debt discount amortization recorded on the Company’s notes for the twelve months ended December 31, 2022 was $482,852.

 

Future maturities of all notes payable as of December 31, 2022, are as follows: 

 

Years Ending December 31,    
2023   904,427 
2024   
-
 
2025   
-
 
2026   
-
 
2027   
-
 
Thereafter   
-
 
   $904,427 

 

F-16

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Note 7 – Note Payable to Shareholder

 

Robert Goldstein, the CEO and majority shareholder, has loaned funds to the Company from time to time to cover general operating expenses. These loans are evidenced by unsecured, non-interest-bearing demand notes payable. During the year ended December 31, 2021, the Company’s majority shareholder paid expenses on behalf of the Company of $87,410 and loaned an additional $45,000 to the Company. During the year ended December 31, 2022, the Company’s majority shareholder loaned an additional $304,633 to the Company and was repaid $6,214.  The amounts due to Mr. Goldstein are $874,679 and $576,260 as of December 31, 2022 and 2021, respectively

 

Note 8 – Line of Credit 

 

As of December 31, 2022, the Company had four lines of credit with a maximum borrowing amount of $400,000 with interest ranging from 5.5% to 11.5%. As of December 31, 2022 and 2021, the amounts outstanding under these lines of credit were $307,321 and $285,474, respectively.

 

Note 9 – Leases

 

The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate which is based on the interest rate of similar debt outstanding.

 

The Company leases its current facilities from Gold Team Inc., a company owned by the Company’s CEO, which owns both the Canoga Park, CA and Milford, Ohio locations. The leases expired on April 30, 2020 and the Company exercised its renewal option for an additional 12 months. The new lease is not more than 12 months; therefore, the disclosures under ASC 842 are not required. Future minimum lease payments under this agreement for the twelve months ending December 31, 2023 is $168,000. Effective January 1, 2019, the Company adopted the provision of ASC 842 Leases.

 

F-17

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

The lease expense for the years ended December 31, 2022 and 2021 was $168,000 and $168,000, respectively. The cash paid under operating leases during the years ended December 31, 2022 and 2021 was $16,500 and $42,000, respectively. At December 31, 2022, $280,000 has been accrued and is shown on the balance sheet as accounts payable- related party. At December 31, 2022, the weighted average remaining lease terms were 0.3 years and the weighted average discount rate was 8%.

 

Note 10 – Shareholders’ Equity

 

Common stock

 

During the year ended December 31, 2022, the Company issued:

 

  625,000 shares of common stock valued at $100,019 in relation to the debt that was obtained;

 

  1,600,000 shares of common stock valued at $260,000 in satisfaction of convertible debt and interest;
     
  1,043,027 shares of common stock to consultants for services rendered valued at $236,970; of which $39,000 is recorded as shares to be issued. Pursuant to ASC 718 the company has allocated a portion of stock-based compensation to prepaid expenses until the services are provided to the Company. The amount allocated to prepaid expense at December 31, 2022 is $9,750. The fair value was determined based on the Company’s stock price on the grant date.

 

During the year ended December 31, 2021, the Company issued:

 

  1,252,300 shares of common stock to consultants for services rendered valued at $737,738. The fair value was determined based on the Company’s stock price on the grant date;

 

  250,000 shares of common stock for cash; and

 

  1,121,071 shares of common stock for an investment in Grapheton valued at $633,405. The fair value was determined based on the Company’s stock price on the grant date.

 

F-18

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Warrants

 

The following table summarizes the activity related to warrants:

 

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Warrants   Exercise   Contractual   Intrinsic 
   Outstanding   Price   Life   Value 
Outstanding, December 31, 2020   333,333   $0.40    1.50   $
      -
 
Granted   
-
                
Forfeited   
-
                
Exercised   
-
                
Outstanding, December 31, 2021   333,333   $0.36    0.90   $
-
 
Granted   2,500,000   $0.14    3.00   $
-
 
Forfeited   (333,333)               
Exercised   
-
                
Outstanding, December 31, 2022   2,500,000   $0.14    2.56   $
-
 
Exercisable, December 31, 2022   2,500,000   $0.14    2.56   $
-
 

 

The above warrants contain a down round provision that requires the exercise price to be adjusted if the Company sells shares of common stock below the current exercise price. During the twelve months ended December 31, 2022, the Company issued shares of common stock for $0.14 therefore, the exercise price of these warrants was adjusted from $0.75 and $0.475 to $0.14 pursuant to the down-round provision in the warrant agreement.  The change in fair value between the value of the warrants using the new exercise price versus the old exercise price was calculated to be $17,924. This amount is recorded as a deemed dividend in the accompanying consolidated financial statements during the year ended December 31, 2022.

 

The following table summarizes information about options outstanding and exercisable as of December 31, 2022

 

Outstanding and Exercisable 
Number of Warrants   Exercise Price 
 2,500,000   $0.14 
 2,500,000      

 

Note 11 – Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has two reportable segments: Optron and Overhoff. Optron is located in Canoga Park, California and Overhoff is located in Milford, Ohio. The assets and operations of the Company’s recent acquisition of the assets of Electronic Control Concepts are included with Overhoff in the table below. The assets and operations of the Company’s newest subsidiary, Cali From Above are included with Optron in the table below.

 

F-19

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

The following tables summarize the Company’s segment information for the years ended December 31, 2022 and 2021:

 

   Years Ended
December 31,
 
   2022   2021 
Sales        
Optron  $220,368   $482,582 
Overhoff   1,870,998    1,655,025 
Corporate   
-
    
-
 
   $2,091,366   $2,137,607 
           
Gross profit          
Optron  $(547,531)  $101,447 
Overhoff   1,335,599    1,275,205 
Corporate   
-
    
-
 
   $788,068   $1,376,652 
           
Income (loss) from operations          
Optron  $(1,484,631)  $(799,837)
Overhoff   486,382    264,763 
Corporate   (497,782)   (1,757,739)
   $(1,496,031)  $(1,876,684)
Interest Expenses          
Optron  $21,725   $10,076 
Overhoff   6,545    
-
 
Corporate   35,643    925 
   $63,912   $11,001 
           
Net income (loss)          
Optron  $(1,506,356)  $(799,837)
Overhoff   479,837    680,892 
Corporate   (1,016,275)   (1,763,901)
   $(2,042,794)  $(1,882,846)

 

   As of December 31, 
   2022   2021 
Total Assets        
Optron  $1,021,817   $1,027,669 
Overhoff   2,037,988    1,754,485 
Corporate   48,932    69,032 
   $3,108,737   $2,851,186 
           
Goodwill          
Optron  $
-
   $
-
 
Overhoff   570,176    570,176 
Corporate   
-
    
-
 
   $570,176   $570,176 

 

F-20

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

Note 12 – Geographical Sales  

 

The geographical distribution of the Company’s sales for the years ended December 31, 2022 and 2021 is as follows:

 

   2022   2021 
Geographical sales        
North America  $1,535,671   $1,522,412 
Asia   523,434    473,157 
South America   5,475    4,932 
Other   26,786    137,106 
   $2,091,366   $2,137,607 

 

Note 13 – Income Taxes  

 

At December 31, 2022 and 2021, the significant components of the deferred tax assets are summarized below:

 

   2022   2021 
         
Approximate net operating loss carry forwards  $12,649,000   $10,605,000 
           
Deferred tax assets:          
Federal net operating loss  $2,031,310   $1,602,310 
State net operating loss   846,270    723,270 
Tax credit   49,740    49,740 
Goodwill   (148,373)   (148,373)
Total deferred tax assets   2,778,947    2,226,947 
Less valuation allowance   (2,778,947)   (2,226,947)
   $
-
   $
-
 

 

The valuation allowance increased by $552,000 and $526,103 in 2022 and 2021, respectively, due to the Company generating additional net operating losses. The Company’s remaining tax credit carryforwards of $49,740 begin to expire in 2027 and its net operating loss carryforward of approximately $12,649,000 begin to expire in 2027.

 

Income tax expense reflected in the consolidated statements of income consist of the following for 2022 and 2021:

 

   2022   2021 
Current          
Federal  $     -   $     - 
State   -    - 
    -    - 
Deferred          
Federal   -    - 
State   -    - 
    -    - 
Income tax expense  $-   $- 

 

F-21

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

The reconciliation of the effective income tax rate to the federal statutory rate for the years ended December 31, 2022 and 2021 is as follows:

 

   2022   2021 
         
Federal income tax rate   21.0%   21.0%
State tax, net of federal benefit   6.0%   6.0%
Net operating losses   -16.7%   -16.7%
Permanent differences   -10.6%   -10.6%
Amortization of goodwill   0.3%   0.3%
Effective income tax rate   0.0%   0.0%

 

The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2019.

 

The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carryforward periods available to the Company for tax reporting purposes, and other relevant factors.

 

Future changes in the unrecognized tax benefit will have no impact on the effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change significantly within the next twelve months. The Company will continue to classify income tax penalties and interest as part of general and administrative expense in its consolidated statements of operations. There were no interest or penalties accrued as of December 31, 2022 and 2021.

 

Note 14 – Related Party Transactions  

 

The Company leases its current facilities from Gold Team Inc., a company owned by the Company’s CEO, which owns both the Canoga Park, CA and Milford, Ohio locations. Rent expense for the year ended December 31, 2022 and 2021 were $168,000 and $168,000, respectively. As of December 31, 2022 and 2021, the payable to Gold Team Inc. in connection with the above leases was to $280,000 and $128,500, respectively. (See Note 9).

 

F-22

 

 

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2022 and 2021

 

As of December 31, 2022 and 2021, the Company had accrued compensation payable to its majority shareholder of $695,000 and $590,000, respectively.

 

During the year ended, December 31, 2021, the company issued 242,823 shares of common stock to Richard Landry in connection with the consulting services agreement entered by and between US Nuclear Corp and Richard Landry.

 

Also see Note 7. 

 

Note 15 – Concentrations  

 

For the year ended December 31, 2022, two customers accounted for more than 10% of the Company sales, 42.3% and 13.61%, respectively. At December 31, 2022 two customers accounted for more than 10% of the accounts receivable balance, 55.5% and 28.4%, respectively.

 

For the year ended December 31, 2021, two customers accounted for more than 10% of the Company sales, 30.7% and 15.2%, respectively. At December 31, 2021 two customers accounted for more than 10% of the accounts receivable balance, 23.9% and 15%, respectively.

 

No vendors accounted for more than 10% of the Company’s purchases for the years ended December 31, 2022 and 2021.

 

Note 16 – Subsequent Events

 

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were available to be issued and has determined that no material subsequent events exist other than the following:

 

On January 9, 2023, the Company issued 100,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which is $11,100 or $0.111 per share.

 

On January 19, 2023, the Company issued 400,000 shares in satisfaction of principle, accrued interest, and fees on convertible debt. The value of the shares issued was $60,000 or $0.15 per share.

 

On January 23, the Company issued an aggregate of 260,000 shares to consultants as compensation for investor relations services. The shares were valued at their fair value on the date of grant, which was $37,960 or $0.146 per share.

 

On February 23, the Company issued 400,000 shares in satisfaction of principle, accrued interest, and fees on convertible debt. The value of the shares issued was $60,000 or $0.15 per share.

 

On February 24, the Company issued 200,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which was $29,200 or $0.146 per share.

 

Effective March 3, 2023, the Company entered into a Membership Unit Purchase Agreement whereby the Company transferred, assigned, and conveyed the capital account of its wholly-owned subsidiary Cali From Above, in exchange for 65,000,000 shares of INNOVATION NATION, INC., a Nevada Corporation, owned and held by Robert Goldstein. As a result, the Company has divested itself of its ownership of Cali From Above and the Company now holds a 26% interest in Innovation Nation, an OTC reporting company under the symbol (OTC:AVRI).

 

On March 14, 2023, the Company issued an aggregate of 1,500,000 shares of common stock to our Board members. The shares were valued at their fair value on the date of grant, which was $175,500 or $0.117 per share.

 

On March 31, 2023, the Company issued 75,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which was $8,550 or $0.114 per share.

 

On April 11, 2023, the Company issued 771,845 shares of common stock, by cashless exercise, pursuant to a Warrant Agreement associated with a convertible note payable entered into on May 5, 2022.

 

F-23

 

 

15(a)(2). Financial Statement Schedules.

 

None.

 

15(a)(3). Exhibits.

 

            Incorporated by reference
Exhibit   Exhibit Description   Filed herewith   Form   Period ending   Exhibit   Filing date
                         
3.1   Certificate of Incorporation       10       3.1   02/14/2012
3.2   By-Laws       10       3.2   02/14/2012
3.3   Amendment to Certificate of Incorporation       8-K       3.3   05/29/2012
4.1   Specimen Stock Certificate       10       4.1   02/14/2012
4.2   Description of Securities   X                
10.1   Robert I. Goldstein Employment Agreement       10-Q       10.1   11/11/2014
10.2   Forgiveness of Debt and Conversion Agreement       10-Q       10.2   11/11/2014
23.2   Consent of Independent Auditor   X          
31.1   Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   X                
31.2   Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   X                
32.1   Certification pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X                
32.2   Certification pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   X                
                         
101.INS   Inline XBRL Instance Document   X                
101.SCH   Inline XBRL Taxonomy Extension Schema Document   X                
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document   X                
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document   X                
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document   X                
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document   X                
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)   X                

 

32

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: May 11, 2023 US Nuclear Corp.
     
  By: /s/ Robert I. Goldstein
    Robert I. Goldstein
   

President, Chief Executive Officer,

Chairman of the Board of Directors

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Date: May 11, 2023 US Nuclear Corp
     
  By: /s/ Richard Landry
    Chief Financial Officer

 

 

33

 

 

5525 27375508 29504433 0.03 0.07 false FY 0001543623 NONE NA 0001543623 2022-01-01 2022-12-31 0001543623 2022-06-30 0001543623 2023-05-10 0001543623 2022-12-31 0001543623 2021-12-31 0001543623 2021-01-01 2021-12-31 0001543623 us-gaap:CommonStockMember 2020-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001543623 us-gaap:RetainedEarningsMember 2020-12-31 0001543623 2020-12-31 0001543623 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001543623 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001543623 us-gaap:CommonStockMember 2021-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001543623 us-gaap:RetainedEarningsMember 2021-12-31 0001543623 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001543623 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001543623 ucle:CommonSharesToBeIssuedMember 2022-01-01 2022-12-31 0001543623 us-gaap:CommonStockMember 2022-12-31 0001543623 ucle:CommonSharesToBeIssuedMember 2022-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001543623 us-gaap:RetainedEarningsMember 2022-12-31 0001543623 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001543623 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001543623 us-gaap:EquipmentMember 2022-01-01 2022-12-31 0001543623 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001543623 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001543623 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001543623 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001543623 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001543623 us-gaap:EquipmentMember 2022-12-31 0001543623 us-gaap:EquipmentMember 2021-12-31 0001543623 us-gaap:ComputerEquipmentMember 2022-12-31 0001543623 us-gaap:ComputerEquipmentMember 2021-12-31 0001543623 2018-08-03 0001543623 ucle:OwnershipInterestMember ucle:MIFTECMember 2018-08-03 0001543623 ucle:MIFTECMember 2018-08-03 0001543623 ucle:MIFTECMember 2018-08-01 2018-08-03 0001543623 ucle:MIFTECMember 2018-12-31 0001543623 ucle:MIFTECMember 2018-01-01 2018-12-31 0001543623 ucle:MIFTECMember 2019-01-01 2019-12-31 0001543623 ucle:MIFTECMember 2022-01-01 2022-12-31 0001543623 ucle:MIFTECMember 2021-01-01 2021-12-31 0001543623 ucle:MIFTIMember 2019-04-01 2019-04-30 0001543623 2019-04-30 0001543623 ucle:MIFTIMember 2019-01-01 2019-12-31 0001543623 ucle:MIFTIMember 2022-01-01 2022-12-31 0001543623 ucle:MIFTIMember 2021-01-01 2021-12-31 0001543623 2021-04-01 2021-06-30 0001543623 ucle:GraphetonMember 2021-04-01 2021-06-30 0001543623 ucle:GraphetonMember 2022-12-31 0001543623 ucle:GraphetonMember 2022-01-01 2022-12-31 0001543623 2021-04-01 2021-04-15 0001543623 2020-06-01 2020-06-30 0001543623 2021-02-28 0001543623 2020-12-01 2020-12-26 0001543623 ucle:MayFiveMember 2022-05-01 2022-05-05 0001543623 ucle:MayFiveMember 2022-05-05 0001543623 ucle:MayFiveMember 2022-01-01 2022-12-31 0001543623 ucle:OctoberTenMember 2022-10-01 2022-10-10 0001543623 ucle:OctoberTenMember 2022-10-10 0001543623 ucle:OctoberTenMember 2022-01-01 2022-12-31 0001543623 ucle:MrGoldsteinMember 2022-12-31 0001543623 ucle:MrGoldsteinMember 2021-12-31 0001543623 us-gaap:LineOfCreditMember 2022-12-31 0001543623 srt:MinimumMember us-gaap:LineOfCreditMember 2022-12-31 0001543623 srt:MaximumMember us-gaap:LineOfCreditMember 2022-12-31 0001543623 srt:ScenarioForecastMember 2023-12-01 2023-12-31 0001543623 ucle:ConsultantsMember 2022-01-01 2022-12-31 0001543623 ucle:ConsultantsMember 2021-01-01 2021-12-31 0001543623 us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001543623 us-gaap:ConvertibleDebtMember 2021-12-31 0001543623 srt:MinimumMember 2022-01-01 2022-12-31 0001543623 srt:MaximumMember 2022-01-01 2022-12-31 0001543623 us-gaap:WarrantMember 2020-12-31 0001543623 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001543623 us-gaap:WarrantMember 2021-12-31 0001543623 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001543623 us-gaap:WarrantMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2022-01-01 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2021-01-01 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2022-01-01 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2021-01-01 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2022-01-01 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2021-01-01 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2021-12-31 0001543623 srt:NorthAmericaMember 2022-01-01 2022-12-31 0001543623 srt:NorthAmericaMember 2021-01-01 2021-12-31 0001543623 srt:AsiaMember 2022-01-01 2022-12-31 0001543623 srt:AsiaMember 2021-01-01 2021-12-31 0001543623 srt:SouthAmericaMember 2022-01-01 2022-12-31 0001543623 srt:SouthAmericaMember 2021-01-01 2021-12-31 0001543623 ucle:OtherMember 2022-01-01 2022-12-31 0001543623 ucle:OtherMember 2021-01-01 2021-12-31 0001543623 ucle:GoldTeamIncMember 2022-12-31 0001543623 ucle:GoldTeamIncMember 2021-12-31 0001543623 ucle:RichardLandryMember 2021-12-31 0001543623 us-gaap:SalesMember 2022-01-01 2022-12-31 0001543623 ucle:CustomersOneMember us-gaap:SalesMember 2022-01-01 2022-12-31 0001543623 ucle:CustomersTwoMember us-gaap:SalesMember 2022-01-01 2022-12-31 0001543623 us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001543623 ucle:CustomersOneMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001543623 ucle:CustomersTwoMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001543623 us-gaap:SalesMember 2021-01-01 2021-12-31 0001543623 ucle:CustomersOneMember us-gaap:SalesMember 2021-01-01 2021-12-31 0001543623 ucle:CustomersTwoMember us-gaap:SalesMember 2021-01-01 2021-12-31 0001543623 us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001543623 ucle:CustomersOneMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001543623 ucle:CustomersTwoMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001543623 us-gaap:SubsequentEventMember 2023-01-01 2023-01-09 0001543623 us-gaap:SubsequentEventMember 2023-01-09 0001543623 us-gaap:SubsequentEventMember 2023-01-01 2023-01-19 0001543623 us-gaap:SubsequentEventMember 2023-01-19 0001543623 us-gaap:SubsequentEventMember 2023-01-01 2023-01-23 0001543623 us-gaap:SubsequentEventMember 2023-01-23 0001543623 us-gaap:SubsequentEventMember 2023-02-01 2023-02-23 0001543623 us-gaap:SubsequentEventMember 2023-02-23 0001543623 us-gaap:SubsequentEventMember 2023-02-01 2023-02-24 0001543623 us-gaap:SubsequentEventMember 2023-02-24 0001543623 us-gaap:SubsequentEventMember 2023-03-01 2023-03-03 0001543623 us-gaap:SubsequentEventMember 2023-03-03 0001543623 us-gaap:SubsequentEventMember 2023-03-01 2023-03-14 0001543623 us-gaap:SubsequentEventMember 2023-03-14 0001543623 us-gaap:SubsequentEventMember 2023-03-01 2023-03-31 0001543623 us-gaap:SubsequentEventMember 2023-03-31 0001543623 srt:ScenarioForecastMember 2023-04-01 2023-04-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure
EX-4.2 2 f10k2022ex4-2_usnuclear.htm DESCRIPTION OF SECURITIES

Exhibit 4.2

 

Description of the Company’s Common Stock Registered

Under Section 12 of the Exchange Act of 1934

 

The following is a summary of the current material terms of our capital stock. Because it is only a summary, it does not contain all information that may be important to you. Therefore, you should read carefully the more detailed provisions of our certificate of incorporation and bylaws.

 

As of April 10, 2023, US Nuclear Corp has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) our Common Stock,

 

Description of Common Stock

 

The following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Articles of Incorporation (the “Articles of Incorporation”) and our Amended and Restated Bylaws (the “Bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part.

 

Authorized Capital Shares

 

Our authorized capital shares consist of 100,000,000 shares of common stock, $0.0001 par value per share (“Common Stock”). The outstanding shares of our Common Stock are fully paid and nonassessable.

 

Voting Rights

 

Holders of Common Stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors. Our Common Stock does not have cumulative voting rights.

 

Dividend Rights

 

Subject to the rights of holders of outstanding shares of Preferred Stock, if any, the holders of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Board of Directors in its discretion out of funds legally available for the payment of dividends.

 

Liquidation Rights

 

Subject to any preferential rights of outstanding shares of Preferred Stock, if any, holders of Common Stock will share ratably in all assets legally available for distribution to our stockholders in the event of dissolution.

 

Other Rights and Preferences

 

Our Common Stock has no sinking fund or redemption provisions or preemptive, conversion or exchange rights. Holders of Common Stock may act by unanimous written consent.

 

Listing

 

The Common Stock is traded on OTC:QB under the trading symbol “UCLE.”

 

The Company believes that the provisions described above apply to actions arising under the Securities Act and the Exchange Act. There is uncertainty as to whether a court would enforce such provisions, as Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

 

The foregoing summary is subject to the full text of our certificate of incorporation and bylaws.

 

EX-23.2 3 f10k2022ex23-2_usnuclear.htm CONSENT OF INDEPENDENT AUDITOR

Exhibit 23.2

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in our Registration Statement on Form S-1 (File No. 333-265999) of our audit report dated May 11, 2023, with respect to the consolidated balance sheets of US Nuclear Corp. and Subsidiaries as of December 31, 2022 and 2021, and the related consolidated statements of operations, changes in shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2022 and 2021. Our report relating to those financial statements includes an emphasis of matter paragraph regarding substantial doubt as to the Company’s ability to continue as a going concern.

 

We also consent to the reference to us under the heading “Experts” within the Registartion Statement.

 

 

Spokane, Washington

May 11, 2023

 

EX-31.1 4 f10k2022ex31-1_usnuclear.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(A)/15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 31.1

 

US Nuclear Corp.

OFFICER’S CERTIFICATE PURSUANT TO SECTION 302

  

I, Robert I. Goldstein, certify that:

  

1. I have reviewed this annual report on Form 10-K for the year ended December 31, 2022 (the “report”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 

 

Dated: May 11, 2023

 

By: /s/ Robert I. Goldstein  
  Robert I. Goldstein  
  President, Chief Executive Officer, Chairman  
  (Principal Executive Officer)  

 

 

 

EX-31.2 5 f10k2022ex31-2_usnuclear.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(A)/15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 31.2

 

US Nuclear Corp.

OFFICER’S CERTIFICATE PURSUANT TO SECTION 302

  

I, Richard Landry, certify that:

  

1. I have reviewed this annual report on Form 10-K for the year ended December 31, 2022 (the “report”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 

 

Dated: May 11, 2023

 

By: /s/ Richard Landry  
  Richard Landry  
  Chief Financial Officer  
  (Principal Executive Officer)  

 

 

 

EX-32.1 6 f10k2022ex32-1_usnuclear.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.1

 

US Nuclear Corp.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, 

AS ADOPTED PURSUANT TO SECTION 906 OF 

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of US Nuclear Corp. (the Registrant) on Form 10-K for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert I. Goldstein, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.  ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

  

(1)  The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

  

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

A signed original of this written statement required by Section 906 has been provided to Robert I. Goldstein and will be retained by US Nuclear Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Dated: May 11, 2023

 

By: /s/ Robert I. Goldstein  
  Robert I. Goldstein  
  President, Chief Executive Officer, Chairman  
  (Principal Executive Officer)  

 

 

 

EX-32.2 7 f10k2022ex32-2_usnuclear.htm CERTIFICATION PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(A)/15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.2

 

US Nuclear Corp.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, 

AS ADOPTED PURSUANT TO SECTION 906 OF 

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of US Nuclear Corp. (the Registrant) on Form 10-K for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Richard Landry, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.  ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

  

(1)  The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

  

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

A signed original of this written statement required by Section 906 has been provided to Richard Landry and will be retained by US Nuclear Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Dated: May 11, 2023

 

By: /s/ Richard Landry  
  Richard Landry  
  Chief Financial Officer  
  (Principal Executive Officer)  

 

 

 

GRAPHIC 8 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 9 image_002.jpg GRAPHIC begin 644 image_002.jpg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end GRAPHIC 10 ex23-2_001.jpg GRAPHIC begin 644 ex23-2_001.jpg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end GRAPHIC 11 ex23-2_002.jpg GRAPHIC begin 644 ex23-2_002.jpg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end EX-101.SCH 12 ucle-20221231.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Investments link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Note Payable to Shareholder link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Line of Credit link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Shareholders’ Equity link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Geographical Sales link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Concentrations link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Shareholders’ Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Geographical Sales (Tables) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Organization and Basis of Presentation (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Inventories (Details) - Schedule of inventory link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Investments (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Investments (Details) - Schedule of information regarding grapheton link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Notes Payable (Details) - Schedule of future maturities of notes payable link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Note Payable to Shareholder (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Line of Credit (Details) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Shareholders’ Equity (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Shareholders’ Equity (Details) - Schedule of activity related to warrants link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Shareholders’ Equity (Details) - Schedule of information about options outstanding and exercisable link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Segment Reporting (Details) - Schedule of company’s segment information link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Geographical Sales (Details) - Schedule of geographical distribution link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Income Taxes (Details) - Schedule of consolidated statements of income link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate to the federal statutory rate link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - Concentrations (Details) link:presentationLink link:definitionLink link:calculationLink 059 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 13 ucle-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 14 ucle-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 15 ucle-20221231_lab.xml XBRL LABEL FILE EX-101.PRE 16 ucle-20221231_pre.xml XBRL PRESENTATION FILE XML 17 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2022
May 10, 2023
Jun. 30, 2022
Document Information Line Items      
Entity Registrant Name US NUCLEAR CORP.    
Trading Symbol NA    
Document Type 10-K    
Current Fiscal Year End Date --12-31    
Entity Common Stock, Shares Outstanding   35,798,087  
Entity Public Float     $ 2,938,723
Amendment Flag false    
Entity Central Index Key 0001543623    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
ICFR Auditor Attestation Flag false    
Document Annual Report true    
Document Transition Report false    
Entity File Number 000-54617    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 45-4535739    
Entity Address, Address Line One 7051 Eton Avenue    
Entity Address, City or Town Canoga Park    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91303    
City Area Code (818)    
Local Phone Number 883-7043    
Title of 12(g) Security Common Stock, $0.0001 par value per share    
Entity Interactive Data Current Yes    
Auditor Firm ID 5525    
Auditor Name Fruci & Associates II, PLLC    
Auditor Location Spokane, Washington    
Security Exchange Name NONE    
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
CURRENT ASSETS    
Cash $ 126,109 $ 246,317
Accounts receivable, net 329,858 163,577
Inventories 2,024,664 1,792,312
Prepaid expenses and other current assets 26,370 44,026
TOTAL CURRENT ASSETS 2,507,001 2,246,232
Property and equipment, net 6,501 9,719
Investments 10,059 10,059
Acquisition deposit 15,000 15,000
Goodwill 570,176 570,176
TOTAL ASSETS 3,108,737 2,851,186
CURRENT LIABILITIES    
Accounts payable 100,398 91,859
Accounts payable - related party 280,000 128,500
Accrued liabilities 688,422 587,941
Accrued compensation - officers 695,000 590,000
Customer deposit 88,694 101,342
Notes payable 9,574 48,541
Convertible notes payable, net of debt discount 412,953
Note payable to shareholder 874,679 576,260
Line of credit 307,321 285,474
TOTAL CURRENT LIABILITIES 3,457,041 2,409,917
Note payable, net of current portion
TOTAL LIABILITIES 3,457,041 2,409,917
COMMITMENTS & CONTINGENCIES
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value; 100,000,000 shares authorized, 31,621,242 and 28,353,215 shares issued and outstanding 3,162 2,836
Common shares to be issued 39,000
Additional paid in capital 14,740,401 13,508,581
Accumulated deficit (15,130,867) (13,070,148)
TOTAL SHAREHOLDERS’ EQUITY (348,304) 441,269
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 3,108,737 $ 2,851,186
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 31,621,242 28,353,215
Common stock, shares outstanding 31,621,242 28,353,215
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Sales $ 2,091,366 $ 2,137,607
Cost of sales 1,303,298 760,955
Gross profit 788,068 1,376,652
Operating expenses    
Consulting expense 592,659
Professional fees 326,118 171,024
Officer compensation 170,000 372,978
Payroll and related expense 957,954 939,061
Selling, general and administrative expenses 830,027 663,119
Total operating expenses 2,284,099 2,738,841
Loss from operations (1,496,031) (1,362,189)
Other income (expense)    
Interest expense (63,912) (11,001)
Other income 2,950
Amortization of debt discount (482,852)
Gain on forgiveness of debt 329,018
Equity loss in investment (835,462)
Total other income (expense) (546,764) (514,495)
Loss before provision for income taxes (2,042,795) (1,876,684)
Provision for income taxes
Net loss (2,042,795) (1,876,684)
Deemed dividend for down-round provision in warrants (17,924) (52,861)
Net loss attributed to common stockholders $ (2,060,719) $ (1,929,545)
Weighted average shares outstanding - basic (in Shares) 29,504,433 27,375,508
Loss per share – basic (in Dollars per share) $ (0.07) $ (0.07)
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations (Parentheticals) - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Weighted average shares outstanding - diluted 29,504,433 27,375,508
Loss per share - diluted $ (0.03) $ (0.07)
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statement of Changes in Shareholders' Equity - USD ($)
Common Stock
Additional Paid in Capital
Accumulated Deficit
Common Shares to be Issued
Total
Balance at Dec. 31, 2020 $ 2,572 $ 11,985,191 $ (11,140,603)   $ 847,160
Balance (in Shares) at Dec. 31, 2020 25,724,844        
Issuance of common stock for services $ 126 737,262   737,388
Issuance of common stock for services (in Shares) 1,257,300        
Issuance of common stock for conversion of convertible debenture and accrued interest $ 25 99,975   100,000
Issuance of common stock for conversion of convertible debenture and accrued interest (in Shares) 250,000        
Issuance of common stock for investment $ 112 633,293   633,405
Issuance of common stock for investment (in Shares) 1,121,071        
Deemed dividend for down round provision in warrants 52,861 (52,861)  
Net loss (1,876,684)   (1,876,684)
Balance at Dec. 31, 2021 $ 2,835 13,508,582 (13,070,148)   441,269
Balance (in Shares) at Dec. 31, 2021 28,353,215        
Issuance of common stock for services $ 105 197,865   197,970
Issuance of common stock for services (in Shares) 1,043,027        
Issuance of common stock for loan incentive $ 62 99,957   100,019
Issuance of common stock for loan incentive (in Shares) 625,000        
Issuance of common stock for conversion of debt and accrued interest $ 160 259,840   260,000
Issuance of common stock for conversion of debt and accrued interest (in Shares) 1,600,000        
Debt discount on issuance of convertible debt 656,233   656,233
Deemed dividend for down round provision in warrants 17,924 (17,924)  
Common stock to be issued for services   39,000
Common stock to be issued for services (in Shares)       39,000  
Net loss (2,042,795)   (2,042,795)
Balance at Dec. 31, 2022 $ 3,162 $ 14,740,401 $ (15,130,867)   $ (348,304)
Balance (in Shares) at Dec. 31, 2022 31,621,242     39,000  
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
OPERATING ACTIVITIES    
Net loss $ (2,042,795) $ (1,876,684)
Depreciation and amortization 3,218 2,571
Bad debt expense 11,000
Issuance of common stock for services 267,246 673,617
Expenses paid directly by majority shareholder 87,410
Operating lease expense 55,079
Amortization of debt discounts 482,852
Forgiveness of PPP Loan (329,018)
Finance costs 8,750
Equity loss in investment 835,462
Write-down of investments
Accounts receivable (166,281) 80,625
Inventories (232,352) (474,625)
Prepaid expenses and other current assets (12,620)
Accounts payable 8,539 30,882
Accounts payable - related parties 151,500 128,500
Accrued liabilities 115,532 322,203
Accrued compensation - officers 105,000 160,000
Customer deposits (12,648) (92,969)
Operating lease liability (55,079)
Net cash used in operating activities (1,324,059) (441,026)
INVESTING ACTIVITIES    
Purchase of property and equipment (6,446)
Payment of acquisition deposit (15,000)
Cash paid for investment
Net cash used in investing activities (21,446)
FINANCING ACTIVITIES    
Net borrowings (repayments) under lines of credit 26,149 119,600
Proceeds from sale of common stock 100,000
Proceeds from notes payable 221,431
Repayments for notes payable (37,217) (4,546)
Proceeds from convertible notes payable 916,500
Proceeds from note payable to shareholder 304,633 608,010
Repayments for note payable to shareholder (6,214) (563,010)
Net cash provided by (used in) financing activities 1,203,851 481,485
NET INCREASE (DECREASE) IN CASH (120,208) 19,013
CASH    
Beginning of period 246,317 227,304
End of period 126,109 246,317
Supplemental disclosures of cash flow information    
Taxes paid
Interest paid 11,973 11,001
Non-Cash investing and financing activities    
Beneficial conversion feature on down-round provision 239,044
Common shares issued for future services 39,000 135,859
Deemed dividend on down round provision 17,924 52,861
Common stock issued for conversion of convertible debt and accrued interest 260,000
Original issue debt discount $ 751,026
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Basis of Presentation
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Organization and Basis of Presentation

Note 1 – Organization and Basis of Presentation

 

Organization and Line of Business

  

US Nuclear Corp., formerly known as APEX 3, Inc., (the “Company” or “US Nuclear”) was incorporated under the laws of the State of Delaware on February 14, 2012.

 

On May 31, 2016, the Company entered into an Asset Purchase Agreement with Electronic Control Concepts (“ECC”) whereby the Company purchased certain tangible and intangible assets of ECC.

 

The Company is engaged in developing, manufacturing and selling radiation detection and measuring equipment. The Company markets and sells its products to consumers throughout the world.

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company recorded a net loss of $2,042,795 for the year ended December 31, 2022 and had an accumulated deficit of $15,130,867 as of December 31, 2022, which raises substantial doubt about its ability to continue as a going concern. 

 

The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through some private placement offerings of debt and equity securities. These plans, if successful, will mitigate the factors which raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. 

XML 25 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

Principles of Consolidation 

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Cali From Above, LLC, and Optron and its wholly-owned subsidiary, Overhoff Technology Corporation (“Overhoff”), and its wholly-owned subsidiary, Electronic Control Concepts (“ECC”), have been prepared in conformity with accounting principles generally accepted in the United States of America. All significant intercompany transactions and balances have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash on hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. There were no cash equivalents as of December 31, 2022 and 2021.

 

Concentration of Credit Risk

 

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company places its cash with high quality financial institutions and at times may exceed the FDIC insurance limit. The Company has not and does not anticipate incurring any losses related to this credit risk. 

 

Accounts Receivable

 

The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves.  Reserves are recorded based on the Company’s historical collection history. Allowance for doubtful accounts as of December 31, 2022 and 2021 were $5,000 and $16,000, respectively.

 

Inventories

 

Inventories are valued at the lower of cost (determined primarily by the average cost method) or net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. As of December 31, 2022 and 2021, there was no allowance for slow moving or obsolete inventory. The Company periodically assessed its inventory for slow moving and/or obsolete items. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired.

 

Property and Equipment

 

Property and Equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:

 

Furniture and fixtures 5 years
Leasehold improvement Lesser of lease life or economic life
Equipment 5 years
Computers and software 5 years

 

Long-Lived Assets

 

The Company applies the provisions of Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at December 31, 2022 and 2021, the Company believes there was no impairment of its long-lived assets.

 

Goodwill

 

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. The entire goodwill balance in the accompanying financial statements resulted from the Company’s acquisition of Overhoff Technology Corporation in 2006. The Company complies with ASC 350, Goodwill and Other Indefinite Lived Intangible Assets, requiring that a test for impairment be performed at least annually. As of December 31, 2022 and 2021 the Company performed the required impairment analysis which resulted in no impairment adjustments. Although the Company experienced a significant decline in revenue due to the effects of COVID-19, management expects that it is more likely than not that its revenue and cost of goods sold will be more in-line with pre-COVID-19 levels in upcoming periods. Significant estimates used in the goodwill impairment analysis may change in the upcoming year if revenues do not rebound and cost of materials continue to increase.

 

Derivative Financial Instruments

 

The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. During the years ended December 31, 2022 and 2021, there were no derivative liabilities associated with our convertible notes payable.

 

Investments

 

The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, the Company measures the equity security at fair value as of the date that the observable transaction occurred (“the measurement alternative”) in accordance with ASC 321. The Company accounts for investments for which it owns 20% or more, but less than 50% on the equity method in accordance with ASC 323. 

 

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities, customer deposits, and line of credit, the carrying amounts approximate their fair values due to their short maturities. In addition, the Company has a note payable to shareholder that the carrying amount also approximates fair value.

 

Revenue Recognition

 

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on January 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from the sale of products to customers, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

 

Revenue from the product sales is recognized under Topic 606 in a manner that reasonably reflects the delivery of its products to customers in return for expected consideration and includes the following elements:

 

  executed contracts with the Company’s customers that it believes are legally enforceable;

 

  identification of performance obligations in the respective contract;

 

  determination of the transaction price for each performance obligation in the respective contract;

 

  allocation the transaction price to each performance obligation; and

 

  recognition of revenue only when the Company satisfies each performance obligation.

 

These five elements, as applied to each of the Company’s revenue category, is summarized below:

 

  Product sales - revenue is recognized when the Company performs its obligations under the contracts it has with its customers to deliver products at an agreed upon price and it is generally when the control of the product has been transferred to the customer.

 

Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits.

 

Sales returns and allowances was $0 and $0 for the years ended December 31, 2022 and 2021, respectively. The Company provides a one-year warranty on all sales. Warranty expense for the years ended December 31, 2022 and 2021 was insignificant. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.

 

See Notes 11 and 12 for disclosures of revenue disaggregated by geographical area and product line.

 

Customer Deposits

 

Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718,” Compensation – Stock Compensation.” FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

 

Basic and Diluted Earnings Per Share

 

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. As of December 31, 2022 and 2021 there were 2,500,000 and 333,333 warrants outstanding, respectively, to purchase shares of common stock. Basic and diluted earnings per share are the same during the years ended December 31, 2022 and 2021 due to the net loss incurred. As of December 31, 2022, the number of potentially dilutive shares issuable on our convertible notes and accrued interest was 6,430,544.

 

Segment Reporting

 

FASB ASC Topic 280, Segment Reporting, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments. See Note 11. 

 

Related Parties

 

The Company accounts for related party transactions in accordance with ASC 850, Related Party Disclosures. A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

 

Reclassifications

 

Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.

 

Recent Accounting Pronouncements    

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 was issued to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard represents significant changes to accounting for credit losses.  Full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope.  The current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold.  The expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts.  This ASU as amended by ASU 2019-10, is effective for fiscal years beginning after December 15, 2022.  The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures.

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes which amends ASC 740 Income Taxes (ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021.  The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted.  The adoption had no effect on the Company’s consolidated financial statements and related disclosures.

 

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 also removes certain conditions that should be considered in the derivatives scope exception evaluation under Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and clarify the scope and certain requirements under Subtopic 815-40. In addition, ASU 2020-06 improves the guidance related to the disclosures and earnings-per-share (EPS) for convertible instruments and contract in entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluation the impact this ASU will have on its consolidated financial statements.

XML 26 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories
12 Months Ended
Dec. 31, 2022
Inventories [Abstract]  
Inventories

Note 3 – Inventories

 

Inventory at December 31, 2022 and 2021 consisted of the following:

 

   2022   2021 
Raw materials  $1,244,880   $972,759 
Work in Progress   409,637    157,024 
Finished goods   370,127    662,529 
Total inventories  $2,024,664   $1,792,312 

 

At December 31, 2022 and 2021 the inventory reserve was $0.

XML 27 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment
12 Months Ended
Dec. 31, 2022
Property and Equipment [Abstract]  
Property and Equipment

Note 4 – Property and Equipment

 

The following are the details of property and equipment at December 31, 2022 and 2021:

 

   2022   2021 
Furniture and fixtures  $148,033   $148,033 
Leasehold Improvements   50,091    50,091 
Equipment   237,418    237,418 
Computers and software   39,482    39,482 
    475,024    475,024 
Less accumulated depreciation   (468,523)   (465,305)
Property and equipment, net  $6,501   $9,719 

 

Depreciation expense for the years ended December 31, 2022 and 2021 was $3,218 and $2,571, respectively. At December 31, 2022 and 2021, the Company had $440,628 of fully depreciated property and equipment that is still in use.

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Investments
12 Months Ended
Dec. 31, 2022
Investments [Abstract]  
Investments

Note 5 – Investments

 

MIFTEC

 

On August 3, 2018, the Company closed an agreement by and among, MIFTEC Laboratories, Inc. (“MIFTEC”), a licensee of Magneto-Inertial Fusion Technologies, Inc., (“MIFTI”), and the Company. MIFTEC is a licensee of MIFTI radionuclide technology. MIFTEC will engage the Company to manufacture equipment pursuant to MIFTEC’s specifications and designs and have the Company as a sales representative for the manufactured equipment. The Company will be the exclusive manufacturer and supplier to MIFTEC of equipment in North America and Asia. In addition, the Company received a 10% ownership interest in MIFTEC. The consideration for the exclusive manufacturing rights and a 10% ownership interest in MIFTEC was $500,000 and 300,000 shares of the Company’s common stock valued at $594,000. The fair value was determined based on the Company’s stock price on August 3, 2018. The Company recorded the value of the 10% interest in MIFTEC at $10,000 and recorded $1,084,000 as the acquisition of manufacturing and supply rights in the accompanying consolidated statement of operations during the year ended December 31, 2018. The Company evaluated this investment for impairment and determined that an impairment of $9,000 was necessary during the year ended December 31, 2019. The carrying value of this investment at December 31, 2022 and 2021 was $1,000 and $1,000, respectively.

 

MIFTI

 

In April 2019, the Company also entered into a Cooperative Agreement with MIFTI whereby the Company acquired certain exclusive manufacturing and supply rights, including thermonuclear fusion-powered reactor for production of electricity per MIFTI designs in return for $500,000, of which $100,000 is payable upon signing, $200,000 within four months of the agreement and $200,000 within nine months of the agreement. The $500,000 is an option to buy a 10% interest in MIFTI for $2,700,000, if completed with 24 months of the agreement date. If the option expires, MIFTI shall issue the Company 500,000 shares of common stock and rescind all other exclusive rights contained in the agreement. The option was rescinded and the Company received 500,000 shares of MIFTI common stock which represents an ownership of approximately 0.56% for its $500,000 investment. The Company evaluated this investment for impairment and determined that an impairment of $499,000 was necessary during the year ended December 31, 2019. The carrying value of this investment at December 31, 2022 and 2021 was $1,000 and $1,000, respectively.

 

Grapheton

 

On February 5, 2020, the Company entered into a Stock Purchase Agreement (“SPA”) with Grapheton, Inc., a California corporation (“Grapheton”). The transaction was closed on March 12, 2020. Grapheton is a start-up company that focuses on building energy storage devises, known as supercapacitors, from a new material system. The technology utilized by Grapheton has been proven to provide a compelling advantage in microelectrode arrays with superior electrical and electrochemical properties.

 

Pursuant to the terms of the SPA, the Corporation will acquire a total of 2,552 shares of Grapheton’s common stock over a two-year period. At closing, the Company was issued at total of 1,452 shares of Grapheton’s common stock for $235,000 and 858,896 shares of the Company’s common stock valued at $601,227.

 

In connection with the SPA, during the second quarter of 2021 the Company received an additional 1,100 shares of Grapheton’s common stock in exchange for the Company’s issuing an additional 1,121,071 shares of common stock valued at $633,405. In addition, Grapheton fulfilled its requirements under the earn out provision and the Company is obligated to make the first earn out payment of $192,500. This amount is recorded as accrued expense in the accompanying consolidated balance sheet.

 

An additional “true up” issuance of the Company’s common stock to Grapheton may be made on the second anniversary of the closing of the SPA, based on the valuation of the Company’s common stock on that date by a third-party valuator.

 

The Company currently owns 35.8% of Grapheton and accounts for its investment in Grapheton using the equity method of accounting is in accordance with ASC 323.

 

Information regarding Grapheton as of and for the year ended December 31, 2022 is below:

 

Current assets  $17,396 
Total assets   25,691 
Current liabilities   593,333 
Total liabilities   593,333 
Total stockholders’ equity   (567,642)
      
Revenue  $- 
Operating expenses   (760,257)
Other expenses   (246,154)
Net loss   (1,006,411)

 

The Company evaluated this investment and recorded a loss attributed to equity investment of $0 during the year ended December 31, 2022. The carrying value of this investment at December 31, 2022 was $8,059. 

XML 29 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Notes Payable
12 Months Ended
Dec. 31, 2022
Notes Payable [Abstract]  
Notes Payable

Note 6 – Notes Payable

 

In connection with the acquisition of assets from ECC the Company issued a note payable to the owner of ECC. The note accrued interest at 5% per annum, requires quarterly principal and interest payments of $4,518 and is due on April 15, 2021. At December 31, 2022 and 2021, the amount outstanding under this note payable was $5,272 and $5,272, respectively.   The Company was in default on payment of the note payable as of December 31, 2022. The Company has communicated with the debt holder, and the amount is considered payable on demand as of December 31, 2022.

 

In June 2020 the Company received a loan under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act for $107,587.  The loan has terms of 24 months and accrues interest at 1% per annum. In February of 2021, the Company received two additional loans totaling $221,431 under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. As of December 31, 2021, the Company has had these loans forgiven in the amount of $329,018 as provided by the CARES Act. 

 

On December 26, 2020, a line of credit held by the company had matured, and based on the terms of the line of credit agreement was converted to a note payable upon demand. The obligation accrues interest at the rate of $10.89 per day until the bank receives full payment. As of December 31, 2022, the balance owed by the Company was $4,302.

 

On May 5, 2022, the Company received a loan in connection with the issuance of stock warrants in the amount of $750,000. The loan has terms of 12 months and accrues interest at 5% per annum. As part of the issuance of the loan, the company identified debt discounts related to the warrants issued, the incentive shares issued as discussed at Note 10, the beneficial conversion feature of the debt, and the expenses paid as part of the issuance. The total debt discounts recorded as of the date of the note was $550,538. At December 31, 2022 and pursuant to the down-round provision of the note and associated warrants, the Company reevaluated the beneficial conversion feature which resulted in additional debt discount recorded of $183,422.

 

On October 10, 2022, the Company received a loan in connection with the issuance of stock warrants in the amount of $375,000. The loan has terms of 12 months and accrues interest at 5% per annum. As part of the issuance of the loan, the company identified debt discounts related to the warrants issued, the beneficial conversion feature of the debt, and the expenses paid as part of the issuance. The total debt discounts recorded as of the date of the note was $200,488. At December 31, 2022 and pursuant to the down-round provision of the note and associated warrants, the Company reevaluated the beneficial conversion feature recorded which resulted in additional debt discount recorded of $30,304.

 

The total debt discount amortization recorded on the Company’s notes for the twelve months ended December 31, 2022 was $482,852.

 

Future maturities of all notes payable as of December 31, 2022, are as follows: 

 

Years Ending December 31,    
2023   904,427 
2024   
-
 
2025   
-
 
2026   
-
 
2027   
-
 
Thereafter   
-
 
   $904,427 
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Note Payable to Shareholder
12 Months Ended
Dec. 31, 2022
Note Payable to Shareholder [Abstract]  
Note Payable to Shareholder

Note 7 – Note Payable to Shareholder

 

Robert Goldstein, the CEO and majority shareholder, has loaned funds to the Company from time to time to cover general operating expenses. These loans are evidenced by unsecured, non-interest-bearing demand notes payable. During the year ended December 31, 2021, the Company’s majority shareholder paid expenses on behalf of the Company of $87,410 and loaned an additional $45,000 to the Company. During the year ended December 31, 2022, the Company’s majority shareholder loaned an additional $304,633 to the Company and was repaid $6,214.  The amounts due to Mr. Goldstein are $874,679 and $576,260 as of December 31, 2022 and 2021, respectively

XML 31 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Line of Credit
12 Months Ended
Dec. 31, 2022
Line of Credit [Abstract]  
Line of Credit

Note 8 – Line of Credit 

 

As of December 31, 2022, the Company had four lines of credit with a maximum borrowing amount of $400,000 with interest ranging from 5.5% to 11.5%. As of December 31, 2022 and 2021, the amounts outstanding under these lines of credit were $307,321 and $285,474, respectively.

XML 32 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Leases

Note 9 – Leases

 

The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate which is based on the interest rate of similar debt outstanding.

 

The Company leases its current facilities from Gold Team Inc., a company owned by the Company’s CEO, which owns both the Canoga Park, CA and Milford, Ohio locations. The leases expired on April 30, 2020 and the Company exercised its renewal option for an additional 12 months. The new lease is not more than 12 months; therefore, the disclosures under ASC 842 are not required. Future minimum lease payments under this agreement for the twelve months ending December 31, 2023 is $168,000. Effective January 1, 2019, the Company adopted the provision of ASC 842 Leases.

 

The lease expense for the years ended December 31, 2022 and 2021 was $168,000 and $168,000, respectively. The cash paid under operating leases during the years ended December 31, 2022 and 2021 was $16,500 and $42,000, respectively. At December 31, 2022, $280,000 has been accrued and is shown on the balance sheet as accounts payable- related party. At December 31, 2022, the weighted average remaining lease terms were 0.3 years and the weighted average discount rate was 8%.

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders’ Equity
12 Months Ended
Dec. 31, 2022
Shareholders’ Equity [Abstract]  
Shareholders’ Equity

Note 10 – Shareholders’ Equity

 

Common stock

 

During the year ended December 31, 2022, the Company issued:

 

  625,000 shares of common stock valued at $100,019 in relation to the debt that was obtained;

 

  1,600,000 shares of common stock valued at $260,000 in satisfaction of convertible debt and interest;
     
  1,043,027 shares of common stock to consultants for services rendered valued at $236,970; of which $39,000 is recorded as shares to be issued. Pursuant to ASC 718 the company has allocated a portion of stock-based compensation to prepaid expenses until the services are provided to the Company. The amount allocated to prepaid expense at December 31, 2022 is $9,750. The fair value was determined based on the Company’s stock price on the grant date.

 

During the year ended December 31, 2021, the Company issued:

 

  1,252,300 shares of common stock to consultants for services rendered valued at $737,738. The fair value was determined based on the Company’s stock price on the grant date;

 

  250,000 shares of common stock for cash; and

 

  1,121,071 shares of common stock for an investment in Grapheton valued at $633,405. The fair value was determined based on the Company’s stock price on the grant date.

 

Warrants

 

The following table summarizes the activity related to warrants:

 

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Warrants   Exercise   Contractual   Intrinsic 
   Outstanding   Price   Life   Value 
Outstanding, December 31, 2020   333,333   $0.40    1.50   $
      -
 
Granted   
-
                
Forfeited   
-
                
Exercised   
-
                
Outstanding, December 31, 2021   333,333   $0.36    0.90   $
-
 
Granted   2,500,000   $0.14    3.00   $
-
 
Forfeited   (333,333)               
Exercised   
-
                
Outstanding, December 31, 2022   2,500,000   $0.14    2.56   $
-
 
Exercisable, December 31, 2022   2,500,000   $0.14    2.56   $
-
 

 

The above warrants contain a down round provision that requires the exercise price to be adjusted if the Company sells shares of common stock below the current exercise price. During the twelve months ended December 31, 2022, the Company issued shares of common stock for $0.14 therefore, the exercise price of these warrants was adjusted from $0.75 and $0.475 to $0.14 pursuant to the down-round provision in the warrant agreement.  The change in fair value between the value of the warrants using the new exercise price versus the old exercise price was calculated to be $17,924. This amount is recorded as a deemed dividend in the accompanying consolidated financial statements during the year ended December 31, 2022.

 

The following table summarizes information about options outstanding and exercisable as of December 31, 2022

 

Outstanding and Exercisable 
Number of Warrants   Exercise Price 
 2,500,000   $0.14 
 2,500,000      
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Segment Reporting

Note 11 – Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has two reportable segments: Optron and Overhoff. Optron is located in Canoga Park, California and Overhoff is located in Milford, Ohio. The assets and operations of the Company’s recent acquisition of the assets of Electronic Control Concepts are included with Overhoff in the table below. The assets and operations of the Company’s newest subsidiary, Cali From Above are included with Optron in the table below.

 

The following tables summarize the Company’s segment information for the years ended December 31, 2022 and 2021:

 

   Years Ended
December 31,
 
   2022   2021 
Sales        
Optron  $220,368   $482,582 
Overhoff   1,870,998    1,655,025 
Corporate   
-
    
-
 
   $2,091,366   $2,137,607 
           
Gross profit          
Optron  $(547,531)  $101,447 
Overhoff   1,335,599    1,275,205 
Corporate   
-
    
-
 
   $788,068   $1,376,652 
           
Income (loss) from operations          
Optron  $(1,484,631)  $(799,837)
Overhoff   486,382    264,763 
Corporate   (497,782)   (1,757,739)
   $(1,496,031)  $(1,876,684)
Interest Expenses          
Optron  $21,725   $10,076 
Overhoff   6,545    
-
 
Corporate   35,643    925 
   $63,912   $11,001 
           
Net income (loss)          
Optron  $(1,506,356)  $(799,837)
Overhoff   479,837    680,892 
Corporate   (1,016,275)   (1,763,901)
   $(2,042,794)  $(1,882,846)

 

   As of December 31, 
   2022   2021 
Total Assets        
Optron  $1,021,817   $1,027,669 
Overhoff   2,037,988    1,754,485 
Corporate   48,932    69,032 
   $3,108,737   $2,851,186 
           
Goodwill          
Optron  $
-
   $
-
 
Overhoff   570,176    570,176 
Corporate   
-
    
-
 
   $570,176   $570,176 
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Geographical Sales
12 Months Ended
Dec. 31, 2022
Geographical Sales [Abstract]  
Geographical Sales

Note 12 – Geographical Sales  

 

The geographical distribution of the Company’s sales for the years ended December 31, 2022 and 2021 is as follows:

 

   2022   2021 
Geographical sales        
North America  $1,535,671   $1,522,412 
Asia   523,434    473,157 
South America   5,475    4,932 
Other   26,786    137,106 
   $2,091,366   $2,137,607 
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 13 – Income Taxes  

 

At December 31, 2022 and 2021, the significant components of the deferred tax assets are summarized below:

 

   2022   2021 
         
Approximate net operating loss carry forwards  $12,649,000   $10,605,000 
           
Deferred tax assets:          
Federal net operating loss  $2,031,310   $1,602,310 
State net operating loss   846,270    723,270 
Tax credit   49,740    49,740 
Goodwill   (148,373)   (148,373)
Total deferred tax assets   2,778,947    2,226,947 
Less valuation allowance   (2,778,947)   (2,226,947)
   $
-
   $
-
 

 

The valuation allowance increased by $552,000 and $526,103 in 2022 and 2021, respectively, due to the Company generating additional net operating losses. The Company’s remaining tax credit carryforwards of $49,740 begin to expire in 2027 and its net operating loss carryforward of approximately $12,649,000 begin to expire in 2027.

 

Income tax expense reflected in the consolidated statements of income consist of the following for 2022 and 2021:

 

   2022   2021 
Current          
Federal  $     -   $     - 
State   -    - 
    -    - 
Deferred          
Federal   -    - 
State   -    - 
    -    - 
Income tax expense  $-   $- 

 

The reconciliation of the effective income tax rate to the federal statutory rate for the years ended December 31, 2022 and 2021 is as follows:

 

   2022   2021 
         
Federal income tax rate   21.0%   21.0%
State tax, net of federal benefit   6.0%   6.0%
Net operating losses   -16.7%   -16.7%
Permanent differences   -10.6%   -10.6%
Amortization of goodwill   0.3%   0.3%
Effective income tax rate   0.0%   0.0%

 

The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2019.

 

The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carryforward periods available to the Company for tax reporting purposes, and other relevant factors.

 

Future changes in the unrecognized tax benefit will have no impact on the effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change significantly within the next twelve months. The Company will continue to classify income tax penalties and interest as part of general and administrative expense in its consolidated statements of operations. There were no interest or penalties accrued as of December 31, 2022 and 2021.

XML 37 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

Note 14 – Related Party Transactions  

 

The Company leases its current facilities from Gold Team Inc., a company owned by the Company’s CEO, which owns both the Canoga Park, CA and Milford, Ohio locations. Rent expense for the year ended December 31, 2022 and 2021 were $168,000 and $168,000, respectively. As of December 31, 2022 and 2021, the payable to Gold Team Inc. in connection with the above leases was to $280,000 and $128,500, respectively. (See Note 9).

 

As of December 31, 2022 and 2021, the Company had accrued compensation payable to its majority shareholder of $695,000 and $590,000, respectively.

 

During the year ended, December 31, 2021, the company issued 242,823 shares of common stock to Richard Landry in connection with the consulting services agreement entered by and between US Nuclear Corp and Richard Landry.

 

Also see Note 7. 

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Concentrations
12 Months Ended
Dec. 31, 2022
Concentrations [Abstract]  
Concentrations

Note 15 – Concentrations  

 

For the year ended December 31, 2022, two customers accounted for more than 10% of the Company sales, 42.3% and 13.61%, respectively. At December 31, 2022 two customers accounted for more than 10% of the accounts receivable balance, 55.5% and 28.4%, respectively.

 

For the year ended December 31, 2021, two customers accounted for more than 10% of the Company sales, 30.7% and 15.2%, respectively. At December 31, 2021 two customers accounted for more than 10% of the accounts receivable balance, 23.9% and 15%, respectively.

 

No vendors accounted for more than 10% of the Company’s purchases for the years ended December 31, 2022 and 2021.

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 16 – Subsequent Events

 

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were available to be issued and has determined that no material subsequent events exist other than the following:

 

On January 9, 2023, the Company issued 100,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which is $11,100 or $0.111 per share.

 

On January 19, 2023, the Company issued 400,000 shares in satisfaction of principle, accrued interest, and fees on convertible debt. The value of the shares issued was $60,000 or $0.15 per share.

 

On January 23, the Company issued an aggregate of 260,000 shares to consultants as compensation for investor relations services. The shares were valued at their fair value on the date of grant, which was $37,960 or $0.146 per share.

 

On February 23, the Company issued 400,000 shares in satisfaction of principle, accrued interest, and fees on convertible debt. The value of the shares issued was $60,000 or $0.15 per share.

 

On February 24, the Company issued 200,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which was $29,200 or $0.146 per share.

 

Effective March 3, 2023, the Company entered into a Membership Unit Purchase Agreement whereby the Company transferred, assigned, and conveyed the capital account of its wholly-owned subsidiary Cali From Above, in exchange for 65,000,000 shares of INNOVATION NATION, INC., a Nevada Corporation, owned and held by Robert Goldstein. As a result, the Company has divested itself of its ownership of Cali From Above and the Company now holds a 26% interest in Innovation Nation, an OTC reporting company under the symbol (OTC:AVRI).

 

On March 14, 2023, the Company issued an aggregate of 1,500,000 shares of common stock to our Board members. The shares were valued at their fair value on the date of grant, which was $175,500 or $0.117 per share.

 

On March 31, 2023, the Company issued 75,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which was $8,550 or $0.114 per share.

 

On April 11, 2023, the Company issued 771,845 shares of common stock, by cashless exercise, pursuant to a Warrant Agreement associated with a convertible note payable entered into on May 5, 2022.

XML 40 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Accounting Policies, by Policy (Policies)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation 

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Cali From Above, LLC, and Optron and its wholly-owned subsidiary, Overhoff Technology Corporation (“Overhoff”), and its wholly-owned subsidiary, Electronic Control Concepts (“ECC”), have been prepared in conformity with accounting principles generally accepted in the United States of America. All significant intercompany transactions and balances have been eliminated.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents include cash on hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. There were no cash equivalents as of December 31, 2022 and 2021.

 

Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company places its cash with high quality financial institutions and at times may exceed the FDIC insurance limit. The Company has not and does not anticipate incurring any losses related to this credit risk. 

 

Accounts Receivable

Accounts Receivable

 

The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves.  Reserves are recorded based on the Company’s historical collection history. Allowance for doubtful accounts as of December 31, 2022 and 2021 were $5,000 and $16,000, respectively.

 

Inventories

Inventories

 

Inventories are valued at the lower of cost (determined primarily by the average cost method) or net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. As of December 31, 2022 and 2021, there was no allowance for slow moving or obsolete inventory. The Company periodically assessed its inventory for slow moving and/or obsolete items. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired.

 

Property and Equipment

Property and Equipment

 

Property and Equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:

 

Furniture and fixtures 5 years
Leasehold improvement Lesser of lease life or economic life
Equipment 5 years
Computers and software 5 years

 

Long-Lived Assets

Long-Lived Assets

 

The Company applies the provisions of Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at December 31, 2022 and 2021, the Company believes there was no impairment of its long-lived assets.

 

Goodwill

Goodwill

 

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. The entire goodwill balance in the accompanying financial statements resulted from the Company’s acquisition of Overhoff Technology Corporation in 2006. The Company complies with ASC 350, Goodwill and Other Indefinite Lived Intangible Assets, requiring that a test for impairment be performed at least annually. As of December 31, 2022 and 2021 the Company performed the required impairment analysis which resulted in no impairment adjustments. Although the Company experienced a significant decline in revenue due to the effects of COVID-19, management expects that it is more likely than not that its revenue and cost of goods sold will be more in-line with pre-COVID-19 levels in upcoming periods. Significant estimates used in the goodwill impairment analysis may change in the upcoming year if revenues do not rebound and cost of materials continue to increase.

 

Derivative Financial Instruments

Derivative Financial Instruments

 

The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. During the years ended December 31, 2022 and 2021, there were no derivative liabilities associated with our convertible notes payable.

 

Investments

Investments

 

The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, the Company measures the equity security at fair value as of the date that the observable transaction occurred (“the measurement alternative”) in accordance with ASC 321. The Company accounts for investments for which it owns 20% or more, but less than 50% on the equity method in accordance with ASC 323. 

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities, customer deposits, and line of credit, the carrying amounts approximate their fair values due to their short maturities. In addition, the Company has a note payable to shareholder that the carrying amount also approximates fair value.

 

Revenue Recognition

Revenue Recognition

 

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on January 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from the sale of products to customers, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

 

Revenue from the product sales is recognized under Topic 606 in a manner that reasonably reflects the delivery of its products to customers in return for expected consideration and includes the following elements:

 

  executed contracts with the Company’s customers that it believes are legally enforceable;

 

  identification of performance obligations in the respective contract;

 

  determination of the transaction price for each performance obligation in the respective contract;

 

  allocation the transaction price to each performance obligation; and

 

  recognition of revenue only when the Company satisfies each performance obligation.

 

These five elements, as applied to each of the Company’s revenue category, is summarized below:

 

  Product sales - revenue is recognized when the Company performs its obligations under the contracts it has with its customers to deliver products at an agreed upon price and it is generally when the control of the product has been transferred to the customer.

 

Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits.

 

Sales returns and allowances was $0 and $0 for the years ended December 31, 2022 and 2021, respectively. The Company provides a one-year warranty on all sales. Warranty expense for the years ended December 31, 2022 and 2021 was insignificant. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.

 

See Notes 11 and 12 for disclosures of revenue disaggregated by geographical area and product line.

 

Customer Deposits

Customer Deposits

 

Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped.

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.

 

Stock-Based Compensation

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718,” Compensation – Stock Compensation.” FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

 

Basic and Diluted Earnings Per Share

Basic and Diluted Earnings Per Share

 

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. As of December 31, 2022 and 2021 there were 2,500,000 and 333,333 warrants outstanding, respectively, to purchase shares of common stock. Basic and diluted earnings per share are the same during the years ended December 31, 2022 and 2021 due to the net loss incurred. As of December 31, 2022, the number of potentially dilutive shares issuable on our convertible notes and accrued interest was 6,430,544.

 

Segment Reporting

Segment Reporting

 

FASB ASC Topic 280, Segment Reporting, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments. See Note 11. 

 

Related Parties

Related Parties

 

The Company accounts for related party transactions in accordance with ASC 850, Related Party Disclosures. A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

 

Reclassifications

Reclassifications

 

Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements    

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 was issued to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard represents significant changes to accounting for credit losses.  Full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope.  The current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold.  The expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts.  This ASU as amended by ASU 2019-10, is effective for fiscal years beginning after December 15, 2022.  The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures.

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes which amends ASC 740 Income Taxes (ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021.  The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted.  The adoption had no effect on the Company’s consolidated financial statements and related disclosures.

 

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 also removes certain conditions that should be considered in the derivatives scope exception evaluation under Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and clarify the scope and certain requirements under Subtopic 815-40. In addition, ASU 2020-06 improves the guidance related to the disclosures and earnings-per-share (EPS) for convertible instruments and contract in entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluation the impact this ASU will have on its consolidated financial statements.

XML 41 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of estimated useful lives of property and equipment
Furniture and fixtures 5 years
Leasehold improvement Lesser of lease life or economic life
Equipment 5 years
Computers and software 5 years

 

XML 42 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Tables)
12 Months Ended
Dec. 31, 2022
Inventories [Abstract]  
Schedule of inventory
   2022   2021 
Raw materials  $1,244,880   $972,759 
Work in Progress   409,637    157,024 
Finished goods   370,127    662,529 
Total inventories  $2,024,664   $1,792,312 

 

XML 43 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2022
Property and Equipment [Abstract]  
Schedule of property and equipment
   2022   2021 
Furniture and fixtures  $148,033   $148,033 
Leasehold Improvements   50,091    50,091 
Equipment   237,418    237,418 
Computers and software   39,482    39,482 
    475,024    475,024 
Less accumulated depreciation   (468,523)   (465,305)
Property and equipment, net  $6,501   $9,719 

 

XML 44 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Investments (Tables)
12 Months Ended
Dec. 31, 2022
Investments [Abstract]  
Schedule of information regarding grapheton
Current assets  $17,396 
Total assets   25,691 
Current liabilities   593,333 
Total liabilities   593,333 
Total stockholders’ equity   (567,642)
      
Revenue  $- 
Operating expenses   (760,257)
Other expenses   (246,154)
Net loss   (1,006,411)

 

XML 45 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Notes Payable (Tables)
12 Months Ended
Dec. 31, 2022
Notes Payable [Abstract]  
Schedule of future maturities of notes payable
Years Ending December 31,    
2023   904,427 
2024   
-
 
2025   
-
 
2026   
-
 
2027   
-
 
Thereafter   
-
 
   $904,427 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders’ Equity (Tables)
12 Months Ended
Dec. 31, 2022
Shareholders’ Equity [Abstract]  
Schedule of activity related to warrants
           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Warrants   Exercise   Contractual   Intrinsic 
   Outstanding   Price   Life   Value 
Outstanding, December 31, 2020   333,333   $0.40    1.50   $
      -
 
Granted   
-
                
Forfeited   
-
                
Exercised   
-
                
Outstanding, December 31, 2021   333,333   $0.36    0.90   $
-
 
Granted   2,500,000   $0.14    3.00   $
-
 
Forfeited   (333,333)               
Exercised   
-
                
Outstanding, December 31, 2022   2,500,000   $0.14    2.56   $
-
 
Exercisable, December 31, 2022   2,500,000   $0.14    2.56   $
-
 

 

Schedule of information about options outstanding and exercisable
Outstanding and Exercisable 
Number of Warrants   Exercise Price 
 2,500,000   $0.14 
 2,500,000      
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Schedule of company’s segment information
   Years Ended
December 31,
 
   2022   2021 
Sales        
Optron  $220,368   $482,582 
Overhoff   1,870,998    1,655,025 
Corporate   
-
    
-
 
   $2,091,366   $2,137,607 
           
Gross profit          
Optron  $(547,531)  $101,447 
Overhoff   1,335,599    1,275,205 
Corporate   
-
    
-
 
   $788,068   $1,376,652 
           
Income (loss) from operations          
Optron  $(1,484,631)  $(799,837)
Overhoff   486,382    264,763 
Corporate   (497,782)   (1,757,739)
   $(1,496,031)  $(1,876,684)
Interest Expenses          
Optron  $21,725   $10,076 
Overhoff   6,545    
-
 
Corporate   35,643    925 
   $63,912   $11,001 
           
Net income (loss)          
Optron  $(1,506,356)  $(799,837)
Overhoff   479,837    680,892 
Corporate   (1,016,275)   (1,763,901)
   $(2,042,794)  $(1,882,846)

 

   As of December 31, 
   2022   2021 
Total Assets        
Optron  $1,021,817   $1,027,669 
Overhoff   2,037,988    1,754,485 
Corporate   48,932    69,032 
   $3,108,737   $2,851,186 
           
Goodwill          
Optron  $
-
   $
-
 
Overhoff   570,176    570,176 
Corporate   
-
    
-
 
   $570,176   $570,176 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Geographical Sales (Tables)
12 Months Ended
Dec. 31, 2022
Geographical Sales [Abstract]  
Schedule of geographical distribution
   2022   2021 
Geographical sales        
North America  $1,535,671   $1,522,412 
Asia   523,434    473,157 
South America   5,475    4,932 
Other   26,786    137,106 
   $2,091,366   $2,137,607 
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of deferred tax assets
   2022   2021 
         
Approximate net operating loss carry forwards  $12,649,000   $10,605,000 
           
Deferred tax assets:          
Federal net operating loss  $2,031,310   $1,602,310 
State net operating loss   846,270    723,270 
Tax credit   49,740    49,740 
Goodwill   (148,373)   (148,373)
Total deferred tax assets   2,778,947    2,226,947 
Less valuation allowance   (2,778,947)   (2,226,947)
   $
-
   $
-
 

 

Schedule of consolidated statements of income
   2022   2021 
Current          
Federal  $     -   $     - 
State   -    - 
    -    - 
Deferred          
Federal   -    - 
State   -    - 
    -    - 
Income tax expense  $-   $- 

 

Schedule of effective income tax rate to the federal statutory rate
   2022   2021 
         
Federal income tax rate   21.0%   21.0%
State tax, net of federal benefit   6.0%   6.0%
Net operating losses   -16.7%   -16.7%
Permanent differences   -10.6%   -10.6%
Amortization of goodwill   0.3%   0.3%
Effective income tax rate   0.0%   0.0%

 

XML 50 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Basis of Presentation (Details)
12 Months Ended
Dec. 31, 2022
USD ($)
Accounting Policies [Abstract]  
Net loss $ 2,042,795
Accumulated deficit $ 15,130,867
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Allowance for doubtful accounts $ 5,000 $ 16,000
Investments percentage 20.00%  
Equity method percentage 50.00%  
Sales returns and allowances $ 0 $ 0
Tax benefit, percentage 50.00%  
Warrants outstanding (in Shares) 2,500,000 333,333
Convertible notes $ 6,430,544  
Number of reportable segments 2  
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment
12 Months Ended
Dec. 31, 2022
Furniture and fixtures [Member]  
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment [Line Items]  
Property and equipment 5 years
Leasehold improvement [Member]  
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment [Line Items]  
Property and equipment Lesser of lease life or economic life
Equipment [Member]  
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment [Line Items]  
Property and equipment 5 years
Computers and software [Member]  
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment [Line Items]  
Property and equipment 5 years
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Inventory reserve $ 0 $ 0
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Details) - Schedule of inventory - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Schedule of inventories [Abstract]    
Raw materials $ 1,244,880 $ 972,759
Work in Progress 409,637 157,024
Finished goods 370,127 662,529
Total inventories $ 2,024,664 $ 1,792,312
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 3,218 $ 2,571
Depreciated property and equipment $ 440,628 $ 440,628
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Property and Equipment (Details) - Schedule of property and equipment - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 475,024 $ 475,024
Less accumulated depreciation (468,523) (465,305)
Property and equipment, net 6,501 9,719
Furniture and fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 148,033 148,033
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 50,091 50,091
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 237,418 237,418
Computers and software [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 39,482 $ 39,482
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Investments (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 03, 2018
Apr. 30, 2019
Jun. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2019
Dec. 31, 2018
Investments (Details) [Line Items]              
Ownership interest 10.00%            
Investment amount   $ 500,000          
Shares of common stock (in Shares)   500,000   858,896      
Carrying value of investment       $ 8,059      
Ownership interest in MIFTEC   0.56%          
Grapheton’s common stock (in Shares)       2,552      
Shares issued (in Shares)       1,452      
Common stock value       $ 601,227      
Exchange for common stock, shares (in Shares)     1,100        
Out payment     $ 192,500        
Ownership, percentage       35.80%      
Equity investment amount       $ 0      
Common Stock [Member]              
Investments (Details) [Line Items]              
Shares of common stock       235,000      
MIFTEC [Member]              
Investments (Details) [Line Items]              
Investment amount $ 500,000            
Shares of common stock (in Shares) 300,000            
Common stock value $ 594,000            
Interest rate             10.00%
Interest in MIFTEC             $ 10,000
Acquisition of manufacturing and supply right             $ 1,084,000
Investment for impairment           $ 9,000  
Carrying value of investment       1,000 $ 1,000    
MIFTEC [Member] | Ownership Interest [Member]              
Investments (Details) [Line Items]              
Ownership interest 10.00%            
MIFTI [Member]              
Investments (Details) [Line Items]              
Investment for impairment           $ 499,000  
Carrying value of investment       $ 1,000 $ 1,000    
Investment, description   In April 2019, the Company also entered into a Cooperative Agreement with MIFTI whereby the Company acquired certain exclusive manufacturing and supply rights, including thermonuclear fusion-powered reactor for production of electricity per MIFTI designs in return for $500,000, of which $100,000 is payable upon signing, $200,000 within four months of the agreement and $200,000 within nine months of the agreement. The $500,000 is an option to buy a 10% interest in MIFTI for $2,700,000, if completed with 24 months of the agreement date. If the option expires, MIFTI shall issue the Company 500,000 shares of common stock and rescind all other exclusive rights contained in the agreement.          
Grapheton, Inc [Member]              
Investments (Details) [Line Items]              
Exchange for common stock, shares (in Shares)     1,121,071        
Common stock value     $ 633,405        
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Investments (Details) - Schedule of information regarding grapheton - Grapheton [Member]
12 Months Ended
Dec. 31, 2022
USD ($)
Investments (Details) - Schedule of information regarding grapheton [Line Items]  
Current assets $ 17,396
Total assets 25,691
Current liabilities 593,333
Total liabilities 593,333
Total stockholders’ equity (567,642)
Revenue
Operating expenses (760,257)
Other expenses (246,154)
Net loss $ (1,006,411)
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Notes Payable (Details) - USD ($)
1 Months Ended 12 Months Ended
Oct. 10, 2022
May 05, 2022
Apr. 15, 2021
Dec. 26, 2020
Jun. 30, 2020
Dec. 31, 2022
Dec. 31, 2021
Feb. 28, 2021
Notes Payable (Details) [Line Items]                
Interest rate     5.00%     1.00%    
Principal and interest payments     $ 4,518          
Outstanding notes payable           $ 5,272 $ 5,272  
Loan amount         $ 107,587      
Total of additional loans             $ 329,018 $ 221,431
Accrues interest rate       $ 10.89        
Balance amount owed           4,302    
Debt discounts           482,852    
May 5, 2022 [Member]                
Notes Payable (Details) [Line Items]                
Interest rate   5.00%            
Issuance stock warrants   $ 750,000            
Debt discounts   $ 550,538            
Additional debt discount           183,422    
October 10, 2022 [Member]                
Notes Payable (Details) [Line Items]                
Interest rate 5.00%              
Additional debt discount           $ 30,304    
Stock warrants amount $ 375,000              
Total debt discounts $ 200,488              
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Notes Payable (Details) - Schedule of future maturities of notes payable
Dec. 31, 2022
USD ($)
Schedule of future maturities of notes payable [Abstract]  
2023 $ 904,427
2024
2025
2026
2027
Thereafter
Total $ 904,427
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Note Payable to Shareholder (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Note Payable to Shareholder (Details) [Line Items]    
Majority shareholder loaned an additional $ 304,633 $ 87,410
Additional loans   45,000
Repaid amount 6,214  
Mr. Goldstein [Member]    
Note Payable to Shareholder (Details) [Line Items]    
Amounts due $ 874,679 $ 576,260
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Line of Credit (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Line of Credit (Details) [Line Items]    
Line of credit $ 307,321 $ 285,474
Line of Credit [Member]    
Line of Credit (Details) [Line Items]    
Line of credit maximum borrowing amount $ 400,000  
Line of Credit [Member] | Minimum [Member]    
Line of Credit (Details) [Line Items]    
Interest rate on line of credit 5.50%  
Line of Credit [Member] | Maximum [Member]    
Line of Credit (Details) [Line Items]    
Interest rate on line of credit 11.50%  
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases (Details) [Line Items]      
Operating leases payment   $ 16,500 $ 42,000
Lease expense   168,000 $ 168,000
Accounts payable- related party   $ 280,000  
Weighted average remaining lease terms   3 months 18 days  
Weighted average discount rate   8.00%  
Forecast [Member]      
Leases (Details) [Line Items]      
Operating leases payment $ 168,000    
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders’ Equity (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Shareholders’ Equity (Details) [Line Items]    
Common stock shares (in Shares) 1,043,027  
Common stock issued value $ 236,970  
Common shares to be issued 39,000
Prepaid expense $ 9,750  
Issued shares of common stock description The fair value was determined based on the Company’s stock price on the grant date;  
Common stock, shares issued (in Shares) 31,621,242 28,353,215
Issued shares of common stock per share (in Dollars per share) $ 0.14  
Warrant exercise price (in Dollars per share) $ 0.75  
Exercise price $ 17,924  
Common Stock [Member]    
Shareholders’ Equity (Details) [Line Items]    
Shares of common stock (in Shares) 625,000  
Issued debt $ 100,019  
Minimum [Member]    
Shareholders’ Equity (Details) [Line Items]    
Warrant exercise price (in Dollars per share) $ 0.475  
Maximum [Member]    
Shareholders’ Equity (Details) [Line Items]    
Warrant exercise price (in Dollars per share) $ 0.14  
Consultants [Member]    
Shareholders’ Equity (Details) [Line Items]    
Shares of common stock (in Shares)   1,252,300
Issued debt   $ 737,738
Common stock shares (in Shares) 1,600,000  
Common stock issued value $ 260,000  
Convertible Notes [Member]    
Shareholders’ Equity (Details) [Line Items]    
Shares of common stock (in Shares)   250,000
Common stock, shares issued (in Shares)   1,121,071
Investment   $ 633,405
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders’ Equity (Details) - Schedule of activity related to warrants - Warrant [Member] - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Shareholders’ Equity (Details) - Schedule of activity related to warrants [Line Items]    
Warrants Outstanding, at Beginning 333,333 333,333
Weighted Average Exercise Price, at Beginning (in Dollars per share) $ 0.36 $ 0.4
Weighted Average Remaining Contractual Life, at Beginning   1 year 6 months
Aggregate Intrinsic Value, at Beginning (in Dollars)
Warrants Outstanding, Granted 2,500,000
Weighted Average Exercise Price ,Granted (in Dollars per share) $ 0.14  
Weighted Average Remaining Contractual Life, Granted 3 years  
Aggregate Intrinsic Value, Granted  
Warrants Outstanding, Forfeited (333,333)
Warrants Outstanding, Exercised
Warrants Outstanding, at Ending 2,500,000 333,333
Weighted Average Exercise Price, at Ending (in Dollars per share) $ 0.14 $ 0.36
Weighted Average Remaining Contractual Life, at Ending 2 years 6 months 21 days 10 months 24 days
Aggregate Intrinsic Value, at Ending (in Dollars)
Warrants Outstanding, Exercisable 2,500,000  
Weighted Average Exercise Price, Exercisable (in Dollars per share) $ 0.14  
Weighted Average Remaining Contractual Life, Exercisable 2 years 6 months 21 days  
Aggregate Intrinsic Value, Exercisable (in Dollars)  
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders’ Equity (Details) - Schedule of information about options outstanding and exercisable
12 Months Ended
Dec. 31, 2022
$ / shares
shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number of Warrants 2,500,000
Warrant [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number of Warrants 2,500,000
Exercise Price (in Dollars per share) | $ / shares $ 0.14
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting (Details)
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Number of reportable segments 2
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting (Details) - Schedule of company’s segment information - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Sales    
Sales $ 2,091,366 $ 2,137,607
Gross profit    
Gross profit 788,068 1,376,652
Income (loss) from operations    
Loss from operations (1,496,031) (1,876,684)
Interest Expenses    
Interest Expenses 63,912 11,001
Net income (loss)    
Net loss (2,042,794) (1,882,846)
Total Assets    
Total Assets 3,108,737 2,851,186
Goodwill    
Goodwill 570,176 570,176
Segments [Member] | Optron [Member]    
Sales    
Sales 220,368 482,582
Gross profit    
Gross profit (547,531) 101,447
Income (loss) from operations    
Loss from operations (1,484,631) (799,837)
Interest Expenses    
Interest Expenses 21,725 10,076
Net income (loss)    
Net loss (1,506,356) (799,837)
Total Assets    
Total Assets 1,021,817 1,027,669
Goodwill    
Goodwill
Segments [Member] | Overhoff [Member]    
Sales    
Sales 1,870,998 1,655,025
Gross profit    
Gross profit 1,335,599 1,275,205
Income (loss) from operations    
Loss from operations 486,382 264,763
Interest Expenses    
Interest Expenses 6,545
Net income (loss)    
Net loss 479,837 680,892
Total Assets    
Total Assets 2,037,988 1,754,485
Goodwill    
Goodwill 570,176 570,176
Segments [Member] | Corporate [Member]    
Sales    
Sales
Gross profit    
Gross profit
Income (loss) from operations    
Loss from operations (497,782) (1,757,739)
Interest Expenses    
Interest Expenses 35,643 925
Net income (loss)    
Net loss (1,016,275) (1,763,901)
Total Assets    
Total Assets 48,932 69,032
Goodwill    
Goodwill
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Geographical Sales (Details) - Schedule of geographical distribution - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Geographical sales    
Geographical sales total $ 2,091,366 $ 2,137,607
North America [Member]    
Geographical sales    
Geographical sales 1,535,671 1,522,412
Asia [Member]    
Geographical sales    
Geographical sales 523,434 473,157
South America [Member]    
Geographical sales    
Geographical sales 5,475 4,932
Other [Member]    
Geographical sales    
Geographical sales $ 26,786 $ 137,106
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Valuation allowance $ 552,000 $ 526,103
Tax credit carryforwards 49,740  
Net operating loss carryforward $ 12,649,000  
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - Schedule of deferred tax assets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Schedule of Deferred Tax Assets [Abstract]    
Approximate net operating loss carry forwards $ 12,649,000 $ 10,605,000
Deferred tax assets:    
Federal net operating loss 2,031,310 1,602,310
State net operating loss 846,270 723,270
Tax credit 49,740 49,740
Goodwill (148,373) (148,373)
Total deferred tax assets 2,778,947 2,226,947
Less valuation allowance (2,778,947) (2,226,947)
Total
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - Schedule of consolidated statements of income - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Current    
Federal
State
Total
Deferred    
Federal
State
Total
Income tax expense
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - Schedule of effective income tax rate to the federal statutory rate
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Schedule of Effective Income Tax Rate to the Federal Statutory Rate [Abstract]    
Federal income tax rate 21.00% 21.00%
State tax, net of federal benefit 6.00% 6.00%
Net operating losses (16.70%) (16.70%)
Permanent differences (10.60%) (10.60%)
Amortization of goodwill 0.30% 0.30%
Effective income tax rate 0.00% 0.00%
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Related Party Transactions (Details) [Line Items]    
Rent expense $ 168,000 $ 168,000
Accrued compensation payable $ 695,000 $ 590,000
Shares of common stock (in Shares) 1,452  
Richard Landry [Member]    
Related Party Transactions (Details) [Line Items]    
Shares of common stock (in Shares)   242,823
Gold Team Inc [Member]    
Related Party Transactions (Details) [Line Items]    
Payable to related party $ 280,000 $ 128,500
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Concentrations (Details)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Concentrations (Details) [Line Items]    
Concentration percentage 10.00% 10.00%
Sales [Member]    
Concentrations (Details) [Line Items]    
Concentration percentage 10.00% 10.00%
Sales [Member] | Customers One [Member]    
Concentrations (Details) [Line Items]    
Concentration percentage 42.30% 30.70%
Sales [Member] | Customers Two [Member]    
Concentrations (Details) [Line Items]    
Concentration percentage 13.61% 15.20%
Accounts Receivable [Member]    
Concentrations (Details) [Line Items]    
Concentration percentage 10.00% 10.00%
Accounts Receivable [Member] | Customers One [Member]    
Concentrations (Details) [Line Items]    
Concentration percentage 55.50% 23.90%
Accounts Receivable [Member] | Customers Two [Member]    
Concentrations (Details) [Line Items]    
Concentration percentage 28.40% 15.00%
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details) - USD ($)
1 Months Ended
Apr. 11, 2023
Mar. 14, 2023
Mar. 03, 2023
Jan. 09, 2023
Mar. 31, 2023
Feb. 24, 2023
Feb. 23, 2023
Jan. 23, 2023
Jan. 19, 2023
Subsequent Event [Member]                  
Subsequent Events (Details) [Line Items]                  
Shares issued   1,500,000   100,000 75,000 200,000 400,000 260,000 400,000
Fair value on the date of grant (in Dollars)   $ 175,500   $ 11,100 $ 8,550 $ 29,200   $ 37,960  
Fair value date of grant (in Dollars per share)   $ 0.117   $ 0.111 $ 0.114 $ 0.146   $ 0.146  
Value of shares issued (in Dollars)             $ 60,000   $ 60,000
Issuance of per share (in Dollars per share)             $ 0.15   $ 0.15
Shares exchange     65,000,000            
Interest rate     26.00%            
Forecast [Member]                  
Subsequent Events (Details) [Line Items]                  
Shares issued 771,845                
XML 77 f10k2022_usnuclearcorp_htm.xml IDEA: XBRL DOCUMENT 0001543623 2022-01-01 2022-12-31 0001543623 2022-06-30 0001543623 2023-05-10 0001543623 2022-12-31 0001543623 2021-12-31 0001543623 2021-01-01 2021-12-31 0001543623 us-gaap:CommonStockMember 2020-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001543623 us-gaap:RetainedEarningsMember 2020-12-31 0001543623 2020-12-31 0001543623 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001543623 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001543623 us-gaap:CommonStockMember 2021-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001543623 us-gaap:RetainedEarningsMember 2021-12-31 0001543623 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001543623 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001543623 ucle:CommonSharesToBeIssuedMember 2022-01-01 2022-12-31 0001543623 us-gaap:CommonStockMember 2022-12-31 0001543623 ucle:CommonSharesToBeIssuedMember 2022-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001543623 us-gaap:RetainedEarningsMember 2022-12-31 0001543623 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001543623 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001543623 us-gaap:EquipmentMember 2022-01-01 2022-12-31 0001543623 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001543623 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001543623 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001543623 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001543623 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001543623 us-gaap:EquipmentMember 2022-12-31 0001543623 us-gaap:EquipmentMember 2021-12-31 0001543623 us-gaap:ComputerEquipmentMember 2022-12-31 0001543623 us-gaap:ComputerEquipmentMember 2021-12-31 0001543623 2018-08-03 0001543623 ucle:OwnershipInterestMember ucle:MIFTECMember 2018-08-03 0001543623 ucle:MIFTECMember 2018-08-03 0001543623 ucle:MIFTECMember 2018-08-01 2018-08-03 0001543623 ucle:MIFTECMember 2018-12-31 0001543623 ucle:MIFTECMember 2018-01-01 2018-12-31 0001543623 ucle:MIFTECMember 2019-01-01 2019-12-31 0001543623 ucle:MIFTECMember 2022-01-01 2022-12-31 0001543623 ucle:MIFTECMember 2021-01-01 2021-12-31 0001543623 ucle:MIFTIMember 2019-04-01 2019-04-30 0001543623 2019-04-30 0001543623 ucle:MIFTIMember 2019-01-01 2019-12-31 0001543623 ucle:MIFTIMember 2022-01-01 2022-12-31 0001543623 ucle:MIFTIMember 2021-01-01 2021-12-31 0001543623 2021-04-01 2021-06-30 0001543623 ucle:GraphetonMember 2021-04-01 2021-06-30 0001543623 ucle:GraphetonMember 2022-12-31 0001543623 ucle:GraphetonMember 2022-01-01 2022-12-31 0001543623 2021-04-01 2021-04-15 0001543623 2020-06-01 2020-06-30 0001543623 2021-02-28 0001543623 2020-12-01 2020-12-26 0001543623 ucle:MayFiveMember 2022-05-01 2022-05-05 0001543623 ucle:MayFiveMember 2022-05-05 0001543623 ucle:MayFiveMember 2022-01-01 2022-12-31 0001543623 ucle:OctoberTenMember 2022-10-01 2022-10-10 0001543623 ucle:OctoberTenMember 2022-10-10 0001543623 ucle:OctoberTenMember 2022-01-01 2022-12-31 0001543623 ucle:MrGoldsteinMember 2022-12-31 0001543623 ucle:MrGoldsteinMember 2021-12-31 0001543623 us-gaap:LineOfCreditMember 2022-12-31 0001543623 srt:MinimumMember us-gaap:LineOfCreditMember 2022-12-31 0001543623 srt:MaximumMember us-gaap:LineOfCreditMember 2022-12-31 0001543623 srt:ScenarioForecastMember 2023-12-01 2023-12-31 0001543623 ucle:ConsultantsMember 2022-01-01 2022-12-31 0001543623 ucle:ConsultantsMember 2021-01-01 2021-12-31 0001543623 us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001543623 us-gaap:ConvertibleDebtMember 2021-12-31 0001543623 srt:MinimumMember 2022-01-01 2022-12-31 0001543623 srt:MaximumMember 2022-01-01 2022-12-31 0001543623 us-gaap:WarrantMember 2020-12-31 0001543623 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001543623 us-gaap:WarrantMember 2021-12-31 0001543623 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001543623 us-gaap:WarrantMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2022-01-01 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2021-01-01 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2022-01-01 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2021-01-01 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2022-01-01 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2021-01-01 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2021-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2021-12-31 0001543623 srt:NorthAmericaMember 2022-01-01 2022-12-31 0001543623 srt:NorthAmericaMember 2021-01-01 2021-12-31 0001543623 srt:AsiaMember 2022-01-01 2022-12-31 0001543623 srt:AsiaMember 2021-01-01 2021-12-31 0001543623 srt:SouthAmericaMember 2022-01-01 2022-12-31 0001543623 srt:SouthAmericaMember 2021-01-01 2021-12-31 0001543623 ucle:OtherMember 2022-01-01 2022-12-31 0001543623 ucle:OtherMember 2021-01-01 2021-12-31 0001543623 ucle:GoldTeamIncMember 2022-12-31 0001543623 ucle:GoldTeamIncMember 2021-12-31 0001543623 ucle:RichardLandryMember 2021-12-31 0001543623 us-gaap:SalesMember 2022-01-01 2022-12-31 0001543623 ucle:CustomersOneMember us-gaap:SalesMember 2022-01-01 2022-12-31 0001543623 ucle:CustomersTwoMember us-gaap:SalesMember 2022-01-01 2022-12-31 0001543623 us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001543623 ucle:CustomersOneMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001543623 ucle:CustomersTwoMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001543623 us-gaap:SalesMember 2021-01-01 2021-12-31 0001543623 ucle:CustomersOneMember us-gaap:SalesMember 2021-01-01 2021-12-31 0001543623 ucle:CustomersTwoMember us-gaap:SalesMember 2021-01-01 2021-12-31 0001543623 us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001543623 ucle:CustomersOneMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001543623 ucle:CustomersTwoMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001543623 us-gaap:SubsequentEventMember 2023-01-01 2023-01-09 0001543623 us-gaap:SubsequentEventMember 2023-01-09 0001543623 us-gaap:SubsequentEventMember 2023-01-01 2023-01-19 0001543623 us-gaap:SubsequentEventMember 2023-01-19 0001543623 us-gaap:SubsequentEventMember 2023-01-01 2023-01-23 0001543623 us-gaap:SubsequentEventMember 2023-01-23 0001543623 us-gaap:SubsequentEventMember 2023-02-01 2023-02-23 0001543623 us-gaap:SubsequentEventMember 2023-02-23 0001543623 us-gaap:SubsequentEventMember 2023-02-01 2023-02-24 0001543623 us-gaap:SubsequentEventMember 2023-02-24 0001543623 us-gaap:SubsequentEventMember 2023-03-01 2023-03-03 0001543623 us-gaap:SubsequentEventMember 2023-03-03 0001543623 us-gaap:SubsequentEventMember 2023-03-01 2023-03-14 0001543623 us-gaap:SubsequentEventMember 2023-03-14 0001543623 us-gaap:SubsequentEventMember 2023-03-01 2023-03-31 0001543623 us-gaap:SubsequentEventMember 2023-03-31 0001543623 srt:ScenarioForecastMember 2023-04-01 2023-04-11 iso4217:USD shares iso4217:USD shares pure 10-K true 2022-12-31 --12-31 2022 false 000-54617 US NUCLEAR CORP. DE 45-4535739 7051 Eton Avenue Canoga Park CA 91303 (818) 883-7043 Common Stock, $0.0001 par value per share No No Yes Yes Non-accelerated Filer true false false false 2938723 35798087 Fruci & Associates II, PLLC Spokane, Washington 126109 246317 329858 163577 2024664 1792312 26370 44026 2507001 2246232 6501 9719 10059 10059 15000 15000 570176 570176 3108737 2851186 100398 91859 280000 128500 688422 587941 695000 590000 88694 101342 9574 48541 412953 874679 576260 307321 285474 3457041 2409917 3457041 2409917 0.0001 0.0001 5000000 5000000 0.0001 0.0001 100000000 100000000 31621242 31621242 28353215 28353215 3162 2836 39000 14740401 13508581 -15130867 -13070148 -348304 441269 3108737 2851186 2091366 2137607 1303298 760955 788068 1376652 592659 326118 171024 170000 372978 957954 939061 830027 663119 2284099 2738841 -1496031 -1362189 63912 11001 2950 482852 329018 -835462 -546764 -514495 -2042795 -1876684 -2042795 -1876684 -17924 -52861 -2060719 -1929545 29504433 27375508 -0.07 -0.07 25724844 2572 11985191 -11140603 847160 1257300 126 737262 737388 250000 25 99975 100000 1121071 112 633293 633405 52861 -52861 -1876684 -1876684 28353215 2835 13508582 -13070148 441269 1043027 105 197865 197970 625000 62 99957 100019 1600000 160 259840 260000 656233 656233 17924 -17924 39000 39000 -2042795 -2042795 31621242 3162 39000 14740401 -15130867 -348304 -2042795 -1876684 3218 2571 11000 267246 673617 87410 55079 482852 329018 8750 835462 166281 -80625 232352 474625 12620 8539 30882 151500 128500 115532 322203 105000 160000 -12648 -92969 -55079 -1324059 -441026 6446 15000 -21446 26149 119600 100000 221431 37217 4546 916500 304633 608010 6214 563010 1203851 481485 -120208 19013 246317 227304 126109 246317 11973 11001 239044 39000 135859 17924 52861 260000 751026 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note 1 – Organization and Basis of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Organization and Line of Business</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">US Nuclear Corp., formerly known as APEX 3, Inc., (the “Company” or “US Nuclear”) was incorporated under the laws of the State of Delaware on February 14, 2012.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On May 31, 2016, the Company entered into an Asset Purchase Agreement with Electronic Control Concepts (“ECC”) whereby the Company purchased certain tangible and intangible assets of ECC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company is engaged in developing, manufacturing and selling radiation detection and measuring equipment. The Company markets and sells its products to consumers throughout the world.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Basis of Presentation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Going Concern</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company recorded a net loss of $2,042,795 for the year ended December 31, 2022 and had an accumulated deficit of $15,130,867 as of December 31, 2022, which raises substantial doubt about its ability to continue as a going concern. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through some private placement offerings of debt and equity securities. These plans, if successful, will mitigate the factors which raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. </span></p> 2042795 15130867 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 2 – Summary of Significant Accounting Policies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Principles of Consolidation</span> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Cali From Above, LLC, and Optron and its wholly-owned subsidiary, Overhoff Technology Corporation (“Overhoff”), and its wholly-owned subsidiary, Electronic Control Concepts (“ECC”), have been prepared in conformity with accounting principles generally accepted in the United States of America. All significant intercompany transactions and balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Cash and Cash Equivalents</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents include cash on hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. There were no cash equivalents as of December 31, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company places its cash with high quality financial institutions and at times may exceed the FDIC insurance limit. The Company has not and does not anticipate incurring any losses related to this credit risk. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Accounts Receivable</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves.  Reserves are recorded based on the Company’s historical collection history. Allowance for doubtful accounts as of December 31, 2022 and 2021 were $5,000 and $16,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Inventories</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inventories are valued at the lower of cost (determined primarily by the average cost method) or net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. As of December 31, 2022 and 2021, there was no allowance for slow moving or obsolete inventory. The Company periodically assessed its inventory for slow moving and/or obsolete items. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Property and Equipment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Property and Equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-style: normal; font-weight: normal">5 years</b></span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvement</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lesser of lease life or economic life</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and software</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Long-Lived Assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company applies the provisions of Accounting Standards Codification (“ASC”) Topic 360, <i>Property, Plant, and Equipment</i>, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at December 31, 2022 and 2021, the Company believes there was no impairment of its long-lived assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Goodwill</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. The entire goodwill balance in the accompanying financial statements resulted from the Company’s acquisition of Overhoff Technology Corporation in 2006. The Company complies with ASC 350, <i>Goodwill and Other Indefinite Lived Intangible Assets</i>, requiring that a test for impairment be performed at least annually. As of December 31, 2022 and 2021 the Company performed the required impairment analysis which resulted in no impairment adjustments. Although the Company experienced a significant decline in revenue due to the effects of COVID-19, management expects that it is more likely than not that its revenue and cost of goods sold will be more in-line with pre-COVID-19 levels in upcoming periods. Significant estimates used in the goodwill impairment analysis may change in the upcoming year if revenues do not rebound and cost of materials continue to increase.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Derivative Financial Instruments</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. During the years ended December 31, 2022 and 2021, there were no derivative liabilities associated with our convertible notes payable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Investments</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, the Company measures the equity security at fair value as of the date that the observable transaction occurred (“the measurement alternative”) in accordance with ASC 321. The Company accounts for investments for which it owns 20% or more, but less than 50% on the equity method in accordance with ASC 323. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Fair Value of Financial Instruments</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For certain of the Company’s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities, customer deposits, and line of credit, the carrying amounts approximate their fair values due to their short maturities. In addition, the Company has a note payable to shareholder that the carrying amount also approximates fair value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Revenue Recognition</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounting Standards Update (“ASU”) No. 2014-09, <i>Revenue from Contracts with Customers </i>(“<i>Topic 606</i>”), became effective for the Company on January 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of <i>Topic 606. </i>As<i> </i>sales are and have been primarily from the sale of products to customers, and the Company has no significant post-delivery obligations, this new standard did not<i> </i>result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under <i>Topic 605, Revenue Recognition</i>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenue from the product sales is recognized under <i>Topic 606</i> in a manner that reasonably reflects the delivery of its products to customers in return for expected consideration and includes the following elements:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed contracts with the Company’s customers that it believes are legally enforceable;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification of performance obligations in the respective contract;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination of the transaction price for each performance obligation in the respective contract;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation the transaction price to each performance obligation; and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition of revenue only when the Company satisfies each performance obligation.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">These five elements, as applied to each of the Company’s revenue category, is summarized below:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product sales - revenue is recognized when the Company performs its obligations under the contracts it has with its customers to deliver products at an agreed upon price and it is generally when the control of the product has been transferred to the customer.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales returns and allowances was $0 and $0 for the years ended December 31, 2022 and 2021, respectively. The Company provides a one-year warranty on all sales. Warranty expense for the years ended December 31, 2022 and 2021 was insignificant. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">See Notes 11 and 12 for disclosures of revenue disaggregated by geographical area and product line.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Customer Deposits</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Income Taxes</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Stock-Based Compensation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based compensation in accordance with FASB ASC Topic 718,” <i>Compensation – Stock Compensation</i>.” FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Basic and Diluted Earnings Per Share</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Earnings per share is calculated in accordance with ASC Topic 260, <i>Earnings Per Share</i>. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. As of December 31, 2022 and 2021 there were 2,500,000 and 333,333 warrants outstanding, respectively, to purchase shares of common stock. Basic and diluted earnings per share are the same during the years ended December 31, 2022 and 2021 due to the net loss incurred. As of December 31, 2022, the number of potentially dilutive shares issuable on our convertible notes and accrued interest was 6,430,544.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Segment Reporting</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FASB ASC Topic 280, <i>Segment Reporting</i>, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments. See Note 11. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Related Parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company accounts for related party transactions in accordance with ASC 850, <i>Related Party Disclosures</i>. A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Reclassifications</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Recent Accounting Pronouncements</span>    </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 was issued to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard represents significant changes to accounting for credit losses.  Full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope.  The current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold.  The expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts.  This ASU as amended by ASU 2019-10, is effective for fiscal years beginning after December 15, 2022.  The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12, <i>Simplifying the Accounting for Income Taxes</i> which amends ASC 740 <i>Income Taxes </i>(ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021.  The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted.  The adoption had no effect on the Company’s consolidated financial statements and related disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In August 2020, the FASB issued <span>ASU 2020-06<b>, </b><i>Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. </i>ASU 2020-06</span> reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, <i>Derivatives and Hedging</i>, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 also removes certain conditions that should be considered in the derivatives scope exception evaluation under Subtopic 815-40, <i>Derivatives and Hedging—Contracts in Entity’s Own Equity</i>, and clarify the scope and certain requirements under Subtopic 815-40. In addition, ASU 2020-06 improves the guidance related to the disclosures and earnings-per-share (EPS) for convertible instruments and contract in entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluation the impact this ASU will have on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Principles of Consolidation</span> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Cali From Above, LLC, and Optron and its wholly-owned subsidiary, Overhoff Technology Corporation (“Overhoff”), and its wholly-owned subsidiary, Electronic Control Concepts (“ECC”), have been prepared in conformity with accounting principles generally accepted in the United States of America. All significant intercompany transactions and balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Cash and Cash Equivalents</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents include cash on hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. There were no cash equivalents as of December 31, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company places its cash with high quality financial institutions and at times may exceed the FDIC insurance limit. The Company has not and does not anticipate incurring any losses related to this credit risk. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Accounts Receivable</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves.  Reserves are recorded based on the Company’s historical collection history. Allowance for doubtful accounts as of December 31, 2022 and 2021 were $5,000 and $16,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 5000 16000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Inventories</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inventories are valued at the lower of cost (determined primarily by the average cost method) or net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. As of December 31, 2022 and 2021, there was no allowance for slow moving or obsolete inventory. The Company periodically assessed its inventory for slow moving and/or obsolete items. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Property and Equipment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Property and Equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-style: normal; font-weight: normal">5 years</b></span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvement</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lesser of lease life or economic life</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and software</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-style: normal; font-weight: normal">5 years</b></span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvement</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lesser of lease life or economic life</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and software</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 5 years Lesser of lease life or economic life 5 years 5 years <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Long-Lived Assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company applies the provisions of Accounting Standards Codification (“ASC”) Topic 360, <i>Property, Plant, and Equipment</i>, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at December 31, 2022 and 2021, the Company believes there was no impairment of its long-lived assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Goodwill</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. The entire goodwill balance in the accompanying financial statements resulted from the Company’s acquisition of Overhoff Technology Corporation in 2006. The Company complies with ASC 350, <i>Goodwill and Other Indefinite Lived Intangible Assets</i>, requiring that a test for impairment be performed at least annually. As of December 31, 2022 and 2021 the Company performed the required impairment analysis which resulted in no impairment adjustments. Although the Company experienced a significant decline in revenue due to the effects of COVID-19, management expects that it is more likely than not that its revenue and cost of goods sold will be more in-line with pre-COVID-19 levels in upcoming periods. Significant estimates used in the goodwill impairment analysis may change in the upcoming year if revenues do not rebound and cost of materials continue to increase.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Derivative Financial Instruments</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. During the years ended December 31, 2022 and 2021, there were no derivative liabilities associated with our convertible notes payable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Investments</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, the Company measures the equity security at fair value as of the date that the observable transaction occurred (“the measurement alternative”) in accordance with ASC 321. The Company accounts for investments for which it owns 20% or more, but less than 50% on the equity method in accordance with ASC 323. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 0.20 0.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Fair Value of Financial Instruments</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For certain of the Company’s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities, customer deposits, and line of credit, the carrying amounts approximate their fair values due to their short maturities. In addition, the Company has a note payable to shareholder that the carrying amount also approximates fair value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Revenue Recognition</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounting Standards Update (“ASU”) No. 2014-09, <i>Revenue from Contracts with Customers </i>(“<i>Topic 606</i>”), became effective for the Company on January 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of <i>Topic 606. </i>As<i> </i>sales are and have been primarily from the sale of products to customers, and the Company has no significant post-delivery obligations, this new standard did not<i> </i>result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under <i>Topic 605, Revenue Recognition</i>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenue from the product sales is recognized under <i>Topic 606</i> in a manner that reasonably reflects the delivery of its products to customers in return for expected consideration and includes the following elements:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">executed contracts with the Company’s customers that it believes are legally enforceable;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification of performance obligations in the respective contract;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination of the transaction price for each performance obligation in the respective contract;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocation the transaction price to each performance obligation; and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognition of revenue only when the Company satisfies each performance obligation.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">These five elements, as applied to each of the Company’s revenue category, is summarized below:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product sales - revenue is recognized when the Company performs its obligations under the contracts it has with its customers to deliver products at an agreed upon price and it is generally when the control of the product has been transferred to the customer.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales returns and allowances was $0 and $0 for the years ended December 31, 2022 and 2021, respectively. The Company provides a one-year warranty on all sales. Warranty expense for the years ended December 31, 2022 and 2021 was insignificant. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">See Notes 11 and 12 for disclosures of revenue disaggregated by geographical area and product line.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 0 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Customer Deposits</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Income Taxes</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 0.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Stock-Based Compensation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based compensation in accordance with FASB ASC Topic 718,” <i>Compensation – Stock Compensation</i>.” FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Basic and Diluted Earnings Per Share</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Earnings per share is calculated in accordance with ASC Topic 260, <i>Earnings Per Share</i>. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. As of December 31, 2022 and 2021 there were 2,500,000 and 333,333 warrants outstanding, respectively, to purchase shares of common stock. Basic and diluted earnings per share are the same during the years ended December 31, 2022 and 2021 due to the net loss incurred. As of December 31, 2022, the number of potentially dilutive shares issuable on our convertible notes and accrued interest was 6,430,544.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 2500000 333333 6430544 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Segment Reporting</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FASB ASC Topic 280, <i>Segment Reporting</i>, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments. See Note 11. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 2 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Related Parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company accounts for related party transactions in accordance with ASC 850, <i>Related Party Disclosures</i>. A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Reclassifications</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Recent Accounting Pronouncements</span>    </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 was issued to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard represents significant changes to accounting for credit losses.  Full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope.  The current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold.  The expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts.  This ASU as amended by ASU 2019-10, is effective for fiscal years beginning after December 15, 2022.  The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12, <i>Simplifying the Accounting for Income Taxes</i> which amends ASC 740 <i>Income Taxes </i>(ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021.  The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted.  The adoption had no effect on the Company’s consolidated financial statements and related disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In August 2020, the FASB issued <span>ASU 2020-06<b>, </b><i>Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. </i>ASU 2020-06</span> reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, <i>Derivatives and Hedging</i>, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 also removes certain conditions that should be considered in the derivatives scope exception evaluation under Subtopic 815-40, <i>Derivatives and Hedging—Contracts in Entity’s Own Equity</i>, and clarify the scope and certain requirements under Subtopic 815-40. In addition, ASU 2020-06 improves the guidance related to the disclosures and earnings-per-share (EPS) for convertible instruments and contract in entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluation the impact this ASU will have on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 3 – Inventories</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Inventory at December 31, 2022 and 2021 consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,244,880</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">972,759</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Work in Progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,024</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">370,127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">662,529</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total inventories</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,024,664</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,792,312</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">At December 31, 2022 and 2021 the inventory reserve was $0.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,244,880</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">972,759</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Work in Progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,024</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">370,127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">662,529</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total inventories</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,024,664</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,792,312</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 1244880 972759 409637 157024 370127 662529 2024664 1792312 0 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 4 – Property and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following are the details of property and equipment at December 31, 2022 and 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">148,033</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">148,033</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,091</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,091</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">237,418</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">237,418</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computers and software</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">475,024</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">475,024</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(468,523</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(465,305</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,501</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,719</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Depreciation expense for the years ended December 31, 2022 and 2021 was $3,218 and $2,571, respectively. At December 31, 2022 and 2021, the Company had $440,628 of fully depreciated property and equipment that is still in use.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">148,033</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">148,033</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,091</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,091</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">237,418</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">237,418</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computers and software</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,482</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">475,024</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">475,024</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(468,523</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(465,305</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,501</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,719</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 148033 148033 50091 50091 237418 237418 39482 39482 475024 475024 468523 465305 6501 9719 3218 2571 440628 440628 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note 5 – Investments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">MIFTEC</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 3, 2018, the Company closed an agreement by and among, MIFTEC Laboratories, Inc. (“MIFTEC”), a licensee of Magneto-Inertial Fusion Technologies, Inc., (“MIFTI”), and the Company. MIFTEC is a licensee of MIFTI radionuclide technology. MIFTEC will engage the Company to manufacture equipment pursuant to MIFTEC’s specifications and designs and have the Company as a sales representative for the manufactured equipment. The Company will be the exclusive manufacturer and supplier to MIFTEC of equipment in North America and Asia. In addition, the Company received a 10% ownership interest in MIFTEC. The consideration for the exclusive manufacturing rights and a 10% ownership interest in MIFTEC was $500,000 and 300,000 shares of the Company’s common stock valued at $594,000. The fair value was determined based on the Company’s stock price on August 3, 2018. The Company recorded the value of the 10% interest in MIFTEC at $10,000 and recorded $1,084,000 as the acquisition of manufacturing and supply rights in the accompanying consolidated statement of operations during the year ended December 31, 2018. The Company evaluated this investment for impairment and determined that an impairment of $9,000 was necessary during the year ended December 31, 2019. The carrying value of this investment at December 31, 2022 and 2021 was $1,000 and $1,000, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">MIFTI</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In April 2019, the Company also entered into a Cooperative Agreement with MIFTI whereby the Company acquired certain exclusive manufacturing and supply rights, including thermonuclear fusion-powered reactor for production of electricity per MIFTI designs in return for $500,000, of which $100,000 is payable upon signing, $200,000 within four months of the agreement and $200,000 within nine months of the agreement. The $500,000 is an option to buy a 10% interest in MIFTI for $2,700,000, if completed with 24 months of the agreement date. If the option expires, MIFTI shall issue the Company 500,000 shares of common stock and rescind all other exclusive rights contained in the agreement. The option was rescinded and the Company received 500,000 shares of MIFTI common stock which represents an ownership of approximately 0.56% for its $500,000 investment. The Company evaluated this investment for impairment and determined that an impairment of $499,000 was necessary during the year ended December 31, 2019. The carrying value of this investment at December 31, 2022 and 2021 was $1,000 and $1,000, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Grapheton</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 5, 2020, the Company entered into a Stock Purchase Agreement (“SPA”) with Grapheton, Inc., a California corporation (“Grapheton”). The transaction was closed on March 12, 2020. Grapheton is a start-up company that focuses on building energy storage devises, known as supercapacitors, from a new material system. The technology utilized by Grapheton has been proven to provide a compelling advantage in microelectrode arrays with superior electrical and electrochemical properties.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant to the terms of the SPA, the Corporation will acquire a total of 2,552 shares of Grapheton’s common stock over a two-year period. At closing, the Company was issued at total of 1,452 shares of Grapheton’s common stock for $235,000 and 858,896 shares of the Company’s common stock valued at $601,227.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In connection with the SPA, during the second quarter of 2021 the Company received an additional 1,100 shares of Grapheton’s common stock in exchange for the Company’s issuing an additional 1,121,071 shares of common stock valued at $633,405. In addition, Grapheton fulfilled its requirements under the earn out provision and the Company is obligated to make the first earn out payment of $192,500. This amount is recorded as accrued expense in the accompanying consolidated balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">An additional “true up” issuance of the Company’s common stock to Grapheton may be made on the second anniversary of the closing of the SPA, based on the valuation of the Company’s common stock on that date by a third-party valuator.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently owns 35.8% of Grapheton and accounts for its investment in Grapheton using the equity method of accounting is in accordance with ASC 323.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Information regarding Grapheton as of and for the year ended December 31, 2022 is below:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,396</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,691</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">593,333</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">593,333</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total stockholders’ equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(567,642</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(760,257</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(246,154</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,006,411</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated this investment and recorded a loss attributed to equity investment of $0 during the year ended December 31, 2022. The carrying value of this investment at December 31, 2022 was $8,059. </p> 0.10 0.10 500000 300000 594000 0.10 10000 1084000 9000 1000 1000 In April 2019, the Company also entered into a Cooperative Agreement with MIFTI whereby the Company acquired certain exclusive manufacturing and supply rights, including thermonuclear fusion-powered reactor for production of electricity per MIFTI designs in return for $500,000, of which $100,000 is payable upon signing, $200,000 within four months of the agreement and $200,000 within nine months of the agreement. The $500,000 is an option to buy a 10% interest in MIFTI for $2,700,000, if completed with 24 months of the agreement date. If the option expires, MIFTI shall issue the Company 500,000 shares of common stock and rescind all other exclusive rights contained in the agreement. 500000 0.0056 500000 499000 1000 1000 2552 1452 235000 858896 601227 1100 1121071 633405 192500 0.358 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,396</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,691</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">593,333</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">593,333</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total stockholders’ equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(567,642</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(760,257</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(246,154</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,006,411</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p> 17396 25691 593333 593333 -567642 -760257 246154 -1006411 0 8059 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note 6 – Notes Payable</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In connection with the acquisition of assets from ECC the Company issued a note payable to the owner of ECC. The note accrued interest at 5% per annum, requires quarterly principal and interest payments of $4,518 and is due on April 15, 2021. At December 31, 2022 and 2021, the amount outstanding under this note payable was $5,272 and $5,272, respectively.   The Company was in default on payment of the note payable as of December 31, 2022. The Company has communicated with the debt holder, and the amount is considered payable on demand as of December 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In June 2020 the Company received a loan under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act for $107,587.  The loan has terms of 24 months and accrues interest at 1% per annum. In February of 2021, the Company received two additional loans totaling $221,431 under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. As of December 31, 2021, the Company has had these loans forgiven in the amount of $329,018 as provided by the CARES Act. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2020, a line of credit held by the company had matured, and based on the terms of the line of credit agreement was converted to a note payable upon demand. The obligation accrues interest at the rate of $10.89 per day until the bank receives full payment. As of December 31, 2022, the balance owed by the Company was $4,302.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2022, the Company received a loan in connection with the issuance of stock warrants in the amount of $750,000. The loan has terms of 12 months and accrues interest at 5% per annum. As part of the issuance of the loan, the company identified debt discounts related to the warrants issued, the incentive shares issued as discussed at Note 10, the beneficial conversion feature of the debt, and the expenses paid as part of the issuance. The total debt discounts recorded as of the date of the note was $550,538. At December 31, 2022 and pursuant to the down-round provision of the note and associated warrants, the Company reevaluated the beneficial conversion feature which resulted in additional debt discount recorded of $183,422.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 10, 2022, the Company received a loan in connection with the issuance of stock warrants in the amount of $375,000. The loan has terms of 12 months and accrues interest at 5% per annum. As part of the issuance of the loan, the company identified debt discounts related to the warrants issued, the beneficial conversion feature of the debt, and the expenses paid as part of the issuance. The total debt discounts recorded as of the date of the note was $200,488. At December 31, 2022 and pursuant to the down-round provision of the note and associated warrants, the Company reevaluated the beneficial conversion feature recorded which resulted in additional debt discount recorded of $30,304.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total debt discount amortization recorded on the Company’s notes for the twelve months ended December 31, 2022 was $482,852.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future maturities of all notes payable as of December 31, 2022, are as follows: </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold">Years Ending December 31,</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">904,427</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">904,427</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 0.05 4518 5272 5272 107587 0.01 221431 329018 10.89 4302 750000 0.05 550538 183422 375000 0.05 200488 30304 482852 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold">Years Ending December 31,</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">904,427</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">904,427</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 904427 904427 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 7 – Note Payable to Shareholder</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Robert Goldstein, the CEO and majority shareholder, has loaned funds to the Company from time to time to cover general operating expenses. These loans are evidenced by unsecured, non-interest-bearing demand notes payable. During the year ended December 31, 2021, the Company’s majority shareholder paid expenses on behalf of the Company of $87,410 and loaned an additional $45,000 to the Company. During the year ended December 31, 2022, the Company’s majority shareholder loaned an additional $304,633 to the Company and was repaid $6,214.  The amounts due to Mr. Goldstein are $874,679 and $576,260 as of December 31, 2022 and 2021, respectively</p> 87410 45000 304633 6214 874679 576260 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 8 – Line of Credit</b> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company had four lines of credit with a maximum borrowing amount of $400,000 with interest ranging from 5.5% to 11.5%. As of December 31, 2022 and 2021, the amounts outstanding under these lines of credit were $307,321 and $285,474, respectively.</p> 400000 0.055 0.115 307321 285474 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 9 – Leases</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate which is based on the interest rate of similar debt outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company leases its current facilities from Gold Team Inc., a company owned by the Company’s CEO, which owns both the Canoga Park, CA and Milford, Ohio locations. The leases expired on April 30, 2020 and the Company exercised its renewal option for an additional 12 months. The new lease is not more than 12 months; therefore, the disclosures under ASC 842 are not required. Future minimum lease payments under this agreement for the twelve months ending December 31, 2023 is $168,000. Effective January 1, 2019, the Company adopted the provision of ASC 842 Leases.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The lease expense for the years ended December 31, 2022 and 2021 was $168,000 and $168,000, respectively. The cash paid under operating leases during the years ended December 31, 2022 and 2021 was $16,500 and $42,000, respectively. At December 31, 2022, $280,000 has been accrued and is shown on the balance sheet as accounts payable- related party. At December 31, 2022, the weighted average remaining lease terms were 0.3 years and the weighted average discount rate was 8%.</span></p> 168000 168000 168000 16500 42000 280000 P0Y3M18D 0.08 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 10 – Shareholders’ Equity</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Common stock</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended December 31, 2022, the Company issued:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">625,000 shares of common stock valued at $100,019 in relation to the debt that was obtained;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,600,000 shares of common stock valued at $260,000 in satisfaction of convertible debt and interest;</span></td></tr> <tr style="vertical-align: top; "> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,043,027 shares of common stock to consultants for services rendered valued at $236,970; of which $39,000 is recorded as shares to be issued. <span>Pursuant to ASC 718 the company has allocated a portion of stock-based compensation to prepaid expenses until the services are provided to the Company. The amount allocated to prepaid expense at December 31, 2022 is $9,750. </span>The fair value was determined based on the Company’s stock price on the grant date.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">During the year ended December 31, 2021, the Company issued:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,252,300 shares of common stock to consultants for services rendered valued at $737,738. The fair value was determined based on the Company’s stock price on the grant date;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000 shares of common stock for cash; and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,121,071 shares of common stock for an investment in Grapheton valued at $633,405. The fair value was determined based on the Company’s stock price on the grant date.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Warrants</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The following table summarizes the activity related to warrants:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">333,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">      -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(333,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,500,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.56</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,500,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.56</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The above warrants contain a down round provision that requires the exercise price to be adjusted if the Company sells shares of common stock below the current exercise price. During the twelve months ended December 31, 2022, the Company issued shares of common stock for $0.14 therefore, the exercise price of these warrants was adjusted from $0.75 and $0.475 to $0.14 pursuant to the down-round provision in the warrant agreement. </span> <span>The change in fair value between the value of the warrants using the new exercise price versus the old exercise price was calculated to be $17,924. This amount is recorded as a deemed dividend in the accompanying consolidated financial statements during the year ended December 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following table summarizes information about options outstanding and exercisable as of December 31, 2022</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Outstanding and Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 48%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,500,000</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 47%; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.14</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,500,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 625000 100019 1600000 260000 1043027 236970 39000 9750 1252300 737738 The fair value was determined based on the Company’s stock price on the grant date; 250000 1121071 633405 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">333,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">      -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(333,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,500,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.56</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,500,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.14</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.56</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 333333 0.4 P1Y6M 333333 0.36 P0Y10M24D 2500000 0.14 P3Y -333333 2500000 0.14 P2Y6M21D 2500000 0.14 P2Y6M21D 0.14 0.75 0.475 0.14 17924 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Outstanding and Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 48%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,500,000</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 47%; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.14</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,500,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 2500000 0.14 2500000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note 11 – Segment Reporting</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has two reportable segments: Optron and Overhoff. Optron is located in Canoga Park, California and Overhoff is located in Milford, Ohio. The assets and operations of the Company’s recent acquisition of the assets of Electronic Control Concepts are included with Overhoff in the table below. The assets and operations of the Company’s newest subsidiary, Cali From Above are included with Optron in the table below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The following tables summarize the Company’s segment information for the years ended December 31, 2022 and 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Sales</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Optron</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">220,368</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">482,582</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,870,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,655,025</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,091,366</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,137,607</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(547,531</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">101,447</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,335,599</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,275,205</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">788,068</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,376,652</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Income (loss) from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,484,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(799,837</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">486,382</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">264,763</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(497,782</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,757,739</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,496,031</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,876,684</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Interest Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">21,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,076</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,643</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">925</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">63,912</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,001</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,506,356</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(799,837</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">479,837</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">680,892</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,016,275</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,763,901</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,042,794</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,882,846</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Total Assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Optron</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,021,817</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,027,669</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,037,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,754,485</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,932</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">69,032</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,108,737</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,851,186</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">570,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">570,176</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">570,176</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">570,176</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 2 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Sales</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Optron</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">220,368</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">482,582</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,870,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,655,025</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,091,366</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,137,607</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(547,531</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">101,447</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,335,599</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,275,205</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">788,068</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,376,652</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Income (loss) from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,484,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(799,837</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">486,382</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">264,763</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(497,782</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,757,739</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,496,031</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,876,684</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Interest Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">21,725</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,076</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,643</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">925</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">63,912</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,001</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,506,356</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(799,837</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">479,837</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">680,892</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,016,275</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,763,901</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,042,794</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,882,846</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Total Assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Optron</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,021,817</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,027,669</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,037,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,754,485</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,932</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">69,032</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,108,737</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,851,186</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Optron</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Overhoff</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">570,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">570,176</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Corporate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">570,176</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">570,176</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 220368 482582 1870998 1655025 2091366 2137607 -547531 101447 1335599 1275205 788068 1376652 -1484631 -799837 486382 264763 -497782 -1757739 -1496031 -1876684 21725 10076 6545 35643 925 63912 11001 -1506356 -799837 479837 680892 -1016275 -1763901 -2042794 -1882846 1021817 1027669 2037988 1754485 48932 69032 3108737 2851186 570176 570176 570176 570176 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note 12 – Geographical Sales </b> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The geographical distribution of the Company’s sales for the years ended December 31, 2022 and 2021 is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Geographical sales</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">North America</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,535,671</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,522,412</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Asia</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">523,434</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">473,157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">South America</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,932</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,786</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">137,106</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,091,366</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,137,607</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Geographical sales</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">North America</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,535,671</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,522,412</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Asia</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">523,434</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">473,157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">South America</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,932</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,786</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">137,106</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,091,366</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,137,607</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 1535671 1522412 523434 473157 5475 4932 26786 137106 2091366 2137607 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 13 – Income Taxes</b>  </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">At December 31, 2022 and 2021, the significant components of the deferred tax assets are summarized below:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Approximate net operating loss carry forwards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,649,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,605,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Federal net operating loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,031,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,602,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">State net operating loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">846,270</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">723,270</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,740</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,740</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,373</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,373</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,778,947</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,226,947</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,778,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,226,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation allowance increased by $552,000 and $526,103 in 2022 and 2021, respectively, due to the Company generating additional net operating losses. The Company’s remaining tax credit carryforwards of $49,740 begin to expire in 2027 and its net operating loss carryforward of approximately $12,649,000 begin to expire in 2027.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Income tax expense reflected in the consolidated statements of income consist of the following for 2022 and 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">     -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">     -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Income tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The reconciliation of the effective income tax rate to the federal statutory rate for the years ended December 31, 2022 and 2021 is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal income tax rate</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.0</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.0</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State tax, net of federal benefit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-16.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-16.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent differences</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-10.6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-10.6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Amortization of goodwill</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Effective income tax rate</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by the valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of its deferred tax assets, including its recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carryforward periods available to the Company for tax reporting purposes, and other relevant factors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Future changes in the unrecognized tax benefit will have no impact on the effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change significantly within the next twelve months. The Company will continue to classify income tax penalties and interest as part of general and administrative expense in its consolidated statements of operations. There were no interest or penalties accrued as of December 31, 2022 and 2021.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Approximate net operating loss carry forwards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,649,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,605,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Federal net operating loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,031,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,602,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">State net operating loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">846,270</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">723,270</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,740</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,740</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,373</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,373</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,778,947</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,226,947</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,778,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,226,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 12649000 10605000 2031310 1602310 846270 723270 49740 49740 148373 148373 2778947 2226947 2778947 2226947 552000 526103 49740 12649000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">     -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">     -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Income tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal income tax rate</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.0</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.0</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State tax, net of federal benefit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-16.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-16.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent differences</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-10.6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-10.6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Amortization of goodwill</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Effective income tax rate</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 0.21 0.21 0.06 0.06 -0.167 -0.167 -0.106 -0.106 0.003 0.003 0 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Note 14 – Related Party Transactions </b> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company leases its current facilities from Gold Team Inc., a company owned by the Company’s CEO, which owns both the Canoga Park, CA and Milford, Ohio locations. Rent expense for the year ended December 31, 2022 and 2021 were $168,000 and $168,000, respectively. As of December 31, 2022 and 2021, the payable to Gold Team Inc. in connection with the above leases was to $280,000 and $128,500, respectively. (See Note 9).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As of December 31, 2022 and 2021, the Company had accrued compensation payable to its majority shareholder of $695,000 and $590,000, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended, December 31, 2021, the company issued 242,823 shares of common stock to Richard Landry in connection with the consulting services agreement entered by and between US Nuclear Corp and Richard Landry.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Also see Note 7. </span></p> 168000 168000 280000 128500 695000 590000 242823 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note 15 – Concentrations </b> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For the year ended December 31, 2022, two customers accounted for more than 10% of the Company sales, 42.3% and 13.61%, respectively. At December 31, 2022 two customers accounted for more than 10% of the accounts receivable balance, 55.5% and 28.4%, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For the year ended December 31, 2021, two customers accounted for more than 10% of the Company sales, 30.7% and 15.2%, respectively. At December 31, 2021 two customers accounted for more than 10% of the accounts receivable balance, 23.9% and 15%, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">No vendors accounted for more than 10% of the Company’s purchases for the years ended December 31, 2022 and 2021.</span></p> 0.10 0.423 0.1361 0.10 0.555 0.284 0.10 0.307 0.152 0.10 0.239 0.15 0.10 0.10 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Note 16 – Subsequent Events</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were available to be issued and has determined that no material subsequent events exist other than the following:</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2023, the Company issued 100,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which is $11,100 or $0.111 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On January 19, 2023, the Company issued 400,000 shares in satisfaction of principle, accrued interest, and fees on convertible debt. The value of the shares issued was $60,000 or $0.15 per share.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 23, the Company issued an aggregate of 260,000 shares to consultants as compensation for investor relations services. The shares were valued at their fair value on the date of grant, which was $37,960 or $0.146 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, the Company issued 400,000 shares in satisfaction of principle, accrued interest, and fees on convertible debt. The value of the shares issued was $60,000 or $0.15 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, the Company issued 200,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which was $29,200 or $0.146 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Effective March 3, 2023, the Company entered into a Membership Unit Purchase Agreement whereby the Company transferred, assigned, and conveyed the capital account of its wholly-owned subsidiary Cali From Above, in exchange for 65,000,000 shares of INNOVATION NATION, INC., a Nevada Corporation, owned and held by Robert Goldstein. As a result, the Company has divested itself of its ownership of Cali From Above and the Company now holds a 26% interest in Innovation Nation, an OTC reporting company under the symbol (OTC:AVRI).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2023, the Company issued an aggregate of 1,500,000 shares of common stock to our Board members. The shares were valued at their fair value on the date of grant, which was $175,500 or $0.117 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Company issued 75,000 shares of common stock to a consultant. The shares were valued at their fair value on the date of grant, which was $8,550 or $0.114 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 11, 2023, the Company issued 771,845 shares of common stock, by cashless exercise, pursuant to a Warrant Agreement associated with a convertible note payable entered into on May 5, 2022.</p> 100000 11100 0.111 400000 60000 0.15 260000 37960 0.146 400000 60000 0.15 200000 29200 0.146 65000000 0.26 1500000 175500 0.117 75000 8550 0.114 771845 5525 27375508 29504433 -0.03 -0.07 false FY 0001543623 NONE NA EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 79 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 133 353 1 false 38 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://usnuclearcorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://usnuclearcorp.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://usnuclearcorp.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Operations (Parentheticals) Sheet http://usnuclearcorp.com/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statements of Operations (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Equity Sheet http://usnuclearcorp.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statement of Changes in Shareholders' Equity Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows Sheet http://usnuclearcorp.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Organization and Basis of Presentation Sheet http://usnuclearcorp.com/role/OrganizationandBasisofPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://usnuclearcorp.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Inventories Sheet http://usnuclearcorp.com/role/Inventories Inventories Notes 10 false false R11.htm 010 - Disclosure - Property and Equipment Sheet http://usnuclearcorp.com/role/PropertyandEquipment Property and Equipment Notes 11 false false R12.htm 011 - Disclosure - Investments Sheet http://usnuclearcorp.com/role/Investments Investments Notes 12 false false R13.htm 012 - Disclosure - Notes Payable Notes http://usnuclearcorp.com/role/NotesPayable Notes Payable Notes 13 false false R14.htm 013 - Disclosure - Note Payable to Shareholder Sheet http://usnuclearcorp.com/role/NotePayabletoShareholder Note Payable to Shareholder Notes 14 false false R15.htm 014 - Disclosure - Line of Credit Sheet http://usnuclearcorp.com/role/LineofCredit Line of Credit Notes 15 false false R16.htm 015 - Disclosure - Leases Sheet http://usnuclearcorp.com/role/Leases Leases Notes 16 false false R17.htm 016 - Disclosure - Shareholders??? Equity Sheet http://usnuclearcorp.com/role/ShareholdersEquity Shareholders??? Equity Notes 17 false false R18.htm 017 - Disclosure - Segment Reporting Sheet http://usnuclearcorp.com/role/SegmentReporting Segment Reporting Notes 18 false false R19.htm 018 - Disclosure - Geographical Sales Sheet http://usnuclearcorp.com/role/GeographicalSales Geographical Sales Notes 19 false false R20.htm 019 - Disclosure - Income Taxes Sheet http://usnuclearcorp.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 020 - Disclosure - Related Party Transactions Sheet http://usnuclearcorp.com/role/RelatedPartyTransactions Related Party Transactions Notes 21 false false R22.htm 021 - Disclosure - Concentrations Sheet http://usnuclearcorp.com/role/Concentrations Concentrations Notes 22 false false R23.htm 022 - Disclosure - Subsequent Events Sheet http://usnuclearcorp.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 023 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://usnuclearcorp.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://usnuclearcorp.com/role/SummaryofSignificantAccountingPolicies 24 false false R25.htm 024 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://usnuclearcorp.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 025 - Disclosure - Inventories (Tables) Sheet http://usnuclearcorp.com/role/InventoriesTables Inventories (Tables) Tables http://usnuclearcorp.com/role/Inventories 26 false false R27.htm 026 - Disclosure - Property and Equipment (Tables) Sheet http://usnuclearcorp.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://usnuclearcorp.com/role/PropertyandEquipment 27 false false R28.htm 027 - Disclosure - Investments (Tables) Sheet http://usnuclearcorp.com/role/InvestmentsTables Investments (Tables) Tables http://usnuclearcorp.com/role/Investments 28 false false R29.htm 028 - Disclosure - Notes Payable (Tables) Notes http://usnuclearcorp.com/role/NotesPayableTables Notes Payable (Tables) Tables http://usnuclearcorp.com/role/NotesPayable 29 false false R30.htm 029 - Disclosure - Shareholders??? Equity (Tables) Sheet http://usnuclearcorp.com/role/ShareholdersEquityTables Shareholders??? Equity (Tables) Tables http://usnuclearcorp.com/role/ShareholdersEquity 30 false false R31.htm 030 - Disclosure - Segment Reporting (Tables) Sheet http://usnuclearcorp.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://usnuclearcorp.com/role/SegmentReporting 31 false false R32.htm 031 - Disclosure - Geographical Sales (Tables) Sheet http://usnuclearcorp.com/role/GeographicalSalesTables Geographical Sales (Tables) Tables http://usnuclearcorp.com/role/GeographicalSales 32 false false R33.htm 032 - Disclosure - Income Taxes (Tables) Sheet http://usnuclearcorp.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://usnuclearcorp.com/role/IncomeTaxes 33 false false R34.htm 033 - Disclosure - Organization and Basis of Presentation (Details) Sheet http://usnuclearcorp.com/role/OrganizationandBasisofPresentationDetails Organization and Basis of Presentation (Details) Details http://usnuclearcorp.com/role/OrganizationandBasisofPresentation 34 false false R35.htm 034 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesTables 35 false false R36.htm 035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment Sheet http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment Details http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesTables 36 false false R37.htm 036 - Disclosure - Inventories (Details) Sheet http://usnuclearcorp.com/role/InventoriesDetails Inventories (Details) Details http://usnuclearcorp.com/role/InventoriesTables 37 false false R38.htm 037 - Disclosure - Inventories (Details) - Schedule of inventory Sheet http://usnuclearcorp.com/role/ScheduleofinventoryTable Inventories (Details) - Schedule of inventory Details http://usnuclearcorp.com/role/InventoriesTables 38 false false R39.htm 038 - Disclosure - Property and Equipment (Details) Sheet http://usnuclearcorp.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://usnuclearcorp.com/role/PropertyandEquipmentTables 39 false false R40.htm 039 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment Sheet http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable Property and Equipment (Details) - Schedule of property and equipment Details http://usnuclearcorp.com/role/PropertyandEquipmentTables 40 false false R41.htm 040 - Disclosure - Investments (Details) Sheet http://usnuclearcorp.com/role/InvestmentsDetails Investments (Details) Details http://usnuclearcorp.com/role/InvestmentsTables 41 false false R42.htm 041 - Disclosure - Investments (Details) - Schedule of information regarding grapheton Sheet http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable Investments (Details) - Schedule of information regarding grapheton Details http://usnuclearcorp.com/role/InvestmentsTables 42 false false R43.htm 042 - Disclosure - Notes Payable (Details) Notes http://usnuclearcorp.com/role/NotesPayableDetails Notes Payable (Details) Details http://usnuclearcorp.com/role/NotesPayableTables 43 false false R44.htm 043 - Disclosure - Notes Payable (Details) - Schedule of future maturities of notes payable Notes http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable Notes Payable (Details) - Schedule of future maturities of notes payable Details http://usnuclearcorp.com/role/NotesPayableTables 44 false false R45.htm 044 - Disclosure - Note Payable to Shareholder (Details) Sheet http://usnuclearcorp.com/role/NotePayabletoShareholderDetails Note Payable to Shareholder (Details) Details http://usnuclearcorp.com/role/NotePayabletoShareholder 45 false false R46.htm 045 - Disclosure - Line of Credit (Details) Sheet http://usnuclearcorp.com/role/LineofCreditDetails Line of Credit (Details) Details http://usnuclearcorp.com/role/LineofCredit 46 false false R47.htm 046 - Disclosure - Leases (Details) Sheet http://usnuclearcorp.com/role/LeasesDetails Leases (Details) Details http://usnuclearcorp.com/role/Leases 47 false false R48.htm 047 - Disclosure - Shareholders??? Equity (Details) Sheet http://usnuclearcorp.com/role/ShareholdersEquityDetails Shareholders??? Equity (Details) Details http://usnuclearcorp.com/role/ShareholdersEquityTables 48 false false R49.htm 048 - Disclosure - Shareholders??? Equity (Details) - Schedule of activity related to warrants Sheet http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable Shareholders??? Equity (Details) - Schedule of activity related to warrants Details http://usnuclearcorp.com/role/ShareholdersEquityTables 49 false false R50.htm 049 - Disclosure - Shareholders??? Equity (Details) - Schedule of information about options outstanding and exercisable Sheet http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable Shareholders??? Equity (Details) - Schedule of information about options outstanding and exercisable Details http://usnuclearcorp.com/role/ShareholdersEquityTables 50 false false R51.htm 050 - Disclosure - Segment Reporting (Details) Sheet http://usnuclearcorp.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://usnuclearcorp.com/role/SegmentReportingTables 51 false false R52.htm 051 - Disclosure - Segment Reporting (Details) - Schedule of company???s segment information Sheet http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable Segment Reporting (Details) - Schedule of company???s segment information Details http://usnuclearcorp.com/role/SegmentReportingTables 52 false false R53.htm 052 - Disclosure - Geographical Sales (Details) - Schedule of geographical distribution Sheet http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable Geographical Sales (Details) - Schedule of geographical distribution Details http://usnuclearcorp.com/role/GeographicalSalesTables 53 false false R54.htm 053 - Disclosure - Income Taxes (Details) Sheet http://usnuclearcorp.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://usnuclearcorp.com/role/IncomeTaxesTables 54 false false R55.htm 054 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets Sheet http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable Income Taxes (Details) - Schedule of deferred tax assets Details http://usnuclearcorp.com/role/IncomeTaxesTables 55 false false R56.htm 055 - Disclosure - Income Taxes (Details) - Schedule of consolidated statements of income Sheet http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable Income Taxes (Details) - Schedule of consolidated statements of income Details http://usnuclearcorp.com/role/IncomeTaxesTables 56 false false R57.htm 056 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate to the federal statutory rate Sheet http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable Income Taxes (Details) - Schedule of effective income tax rate to the federal statutory rate Details http://usnuclearcorp.com/role/IncomeTaxesTables 57 false false R58.htm 057 - Disclosure - Related Party Transactions (Details) Sheet http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://usnuclearcorp.com/role/RelatedPartyTransactions 58 false false R59.htm 058 - Disclosure - Concentrations (Details) Sheet http://usnuclearcorp.com/role/ConcentrationsDetails Concentrations (Details) Details http://usnuclearcorp.com/role/Concentrations 59 false false R60.htm 059 - Disclosure - Subsequent Events (Details) Sheet http://usnuclearcorp.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://usnuclearcorp.com/role/SubsequentEvents 60 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_usnuclearcorp.htm 3816, 3817 [dq-0542-Deprecated-Concept] Concept RelatedPartyCosts in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_usnuclearcorp.htm 4327, 6939 [dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_usnuclearcorp.htm 4758, 4761, 4764, 4767 [dq-0542-Deprecated-Concept] Concept DueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_usnuclearcorp.htm 5562, 5563 [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_usnuclearcorp.htm 5621 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName, dei:TradingSymbol, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10k2022_usnuclearcorp.htm 6915, 6916, 6917, 6918, 7005, 7006 f10k2022_usnuclearcorp.htm f10k2022ex23-2_usnuclear.htm f10k2022ex31-1_usnuclear.htm f10k2022ex31-2_usnuclear.htm f10k2022ex32-1_usnuclear.htm f10k2022ex32-2_usnuclear.htm f10k2022ex4-2_usnuclear.htm ucle-20221231.xsd ucle-20221231_cal.xml ucle-20221231_def.xml ucle-20221231_lab.xml ucle-20221231_pre.xml image_001.jpg image_002.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10k2022_usnuclearcorp.htm": { "axisCustom": 0, "axisStandard": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 498, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 133, "dts": { "calculationLink": { "local": [ "ucle-20221231_cal.xml" ] }, "definitionLink": { "local": [ "ucle-20221231_def.xml" ] }, "inline": { "local": [ "f10k2022_usnuclearcorp.htm" ] }, "labelLink": { "local": [ "ucle-20221231_lab.xml" ] }, "presentationLink": { "local": [ "ucle-20221231_pre.xml" ] }, "schema": { "local": [ "ucle-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 541, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 84, "http://usnuclearcorp.com/20221231": 22, "http://xbrl.sec.gov/dei/2022": 6, "total": 112 }, "keyCustom": 76, "keyStandard": 277, "memberCustom": 16, "memberStandard": 21, "nsprefix": "ucle", "nsuri": "http://usnuclearcorp.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://usnuclearcorp.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Inventories", "menuCat": "Notes", "order": "10", "role": "http://usnuclearcorp.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Property and Equipment", "menuCat": "Notes", "order": "11", "role": "http://usnuclearcorp.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:InvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Investments", "menuCat": "Notes", "order": "12", "role": "http://usnuclearcorp.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:InvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Notes Payable", "menuCat": "Notes", "order": "13", "role": "http://usnuclearcorp.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:NotePayableToShareholderTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note Payable to Shareholder", "menuCat": "Notes", "order": "14", "role": "http://usnuclearcorp.com/role/NotePayabletoShareholder", "shortName": "Note Payable to Shareholder", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:NotePayableToShareholderTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Line of Credit", "menuCat": "Notes", "order": "15", "role": "http://usnuclearcorp.com/role/LineofCredit", "shortName": "Line of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:LeaseOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Leases", "menuCat": "Notes", "order": "16", "role": "http://usnuclearcorp.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:LeaseOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Shareholders\u2019 Equity", "menuCat": "Notes", "order": "17", "role": "http://usnuclearcorp.com/role/ShareholdersEquity", "shortName": "Shareholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Segment Reporting", "menuCat": "Notes", "order": "18", "role": "http://usnuclearcorp.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:GeographicalSalesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Geographical Sales", "menuCat": "Notes", "order": "19", "role": "http://usnuclearcorp.com/role/GeographicalSales", "shortName": "Geographical Sales", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:GeographicalSalesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://usnuclearcorp.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "21", "role": "http://usnuclearcorp.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Concentrations", "menuCat": "Notes", "order": "22", "role": "http://usnuclearcorp.com/role/Concentrations", "shortName": "Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "23", "role": "http://usnuclearcorp.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "24", "role": "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:EstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "25", "role": "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:EstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "26", "role": "http://usnuclearcorp.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Property and Equipment (Tables)", "menuCat": "Tables", "order": "27", "role": "http://usnuclearcorp.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Investments (Tables)", "menuCat": "Tables", "order": "28", "role": "http://usnuclearcorp.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Notes Payable (Tables)", "menuCat": "Tables", "order": "29", "role": "http://usnuclearcorp.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:ScheduleOfActivityRelatedToWarrants", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Shareholders\u2019 Equity (Tables)", "menuCat": "Tables", "order": "30", "role": "http://usnuclearcorp.com/role/ShareholdersEquityTables", "shortName": "Shareholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ucle:ScheduleOfActivityRelatedToWarrants", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Segment Reporting (Tables)", "menuCat": "Tables", "order": "31", "role": "http://usnuclearcorp.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Geographical Sales (Tables)", "menuCat": "Tables", "order": "32", "role": "http://usnuclearcorp.com/role/GeographicalSalesTables", "shortName": "Geographical Sales (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "33", "role": "http://usnuclearcorp.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAllocatedToGeneralPartners", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Organization and Basis of Presentation (Details)", "menuCat": "Details", "order": "34", "role": "http://usnuclearcorp.com/role/OrganizationandBasisofPresentationDetails", "shortName": "Organization and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAllocatedToGeneralPartners", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "35", "role": "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ucle:EstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment", "menuCat": "Details", "order": "36", "role": "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ucle:EstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryLIFOReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Inventories (Details)", "menuCat": "Details", "order": "37", "role": "http://usnuclearcorp.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryLIFOReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Inventories (Details) - Schedule of inventory", "menuCat": "Details", "order": "38", "role": "http://usnuclearcorp.com/role/ScheduleofinventoryTable", "shortName": "Inventories (Details) - Schedule of inventory", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Property and Equipment (Details)", "menuCat": "Details", "order": "39", "role": "http://usnuclearcorp.com/role/PropertyandEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment", "menuCat": "Details", "order": "40", "role": "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable", "shortName": "Property and Equipment (Details) - Schedule of property and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c36", "decimals": "2", "first": true, "lang": null, "name": "ucle:PercentageOfOwnershipInterest", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Investments (Details)", "menuCat": "Details", "order": "41", "role": "http://usnuclearcorp.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c36", "decimals": "2", "first": true, "lang": null, "name": "ucle:PercentageOfOwnershipInterest", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c52", "decimals": "0", "first": true, "lang": null, "name": "ucle:CurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Investments (Details) - Schedule of information regarding grapheton", "menuCat": "Details", "order": "42", "role": "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable", "shortName": "Investments (Details) - Schedule of information regarding grapheton", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c52", "decimals": "0", "first": true, "lang": null, "name": "ucle:CurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c54", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Notes Payable (Details)", "menuCat": "Details", "order": "43", "role": "http://usnuclearcorp.com/role/NotesPayableDetails", "shortName": "Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c54", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Notes Payable (Details) - Schedule of future maturities of notes payable", "menuCat": "Details", "order": "44", "role": "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable", "shortName": "Notes Payable (Details) - Schedule of future maturities of notes payable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoanProcessingFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note Payable to Shareholder (Details)", "menuCat": "Details", "order": "45", "role": "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails", "shortName": "Note Payable to Shareholder (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoanProcessingFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Line of Credit (Details)", "menuCat": "Details", "order": "46", "role": "http://usnuclearcorp.com/role/LineofCreditDetails", "shortName": "Line of Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "47", "role": "http://usnuclearcorp.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ucle:CommonSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Shareholders\u2019 Equity (Details)", "menuCat": "Details", "order": "48", "role": "http://usnuclearcorp.com/role/ShareholdersEquityDetails", "shortName": "Shareholders\u2019 Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ucle:CommonSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ucle:ScheduleOfActivityRelatedToWarrants", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c78", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Shareholders\u2019 Equity (Details) - Schedule of activity related to warrants", "menuCat": "Details", "order": "49", "role": "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable", "shortName": "Shareholders\u2019 Equity (Details) - Schedule of activity related to warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ucle:ScheduleOfActivityRelatedToWarrants", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c76", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Operations (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Consolidated Statements of Operations (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ucle:NumberOfWarrants", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Shareholders\u2019 Equity (Details) - Schedule of information about options outstanding and exercisable", "menuCat": "Details", "order": "50", "role": "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable", "shortName": "Shareholders\u2019 Equity (Details) - Schedule of information about options outstanding and exercisable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ucle:NumberOfWarrants", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Segment Reporting (Details)", "menuCat": "Details", "order": "51", "role": "http://usnuclearcorp.com/role/SegmentReportingDetails", "shortName": "Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ucle:Revenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Segment Reporting (Details) - Schedule of company\u2019s segment information", "menuCat": "Details", "order": "52", "role": "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable", "shortName": "Segment Reporting (Details) - Schedule of company\u2019s segment information", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ucle:Revenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ucle:GeographicalSalesTotal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Geographical Sales (Details) - Schedule of geographical distribution", "menuCat": "Details", "order": "53", "role": "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable", "shortName": "Geographical Sales (Details) - Schedule of geographical distribution", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ucle:GeographicalSalesTotal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "54", "role": "http://usnuclearcorp.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets", "menuCat": "Details", "order": "55", "role": "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable", "shortName": "Income Taxes (Details) - Schedule of deferred tax assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Income Taxes (Details) - Schedule of consolidated statements of income", "menuCat": "Details", "order": "56", "role": "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable", "shortName": "Income Taxes (Details) - Schedule of consolidated statements of income", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate to the federal statutory rate", "menuCat": "Details", "order": "57", "role": "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable", "shortName": "Income Taxes (Details) - Schedule of effective income tax rate to the federal statutory rate", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Related Party Transactions (Details)", "menuCat": "Details", "order": "58", "role": "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "ucle:ConcentrationRiskPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Concentrations (Details)", "menuCat": "Details", "order": "59", "role": "http://usnuclearcorp.com/role/ConcentrationsDetails", "shortName": "Concentrations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "ucle:ConcentrationRiskPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://usnuclearcorp.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statement of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c128", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "60", "role": "http://usnuclearcorp.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c128", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://usnuclearcorp.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Organization and Basis of Presentation", "menuCat": "Notes", "order": "8", "role": "http://usnuclearcorp.com/role/OrganizationandBasisofPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_usnuclearcorp.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security", "terseLabel": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://usnuclearcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia [Member]", "terseLabel": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r209", "r245", "r263", "r264", "r265", "r266", "r267", "r269", "r273", "r321", "r322", "r323", "r324", "r326", "r327", "r329", "r331", "r332", "r560", "r561" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r209", "r245", "r263", "r264", "r265", "r266", "r267", "r269", "r273", "r321", "r322", "r323", "r324", "r326", "r327", "r329", "r331", "r332", "r560", "r561" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r317", "r318", "r319", "r320", "r375", "r455", "r477", "r497", "r498", "r515", "r517", "r521", "r562", "r606", "r607", "r608", "r609", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails", "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r317", "r318", "r319", "r320", "r375", "r455", "r477", "r497", "r498", "r515", "r517", "r521", "r562", "r606", "r607", "r608", "r609", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails", "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "North America [Member]", "terseLabel": "North America\t[Member]" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r317", "r318", "r319", "r320", "r373", "r375", "r388", "r389", "r390", "r454", "r455", "r477", "r497", "r498", "r515", "r517", "r521", "r559", "r562", "r607", "r608", "r609", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails", "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r317", "r318", "r319", "r320", "r373", "r375", "r388", "r389", "r390", "r454", "r455", "r477", "r497", "r498", "r515", "r517", "r521", "r559", "r562", "r607", "r608", "r609", "r610", "r611" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails", "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r376", "r552" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails", "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r223", "r376", "r531", "r552" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails", "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable", "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable", "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable", "http://usnuclearcorp.com/role/ScheduleofinventoryTable", "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r276", "r277", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r516", "r520", "r564" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "domainItemType" }, "srt_SouthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "South America [Member]", "terseLabel": "South America\t[Member]" } } }, "localname": "SouthAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r276", "r277", "r483", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r516", "r520", "r564" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable", "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r223", "r376", "r531", "r532", "r552" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails", "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable", "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable", "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable", "http://usnuclearcorp.com/role/ScheduleofinventoryTable", "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "ucle_AccumulatedDeficits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "An accumulated deficit is a negative retained earnings balance. This deficit arises when the cumulative amount of losses experienced and dividends paid by a business exceeds the cumulative amount of its profits.", "label": "Accumulated Deficits", "terseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedDeficits", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "ucle_AdditionalLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional loans.", "label": "Additional Loans", "terseLabel": "Additional loans" } } }, "localname": "AdditionalLoans", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails" ], "xbrltype": "monetaryItemType" }, "ucle_AggregateIntrinsicValueGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate Intrinsic Value,Granted.", "label": "Aggregate Intrinsic Value Granted", "terseLabel": "Aggregate Intrinsic Value, Granted" } } }, "localname": "AggregateIntrinsicValueGranted", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "sharesItemType" }, "ucle_Asset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Asset", "terseLabel": "Total Assets" } } }, "localname": "Asset", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "monetaryItemType" }, "ucle_BalanceAmountOwed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Balance amount owed.", "label": "Balance Amount Owed", "terseLabel": "Balance amount owed" } } }, "localname": "BalanceAmountOwed", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ucle_BeneficialConversionFeatureOnDownroundProvision": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Beneficial conversion feature on down-round provision.", "label": "Beneficial Conversion Feature On Downround Provision", "terseLabel": "Beneficial conversion feature on down-round provision" } } }, "localname": "BeneficialConversionFeatureOnDownroundProvision", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ucle_ClassOfWarrantOrRightOutstanding1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Outstanding1", "terseLabel": "Number of Warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding1", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable" ], "xbrltype": "sharesItemType" }, "ucle_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right weighted average remaining contractual life outstanding.", "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Life Outstanding", "terseLabel": "Weighted Average Remaining Contractual Life, at Ending" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOutstanding", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "durationItemType" }, "ucle_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOutstanding3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to class of warrant or right weighted average remaining contractual life outstanding.", "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Life Outstanding3", "terseLabel": "Weighted Average Remaining Contractual Life, at Beginning" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOutstanding3", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "durationItemType" }, "ucle_CommonSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued for services, shares.", "label": "Common Shares Issued", "terseLabel": "Common stock shares (in Shares)" } } }, "localname": "CommonSharesIssued", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "ucle_CommonSharesToBeIssued": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of common shares to be issued.", "label": "Common Shares To Be Issued", "terseLabel": "Common shares to be issued" } } }, "localname": "CommonSharesToBeIssued", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet", "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ucle_CommonSharesToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Shares To Be Issued Member", "terseLabel": "Common Shares to be Issued" } } }, "localname": "CommonSharesToBeIssuedMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ucle_CommonStockIssuedDuringPeriodToBeIssuedForService": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common Stock Issued During Period To Be Issued For Service", "terseLabel": "Common stock to be issued for services (in Shares)" } } }, "localname": "CommonStockIssuedDuringPeriodToBeIssuedForService", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "ucle_CommonStockIssuedDuringPeriodToBeIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common Stock Issued During Period To Be Issued For Services", "terseLabel": "Common stock to be issued for services" } } }, "localname": "CommonStockIssuedDuringPeriodToBeIssuedForServices", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ucle_CommonStockIssuedForDebtAndInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of common stock issued for debt and interest.", "label": "Common Stock Issued For Debt And Interest", "terseLabel": "Common stock issued for conversion of convertible debt and accrued interest" } } }, "localname": "CommonStockIssuedForDebtAndInterest", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ucle_CommonStockIssuedForFutureServices1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of common stock issued for future services.", "label": "Common Stock Issued For Future Services1", "terseLabel": "Common shares issued for future services" } } }, "localname": "CommonStockIssuedForFutureServices1", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ucle_CommonStockValue1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of common stock value.", "label": "Common Stock Value1", "terseLabel": "Common stock value" } } }, "localname": "CommonStockValue1", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ucle_CommonStockValue3": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock value.", "label": "Common Stock Value3", "terseLabel": "Common stock value" } } }, "localname": "CommonStockValue3", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ucle_ConcentrationRiskPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage", "terseLabel": "Concentration percentage" } } }, "localname": "ConcentrationRiskPercentage", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "percentItemType" }, "ucle_ConcentrationsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations (Details) [Line Items]" } } }, "localname": "ConcentrationsDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "ucle_ConcentrationsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations (Details) [Table]" } } }, "localname": "ConcentrationsDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "ucle_ConcentrationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations Line Items", "terseLabel": "Concentrations [Abstract]" } } }, "localname": "ConcentrationsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/Concentrations" ], "xbrltype": "stringItemType" }, "ucle_ConcentrationsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations [Table]" } } }, "localname": "ConcentrationsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/Concentrations" ], "xbrltype": "stringItemType" }, "ucle_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants Member", "terseLabel": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "ucle_ConsultingExpense": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consulting expense.", "label": "Consulting Expense", "terseLabel": "Consulting expense" } } }, "localname": "ConsultingExpense", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ucle_CurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Abstract", "terseLabel": "Current" } } }, "localname": "CurrentAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "stringItemType" }, "ucle_CurrentAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of current assets.", "label": "Current Assets", "terseLabel": "Current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "ucle_CurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of current liabilities.", "label": "Current Liabilities", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "ucle_CustomersOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customers One Member", "terseLabel": "Customers One [Member]" } } }, "localname": "CustomersOneMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "ucle_CustomersTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customers Two Member", "terseLabel": "Customers Two [Member]" } } }, "localname": "CustomersTwoMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "ucle_DeemedDividendOnDownRoundProvision": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deemed dividend on down round provision.", "label": "Deemed Dividend On Down Round Provision", "terseLabel": "Deemed dividend on down round provision" } } }, "localname": "DeemedDividendOnDownRoundProvision", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ucle_DeferredAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Abstract", "terseLabel": "Deferred" } } }, "localname": "DeferredAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "stringItemType" }, "ucle_DeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Abstract", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "ucle_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_EffectiveIncomeTaxBenefitPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax benefit percentage.", "label": "Effective Income Tax Benefit Percentage", "terseLabel": "Tax benefit, percentage" } } }, "localname": "EffectiveIncomeTaxBenefitPercentage", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "ucle_EffectiveIncomeTaxRateAmortizationOfGoodwill": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic amortization of goodwill.", "label": "Effective Income Tax Rate Amortization Of Goodwill", "terseLabel": "Amortization of goodwill" } } }, "localname": "EffectiveIncomeTaxRateAmortizationOfGoodwill", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "ucle_EffectiveIncomeTaxRateNetOperatingLosses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of domesticrate net operating losses.", "label": "Effective Income Tax Rate Net Operating Losses", "terseLabel": "Net operating losses" } } }, "localname": "EffectiveIncomeTaxRateNetOperatingLosses", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "ucle_EquityLossInInvestment": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity loss in investment.", "label": "Equity Loss In Investment", "terseLabel": "Equity loss in investment" } } }, "localname": "EquityLossInInvestment", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ucle_EquityLossInInvestments": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity loss in investments.", "label": "Equity Loss In Investments", "terseLabel": "Equity loss in investment" } } }, "localname": "EquityLossInInvestments", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ucle_EquityMethodInvestmentOwnershipPercentage1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage1", "terseLabel": "Equity method percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage1", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "ucle_EstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of estimated useful lives of property and equipment.", "label": "Estimated Useful Lives Of Property And Equipment Table Text Block", "terseLabel": "Schedule of estimated useful lives of property and equipment" } } }, "localname": "EstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ucle_ExercisePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exercise price.", "label": "Exercise Price", "terseLabel": "Exercise price" } } }, "localname": "ExercisePrice", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ucle_FinancingCost": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing costs.", "label": "Financing Cost", "terseLabel": "Finance costs" } } }, "localname": "FinancingCost", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ucle_FiniteLivedIntangibleAssetsAmortizationExpenseYearSix": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Six", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearSix", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "monetaryItemType" }, "ucle_FirstEarnOutPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "First earn out payment.", "label": "First Earn Out Payment", "terseLabel": "Out payment" } } }, "localname": "FirstEarnOutPayment", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ucle_GeographicalSalesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical Sales Abstract" } } }, "localname": "GeographicalSalesAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_GeographicalSalesAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical Sales Abstract0", "terseLabel": "Geographical sales" } } }, "localname": "GeographicalSalesAbstract0", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "stringItemType" }, "ucle_GeographicalSalesDetailsScheduleofgeographicaldistributionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical Sales (Details) - Schedule of geographical distribution [Line Items]" } } }, "localname": "GeographicalSalesDetailsScheduleofgeographicaldistributionLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "stringItemType" }, "ucle_GeographicalSalesDetailsScheduleofgeographicaldistributionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical Sales (Details) - Schedule of geographical distribution [Table]" } } }, "localname": "GeographicalSalesDetailsScheduleofgeographicaldistributionTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "stringItemType" }, "ucle_GeographicalSalesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical Sales [Abstract]" } } }, "localname": "GeographicalSalesLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/GeographicalSales" ], "xbrltype": "stringItemType" }, "ucle_GeographicalSalesRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Geographical Sales Revenue", "terseLabel": "Geographical sales" } } }, "localname": "GeographicalSalesRevenue", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "monetaryItemType" }, "ucle_GeographicalSalesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical Sales [Table]" } } }, "localname": "GeographicalSalesTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/GeographicalSales" ], "xbrltype": "stringItemType" }, "ucle_GeographicalSalesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical Sales Tables Line Items", "terseLabel": "Geographical Sales [Abstract]" } } }, "localname": "GeographicalSalesTablesLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/GeographicalSalesTables" ], "xbrltype": "stringItemType" }, "ucle_GeographicalSalesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical Sales (Tables) [Table]" } } }, "localname": "GeographicalSalesTablesTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/GeographicalSalesTables" ], "xbrltype": "stringItemType" }, "ucle_GeographicalSalesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Geographical sales", "label": "Geographical Sales Text Block", "terseLabel": "Geographical Sales" } } }, "localname": "GeographicalSalesTextBlock", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/GeographicalSales" ], "xbrltype": "textBlockItemType" }, "ucle_GeographicalSalesTotal": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of geographical sales total.", "label": "Geographical Sales Total", "terseLabel": "Geographical sales total" } } }, "localname": "GeographicalSalesTotal", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "monetaryItemType" }, "ucle_GoldTeamIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gold Team, Inc.", "label": "Gold Team Inc Member", "terseLabel": "Gold Team Inc [Member]" } } }, "localname": "GoldTeamIncMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ucle_GoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill Abstract", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "ucle_GraphetonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grapheton Member", "terseLabel": "Grapheton [Member]", "verboseLabel": "Grapheton, Inc [Member]" } } }, "localname": "GraphetonMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails", "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "domainItemType" }, "ucle_GraphetonsCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number shares of grapheton\u2019s common stock.", "label": "Graphetons Common Stock", "terseLabel": "Grapheton\u2019s common stock (in Shares)" } } }, "localname": "GraphetonsCommonStock", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "sharesItemType" }, "ucle_GrossProfits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profits", "terseLabel": "Gross profit" } } }, "localname": "GrossProfits", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "monetaryItemType" }, "ucle_IncomeLossFromOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Loss From Operations Abstract", "terseLabel": "Income (loss) from operations" } } }, "localname": "IncomeLossFromOperationsAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "ucle_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets [Abstract]" } } }, "localname": "IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "ucle_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of deferred tax assets [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleofdeferredtaxassetsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "ucle_IncomeTaxesDetailsScheduleofeffectiveincometaxratetothefederalstatutoryrateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate to the Federal Statutory Rate [Abstract]" } } }, "localname": "IncomeTaxesDetailsScheduleofeffectiveincometaxratetothefederalstatutoryrateLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable" ], "xbrltype": "stringItemType" }, "ucle_IncomeTaxesDetailsScheduleofeffectiveincometaxratetothefederalstatutoryrateTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of effective income tax rate to the federal statutory rate [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleofeffectiveincometaxratetothefederalstatutoryrateTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable" ], "xbrltype": "stringItemType" }, "ucle_IncomelossFromOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Incomeloss From Operations", "terseLabel": "Loss from operations" } } }, "localname": "IncomelossFromOperations", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "monetaryItemType" }, "ucle_InterestExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expenses Abstract", "terseLabel": "Interest Expenses" } } }, "localname": "InterestExpensesAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "ucle_InterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate.", "label": "Interest Rate", "terseLabel": "Interest rate" } } }, "localname": "InterestRate", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "percentItemType" }, "ucle_InventoriesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } }, "localname": "InventoriesLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/Inventories" ], "xbrltype": "stringItemType" }, "ucle_InventoriesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories [Table]" } } }, "localname": "InventoriesTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/Inventories" ], "xbrltype": "stringItemType" }, "ucle_InventoriesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories Tables Line Items", "terseLabel": "Inventories [Abstract]" } } }, "localname": "InventoriesTablesLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InventoriesTables" ], "xbrltype": "stringItemType" }, "ucle_InventoriesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories (Tables) [Table]" } } }, "localname": "InventoriesTablesTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InventoriesTables" ], "xbrltype": "stringItemType" }, "ucle_InvestmentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment amount.", "label": "Investment Amount", "terseLabel": "Investment amount" } } }, "localname": "InvestmentAmount", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ucle_InvestmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment, description.", "label": "Investment Description", "terseLabel": "Investment, description" } } }, "localname": "InvestmentDescription", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "ucle_InvestmentWarrantExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price of the warrants.", "label": "Investment Warrant Exercise Price", "terseLabel": "Exercise Price (in Dollars per share)" } } }, "localname": "InvestmentWarrantExercisePrice", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable" ], "xbrltype": "perShareItemType" }, "ucle_InvestmentsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments (Details) [Line Items]" } } }, "localname": "InvestmentsDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "ucle_InvestmentsDetailsScheduleofinformationregardinggraphetonLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments (Details) - Schedule of information regarding grapheton [Line Items]" } } }, "localname": "InvestmentsDetailsScheduleofinformationregardinggraphetonLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "stringItemType" }, "ucle_InvestmentsDetailsScheduleofinformationregardinggraphetonTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments (Details) - Schedule of information regarding grapheton [Table]" } } }, "localname": "InvestmentsDetailsScheduleofinformationregardinggraphetonTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "stringItemType" }, "ucle_InvestmentsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments (Details) [Table]" } } }, "localname": "InvestmentsDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "ucle_InvestmentsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments percentage.", "label": "Investments Percentage", "terseLabel": "Investments percentage" } } }, "localname": "InvestmentsPercentage", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "ucle_InvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments.", "label": "Investments Text Block", "terseLabel": "Investments" } } }, "localname": "InvestmentsTextBlock", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "ucle_IssuanceOfCommonStockForLoanIncentive1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuance of common stock for loan incentive.", "label": "Issuance Of Common Stock For Loan Incentive1", "terseLabel": "Issuance of common stock for loan incentive" } } }, "localname": "IssuanceOfCommonStockForLoanIncentive1", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ucle_IssuanceOfCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of common stock shares issued.", "label": "Issuance Of Common Stock Value", "terseLabel": "Common stock issued value" } } }, "localname": "IssuanceOfCommonStockValue", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ucle_IssuanceStockWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance stock warrants.", "label": "Issuance Stock Warrants", "terseLabel": "Issuance stock warrants" } } }, "localname": "IssuanceStockWarrants", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ucle_LeaseOfLesseeDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Lease Of Lessee Disclosure Text Block", "terseLabel": "Leases" } } }, "localname": "LeaseOfLesseeDisclosureTextBlock", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "ucle_LeasesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) [Line Items]" } } }, "localname": "LeasesDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "ucle_LeasesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } }, "localname": "LeasesDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "ucle_LineofCreditDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line of Credit (Details) [Line Items]" } } }, "localname": "LineofCreditDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails" ], "xbrltype": "stringItemType" }, "ucle_LineofCreditDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line of Credit (Details) [Table]" } } }, "localname": "LineofCreditDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails" ], "xbrltype": "stringItemType" }, "ucle_LineofCreditLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line of Credit [Abstract]" } } }, "localname": "LineofCreditLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/LineofCredit" ], "xbrltype": "stringItemType" }, "ucle_LineofCreditTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line of Credit [Table]" } } }, "localname": "LineofCreditTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/LineofCredit" ], "xbrltype": "stringItemType" }, "ucle_LoanAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loan amount.", "label": "Loan Amount", "terseLabel": "Loan amount" } } }, "localname": "LoanAmount", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ucle_MIFTECMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MIFTECMember", "terseLabel": "MIFTEC [Member]" } } }, "localname": "MIFTECMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "ucle_MIFTIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MIFTIMember", "terseLabel": "MIFTI [Member]" } } }, "localname": "MIFTIMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "ucle_MayFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "May Five Member", "terseLabel": "May 5, 2022 [Member]" } } }, "localname": "MayFiveMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "domainItemType" }, "ucle_MrGoldsteinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr Goldstein Member", "terseLabel": "Mr. Goldstein [Member]" } } }, "localname": "MrGoldsteinMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails" ], "xbrltype": "domainItemType" }, "ucle_NetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net loss.", "label": "Net Loss", "terseLabel": "Net loss" } } }, "localname": "NetLoss", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "monetaryItemType" }, "ucle_NotePayableToShareholderAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable To Shareholder Abstract" } } }, "localname": "NotePayableToShareholderAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_NotePayableToShareholderTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for note payable to shareholder.", "label": "Note Payable To Shareholder Text Block", "terseLabel": "Note Payable to Shareholder" } } }, "localname": "NotePayableToShareholderTextBlock", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholder" ], "xbrltype": "textBlockItemType" }, "ucle_NotePayabletoShareholderDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable to Shareholder (Details) [Line Items]" } } }, "localname": "NotePayabletoShareholderDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails" ], "xbrltype": "stringItemType" }, "ucle_NotePayabletoShareholderDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable to Shareholder (Details) [Table]" } } }, "localname": "NotePayabletoShareholderDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails" ], "xbrltype": "stringItemType" }, "ucle_NotePayabletoShareholderLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable to Shareholder [Abstract]" } } }, "localname": "NotePayabletoShareholderLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholder" ], "xbrltype": "stringItemType" }, "ucle_NotePayabletoShareholderTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable to Shareholder [Table]" } } }, "localname": "NotePayabletoShareholderTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholder" ], "xbrltype": "stringItemType" }, "ucle_NotesPayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable (Details) [Line Items]" } } }, "localname": "NotesPayableDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "stringItemType" }, "ucle_NotesPayableDetailsScheduleoffuturematuritiesofnotespayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of future maturities of notes payable [Abstract]" } } }, "localname": "NotesPayableDetailsScheduleoffuturematuritiesofnotespayableLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "stringItemType" }, "ucle_NotesPayableDetailsScheduleoffuturematuritiesofnotespayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable (Details) - Schedule of future maturities of notes payable [Table]" } } }, "localname": "NotesPayableDetailsScheduleoffuturematuritiesofnotespayableTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "stringItemType" }, "ucle_NotesPayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable (Details) [Table]" } } }, "localname": "NotesPayableDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "stringItemType" }, "ucle_NotesPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable [Abstract]" } } }, "localname": "NotesPayableLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayable" ], "xbrltype": "stringItemType" }, "ucle_NotesPayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable [Table]" } } }, "localname": "NotesPayableTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayable" ], "xbrltype": "stringItemType" }, "ucle_NotesPayableTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable Tables Line Items", "terseLabel": "Notes Payable [Abstract]" } } }, "localname": "NotesPayableTablesLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableTables" ], "xbrltype": "stringItemType" }, "ucle_NotesPayableTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable (Tables) [Table]" } } }, "localname": "NotesPayableTablesTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableTables" ], "xbrltype": "stringItemType" }, "ucle_NumberOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants.", "label": "Number Of Warrants", "terseLabel": "Number of Warrants" } } }, "localname": "NumberOfWarrants", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable" ], "xbrltype": "sharesItemType" }, "ucle_OctoberTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October Ten Member", "terseLabel": "October 10, 2022 [Member]" } } }, "localname": "OctoberTenMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "domainItemType" }, "ucle_OptronMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Optron", "label": "Optron Member", "terseLabel": "Optron [Member]" } } }, "localname": "OptronMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "domainItemType" }, "ucle_OriginalIssueDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Original issue debt discount.", "label": "Original Issue Debt Discount", "terseLabel": "Original issue debt discount" } } }, "localname": "OriginalIssueDebtDiscount", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ucle_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Member", "label": "Other Member", "terseLabel": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofgeographicaldistributionTable" ], "xbrltype": "domainItemType" }, "ucle_OverhoffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Overhoff", "label": "Overhoff Member", "terseLabel": "Overhoff [Member]", "verboseLabel": "Overhoff\t[Member]" } } }, "localname": "OverhoffMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "domainItemType" }, "ucle_OwnershipInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership Interest Member", "terseLabel": "Ownership Interest [Member]" } } }, "localname": "OwnershipInterestMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "ucle_OwnershipInterestPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership interest percentage.", "label": "Ownership Interest Percentage", "terseLabel": "Ownership interest in MIFTEC" } } }, "localname": "OwnershipInterestPercentage", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "percentItemType" }, "ucle_OwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership, percentage.", "label": "Ownership Percentage", "terseLabel": "Ownership, percentage" } } }, "localname": "OwnershipPercentage", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "percentItemType" }, "ucle_PayrollAndRelatedExpense": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of payroll and related expense.", "label": "Payroll And Related Expense", "terseLabel": "Payroll and related expense" } } }, "localname": "PayrollAndRelatedExpense", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ucle_PercentageOfOwnershipInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership interest.", "label": "Percentage Of Ownership Interest", "terseLabel": "Ownership interest" } } }, "localname": "PercentageOfOwnershipInterest", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "percentItemType" }, "ucle_PropertyandEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "localname": "PropertyandEquipmentLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/PropertyandEquipment" ], "xbrltype": "stringItemType" }, "ucle_PropertyandEquipmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment [Table]" } } }, "localname": "PropertyandEquipmentTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/PropertyandEquipment" ], "xbrltype": "stringItemType" }, "ucle_PropertyandEquipmentTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Propertyand Equipment Tables Line Items", "terseLabel": "Property and Equipment [Abstract]" } } }, "localname": "PropertyandEquipmentTablesLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/PropertyandEquipmentTables" ], "xbrltype": "stringItemType" }, "ucle_PropertyandEquipmentTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment (Tables) [Table]" } } }, "localname": "PropertyandEquipmentTablesTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/PropertyandEquipmentTables" ], "xbrltype": "stringItemType" }, "ucle_RelatedPartiesPoliciesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related parties.", "label": "Related Parties Policies Text Block", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesPoliciesTextBlock", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ucle_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "ucle_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "ucle_Revenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue", "terseLabel": "Sales" } } }, "localname": "Revenue", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "monetaryItemType" }, "ucle_RichardLandryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Richard Landry Member", "terseLabel": "Richard Landry [Member]" } } }, "localname": "RichardLandryMember", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ucle_SalesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales Abstract", "terseLabel": "Sales" } } }, "localname": "SalesAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "ucle_SalesReturnsAndAllowances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales returns and allowances.", "label": "Sales Returns And Allowances", "terseLabel": "Sales returns and allowances" } } }, "localname": "SalesReturnsAndAllowances", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ucle_ScheduleOfActivityRelatedToWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of activity related to warrants.", "label": "Schedule Of Activity Related To Warrants", "terseLabel": "Schedule of activity related to warrants" } } }, "localname": "ScheduleOfActivityRelatedToWarrants", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "ucle_ScheduleOfActivityRelatedToWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Activity Related To Warrants Abstract" } } }, "localname": "ScheduleOfActivityRelatedToWarrantsAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfCompanySSegmentInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Company SSegment Information Abstract" } } }, "localname": "ScheduleOfCompanySSegmentInformationAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfConsolidatedStatementsOfIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Consolidated Statements Of Income Abstract" } } }, "localname": "ScheduleOfConsolidatedStatementsOfIncomeAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Deferred Tax Assets Abstract" } } }, "localname": "ScheduleOfDeferredTaxAssetsAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfEffectiveIncomeTaxRateToTheFederalStatutoryRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Effective Income Tax Rate To The Federal Statutory Rate Abstract" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateToTheFederalStatutoryRateAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Estimated Useful Lives Of Property And Equipment Abstract" } } }, "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfFutureMaturitiesOfNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Future Maturities Of Notes Payable Abstract" } } }, "localname": "ScheduleOfFutureMaturitiesOfNotesPayableAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfGeographicalDistributionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Geographical Distribution Abstract" } } }, "localname": "ScheduleOfGeographicalDistributionAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfInformationAboutOptionsOutstandingAndExercisableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Information About Options Outstanding And Exercisable Abstract" } } }, "localname": "ScheduleOfInformationAboutOptionsOutstandingAndExercisableAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfInformationRegardingGraphetonAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Information Regarding Grapheton Abstract" } } }, "localname": "ScheduleOfInformationRegardingGraphetonAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfInventoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Inventory Abstract" } } }, "localname": "ScheduleOfInventoryAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ScheduleOfPropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Abstract" } } }, "localname": "ScheduleOfPropertyAndEquipmentAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "xbrltype": "stringItemType" }, "ucle_ShareBasedCompensationArrangementByGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by grant date fair value.", "label": "Share Based Compensation Arrangement By Grant Date Fair Value", "terseLabel": "Fair value on the date of grant (in Dollars)" } } }, "localname": "ShareBasedCompensationArrangementByGrantDateFairValue", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ucle_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable", "terseLabel": "Warrants Outstanding, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "sharesItemType" }, "ucle_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Exercise Price, Exercisable (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "perShareItemType" }, "ucle_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable", "terseLabel": "Aggregate Intrinsic Value, Exercisable (in Dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "monetaryItemType" }, "ucle_ShareholdersEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity (Details) [Line Items]" } } }, "localname": "ShareholdersEquityDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "ucle_ShareholdersEquityDetailsScheduleofactivityrelatedtowarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity (Details) - Schedule of activity related to warrants [Line Items]" } } }, "localname": "ShareholdersEquityDetailsScheduleofactivityrelatedtowarrantsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "stringItemType" }, "ucle_ShareholdersEquityDetailsScheduleofactivityrelatedtowarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity (Details) - Schedule of activity related to warrants [Table]" } } }, "localname": "ShareholdersEquityDetailsScheduleofactivityrelatedtowarrantsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "stringItemType" }, "ucle_ShareholdersEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity (Details) [Table]" } } }, "localname": "ShareholdersEquityDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "ucle_StockIssuedDuringPeriodValueIssuedForServices1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period Value Issued For Services1", "terseLabel": "Shares of common stock" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices1", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ucle_StockIssuedDuringValueConvertibleNoteNetOfDebtDiscounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock issued during value convertible note net of debt discounts.", "label": "Stock Issued During Value Convertible Note Net Of Debt Discounts", "terseLabel": "Debt discount on issuance of convertible debt" } } }, "localname": "StockIssuedDuringValueConvertibleNoteNetOfDebtDiscounts", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ucle_StockIssuedDuringValueIssuanceOfCommonStockForInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuance of common stock for investment.", "label": "Stock Issued During Value Issuance Of Common Stock For Investment", "terseLabel": "Issuance of common stock for investment" } } }, "localname": "StockIssuedDuringValueIssuanceOfCommonStockForInvestment", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ucle_StockIssuedPeriodOfSharesIssuanceOfCommonStockForInvestment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares Issuance of common stock for investment.", "label": "Stock Issued Period Of Shares Issuance Of Common Stock For Investment", "terseLabel": "Issuance of common stock for investment (in Shares)" } } }, "localname": "StockIssuedPeriodOfSharesIssuanceOfCommonStockForInvestment", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "ucle_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "ucle_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "ucle_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesofpropertyandequipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesofpropertyandequipmentLineItems", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "ucle_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesofpropertyandequipmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives of property and equipment [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesofpropertyandequipmentTable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "ucle_TotalAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Assets", "terseLabel": "Total assets" } } }, "localname": "TotalAssets", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "ucle_TotalAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Assets Abstract", "terseLabel": "Total Assets" } } }, "localname": "TotalAssetsAbstract", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "ucle_TotalLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total Liabilities", "terseLabel": "Total liabilities" } } }, "localname": "TotalLiabilities", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "ucle_TotalStockholdersDeficiency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of stockholders\u2019 deficiency.", "label": "Total Stockholders Deficiency", "terseLabel": "Total stockholders\u2019 equity" } } }, "localname": "TotalStockholdersDeficiency", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "ucle_WeightedAverageExercisePriceGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price granted.", "label": "Weighted Average Exercise Price Granted", "terseLabel": "Weighted Average Exercise Price ,Granted (in Dollars per share)" } } }, "localname": "WeightedAverageExercisePriceGranted", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "perShareItemType" }, "ucle_WeightedAverageRemainingContractualLifeExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Contractual Life, Exercisable.", "label": "Weighted Average Remaining Contractual Life Exercisable", "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable" } } }, "localname": "WeightedAverageRemainingContractualLifeExercisable", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "durationItemType" }, "ucle_WeightedAverageRemainingContractualLifeGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual life granted.", "label": "Weighted Average Remaining Contractual Life Granted", "terseLabel": "Weighted Average Remaining Contractual Life, Granted" } } }, "localname": "WeightedAverageRemainingContractualLifeGranted", "nsuri": "http://usnuclearcorp.com/20221231", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "durationItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r519" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable, Other, Current", "terseLabel": "Payable to related party" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r15", "r130", "r131", "r548" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Accounts payable - related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r129", "r138", "r156", "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties", "terseLabel": "Accounts payable- related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r281", "r282" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued compensation payable" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r20", "r502" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued compensation - officers" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r82", "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.", "label": "Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment", "terseLabel": "Depreciated property and equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r7", "r519" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r392", "r393", "r394", "r549", "r550", "r551", "r599" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Additional debt discount" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r88", "r95", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Deemed dividend for down round provision in warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r182", "r285", "r291", "r292", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r33", "r47", "r124", "r352" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discounts" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r352", "r438", "r513", "r514", "r544" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "negatedLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r132", "r146", "r180", "r204", "r253", "r265", "r271", "r289", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r421", "r423", "r429", "r519", "r560", "r561", "r604" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r174", "r186", "r204", "r289", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r421", "r423", "r429", "r519", "r560", "r561", "r604" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "CASH" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r42", "r49", "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r42", "r123" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r534" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding (in Shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r24", "r139", "r151" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS & CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockDiscountOnShares": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.", "label": "Common Stock, Discount on Shares", "terseLabel": "Value of shares issued (in Dollars)" } } }, "localname": "CommonStockDiscountOnShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Issued shares of common stock per share (in Dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common Stock Dividends, Shares", "terseLabel": "Shares issued" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r549", "r550", "r599" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails", "http://usnuclearcorp.com/role/ShareholdersEquityDetails", "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, shares issued (in Shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r95" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r519" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized, 31,621,242 and 28,353,215 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computers and software [Member]", "verboseLabel": "Computers and software\t[Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable", "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r59", "r60", "r120", "r121", "r279", "r484", "r613" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r143", "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentrations" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/Concentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r59", "r60", "r120", "r121", "r279", "r484" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r110", "r503" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r52", "r53", "r54" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Issuance of common stock for conversion of debt and accrued interest (in Shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r3" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Convertible notes payable, net of debt discount" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r87", "r334", "r335", "r343", "r344", "r345", "r348", "r349", "r350", "r351", "r352", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Notes [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible notes" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateMember": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.", "label": "Corporate Segment [Member]", "terseLabel": "Corporate [Member]" } } }, "localname": "CorporateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r29", "r204", "r289", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r429", "r560" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r595" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal, State and Local, Tax Expense (Benefit)", "totalLabel": "Total" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r547", "r595", "r597" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable": { "order": 1.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r547", "r595", "r597" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable": { "order": 2.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerDepositsCurrent": { "auth_ref": [ "r165" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings.", "label": "Customer Deposits, Current", "terseLabel": "Customer deposit" } } }, "localname": "CustomerDepositsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r52", "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Issuance of common stock for conversion of debt and accrued interest" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r52", "r54" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares exchange" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r93", "r202", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r346", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r22", "r125", "r349" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r23", "r142" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Principal and interest payments" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "terseLabel": "Debt discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r547", "r596", "r597" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable": { "order": 1.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r591" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal, State and Local, Tax Expense (Benefit)", "totalLabel": "Total" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r126", "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Total debt discounts" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r547", "r596", "r597" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable": { "order": 2.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r404" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r593" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Total" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r106", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Approximate net operating loss carry forwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r106", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Federal net operating loss" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r106", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State net operating loss" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r105", "r106", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": { "auth_ref": [ "r105", "r106", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r405" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositContractsPolicy": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the treatment of funds received from or paid to insureds, insurers and reinsurers on contracts for which the criteria for transferring or assuming insurance risk has not been satisfied by the insurer or reinsurer.", "label": "Deposit Contracts, Policy [Policy Text Block]", "terseLabel": "Customer Deposits" } } }, "localname": "DepositContractsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r536" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Acquisition deposit" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r47", "r80" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationExpenseOnReclassifiedAssets": { "auth_ref": [ "r78", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).", "label": "Depreciation Expense on Reclassified Assets", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationExpenseOnReclassifiedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Interest rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r114", "r115", "r116", "r117", "r119", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r0" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "terseLabel": "Operating expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Issuance of per share (in Dollars per share)" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r136", "r157", "r181", "r323", "r324", "r325", "r331", "r332", "r333", "r448", "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Amounts due" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r195", "r215", "r216", "r217", "r218", "r219", "r224", "r227", "r230", "r231", "r232", "r233", "r427", "r428", "r472", "r475", "r505" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Loss per share \u2013 basic (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r195", "r215", "r216", "r217", "r218", "r219", "r227", "r230", "r231", "r232", "r233", "r427", "r428", "r472", "r475", "r505" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Loss per share - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r206", "r400", "r414" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "auth_ref": [ "r592", "r598" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r592", "r598" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r592", "r598" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State tax, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofeffectiveincometaxratetothefederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable", "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r95", "r171", "r190", "r191", "r192", "r210", "r211", "r212", "r214", "r220", "r222", "r235", "r290", "r372", "r392", "r393", "r394", "r409", "r410", "r426", "r430", "r431", "r432", "r433", "r434", "r435", "r444", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails", "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable", "http://usnuclearcorp.com/role/ShareholdersEquityDetails", "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.", "label": "Equity Method Investment, Other than Temporary Impairment", "terseLabel": "Investment for impairment" } } }, "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.", "label": "Equity Method Investment, Underlying Equity in Net Assets", "terseLabel": "Equity investment amount" } } }, "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r41", "r71", "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares issued (in Shares)", "verboseLabel": "Shares of common stock (in Shares)" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails", "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r47", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Stock warrants amount" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r75" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r75" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r75" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r74", "r458" ], "calculation": { "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleoffuturematuritiesofnotespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable", "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r47", "r90", "r91" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Gain on forgiveness of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnRestructuringOfDebt": { "auth_ref": [ "r92" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.", "label": "Gains (Losses) on Restructuring of Debt", "negatedLabel": "Forgiveness of PPP Loan" } } }, "localname": "GainsLossesOnRestructuringOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r179", "r300", "r471", "r509", "r519", "r557", "r558" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet", "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r310", "r311", "r509" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r301", "r308", "r509" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "negatedLabel": "Goodwill" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r28", "r204", "r253", "r264", "r270", "r273", "r289", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r429", "r507", "r560" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross Profit [Abstract]", "terseLabel": "Gross profit" } } }, "localname": "GrossProfitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r287" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Write-down of investments" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r76", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r205", "r413" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r312", "r314" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r206", "r401", "r402", "r407", "r411", "r415", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r207", "r221", "r222", "r251", "r399", "r412", "r416", "r476" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement", "http://usnuclearcorp.com/role/ScheduleofconsolidatedstatementsofincomeTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r189", "r397", "r398", "r402", "r403", "r406", "r408" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r43", "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r46" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "terseLabel": "Accounts payable - related parties" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r46" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r46" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r46" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerDeposits": { "auth_ref": [ "r166" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.", "label": "Increase (Decrease) in Customer Deposits", "terseLabel": "Customer deposits" } } }, "localname": "IncreaseDecreaseInCustomerDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r46" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Accrued compensation - officers" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r46" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r543", "r602" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r543" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r126", "r141", "r193", "r247", "r437" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest Expenses" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement", "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r197", "r199", "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r138", "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "terseLabel": "Interest in MIFTEC" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r541" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "terseLabel": "Total inventories" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "terseLabel": "Inventory reserve" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of inventories [Abstract]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r184", "r499", "r519" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r176", "r183", "r234", "r295", "r296", "r297", "r456", "r504" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r539" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in Progress" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInvestmentExpense": { "auth_ref": [ "r34", "r159" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the generation of investment income.", "label": "Investment Income, Investment Expense", "terseLabel": "Carrying value of investment" } } }, "localname": "InvestmentIncomeInvestmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r153" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r47" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Issuance of common stock for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r443", "r518" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvement [Member]", "verboseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable", "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r204", "r289", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r422", "r423", "r424", "r429", "r506", "r560", "r604", "r605" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r135", "r149", "r519", "r546", "r555", "r600" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r175", "r204", "r289", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r422", "r423", "r424", "r429", "r519", "r560", "r604", "r605" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r4", "r134", "r145" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Abstract]" } } }, "localname": "LineOfCreditFacilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": { "auth_ref": [ "r545" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period.", "label": "Line of Credit Facility, Increase, Accrued Interest", "terseLabel": "Accrues interest rate" } } }, "localname": "LineOfCreditFacilityIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Interest rate on line of credit" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit maximum borrowing amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCreditDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r3", "r133" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "terseLabel": "Line of credit" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoanProcessingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees.", "label": "Loan Processing Fee", "terseLabel": "Majority shareholder loaned an additional" } } }, "localname": "LoanProcessingFee", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r4", "r134", "r144" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable", "terseLabel": "Total of additional loans" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r23" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Note payable, net of current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r198" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r198" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r42", "r45", "r48" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r27", "r48", "r140", "r158", "r173", "r187", "r188", "r192", "r204", "r213", "r215", "r216", "r217", "r218", "r221", "r222", "r228", "r253", "r264", "r270", "r273", "r289", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r428", "r429", "r507", "r560" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow", "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement", "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAllocatedToGeneralPartners": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of net income allocated to general partners.", "label": "Net Income (Loss) Allocated to General Partners", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLossAllocatedToGeneralPartners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/OrganizationandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r215", "r216", "r217", "r218", "r224", "r225", "r229", "r232", "r253", "r264", "r270", "r273", "r507" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss", "totalLabel": "Net loss attributed to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement", "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r32" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r4", "r134", "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Outstanding notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SegmentReportingDetails", "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r542" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold", "terseLabel": "Officer compensation" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r253", "r264", "r270", "r273", "r507" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r601" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r439", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating leases payment" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r442", "r518" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r441", "r518" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease terms" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r273" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/OrganizationandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r31", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "negatedLabel": "Other expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r160" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r152", "r535" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Investment" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r20", "r519" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Note payable to shareholder" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-Cash investing and financing activities" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Rent expense" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r35", "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Acquisition of manufacturing and supply right" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r35" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Payment of acquisition deposit" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r37" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Cash paid for investment" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r36" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r356" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r356" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r519" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value, 5,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r185", "r298", "r299", "r500" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r137", "r154", "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid Expense", "terseLabel": "Prepaid expense" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidRoyalties": { "auth_ref": [ "r501", "r508", "r556" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Royalties", "terseLabel": "Repaid amount" } } }, "localname": "PrepaidRoyalties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r39" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible notes payable" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r38" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r39" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r39" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from note payable to shareholder" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net borrowings (repayments) under lines of credit" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r163", "r164" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable", "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r85", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofestimatedusefullivesofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r81", "r177" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r83", "r150", "r474", "r519" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentOtherNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r83", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r196", "r293" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyCosts": { "auth_ref": [ "r29", "r323", "r324", "r325", "r331", "r332", "r333", "r548" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.", "label": "Related Party Costs", "terseLabel": "Expenses paid directly by majority shareholder" } } }, "localname": "RelatedPartyCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r374", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails", "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails", "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r170", "r447", "r448", "r603" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails", "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails", "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r374", "r447", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r603" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotePayabletoShareholderDetails", "http://usnuclearcorp.com/role/RelatedPartyTransactionsDetails", "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r445", "r446", "r448", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r40" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayments for notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r40" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayments for note payable to shareholder" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r97", "r148", "r481", "r482", "r519" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r171", "r210", "r211", "r212", "r214", "r220", "r222", "r290", "r392", "r393", "r394", "r409", "r410", "r426", "r478", "r480" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of geographical distribution" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/GeographicalSalesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAllowances": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition for sales allowances.", "label": "Revenue Recognition, Allowances [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionAllowances", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r194", "r204", "r244", "r245", "r263", "r268", "r269", "r275", "r276", "r279", "r289", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r429", "r473", "r560" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Sales", "verboseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement", "http://usnuclearcorp.com/role/ScheduleofinformationregardinggraphetonTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r109", "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of Stock, Description of Transaction", "terseLabel": "Issued shares of common stock description" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales [Member]" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of consolidated statements of income" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective income tax rate to the federal statutory rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r2", "r12", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "terseLabel": "Line of Credit" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/LineofCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of future maturities of notes payable" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of information regarding grapheton" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r65", "r66", "r67", "r73" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r65", "r66", "r67", "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of company\u2019s segment information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Schedule of information about options outstanding and exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r241", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r279", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r315", "r316", "r509", "r612" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r241", "r242", "r243", "r253", "r256", "r267", "r271", "r272", "r273", "r274", "r275", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r257", "r258", "r259", "r260", "r261", "r262", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Exercise Price, at Ending (in Dollars per share)", "periodStartLabel": "Weighted Average Exercise Price, at Beginning (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Warrants Outstanding, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Warrants Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Warrants Outstanding, at Ending", "periodStartLabel": "Warrants Outstanding, at Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r377", "r385", "r386", "r387", "r388", "r391", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Aggregate Intrinsic Value, at Ending (in Dollars)", "periodStartLabel": "Aggregate Intrinsic Value, at Beginning (in Dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Fair value date of grant (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Shares of common stock (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r56", "r201" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r172", "r241", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r279", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r313", "r315", "r316", "r509", "r612" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofcompanyssegmentinformationTable" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r26", "r95", "r171", "r190", "r191", "r192", "r210", "r211", "r212", "r214", "r220", "r222", "r235", "r290", "r372", "r392", "r393", "r394", "r409", "r410", "r426", "r430", "r431", "r432", "r433", "r434", "r435", "r444", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails", "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable", "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable", "http://usnuclearcorp.com/role/ShareholdersEquityDetails", "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r210", "r211", "r212", "r235", "r457" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r25", "r95", "r96", "r97", "r347" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock for loan incentive (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of common stock for services (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r95", "r97" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock for conversion of convertible debenture and accrued interest (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Exchange for common stock, shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r95", "r97", "r381" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Warrants Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "auth_ref": [ "r5", "r6", "r95", "r97" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of a stock split.", "label": "Stock Issued During Period, Shares, Stock Splits", "terseLabel": "Shares of common stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of common stock for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r6", "r95", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock for conversion of convertible debenture and accrued interest" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Common stock value" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "auth_ref": [ "r26", "r95", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued to shareholders as a dividend during the period.", "label": "Stock Issued During Period, Value, Stock Dividend", "terseLabel": "Issued debt" } } }, "localname": "StockIssuedDuringPeriodValueStockDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r69", "r519", "r546", "r555", "r600" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedBalanceSheet", "http://usnuclearcorp.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r100", "r203", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r372", "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r436", "r452" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r436", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r436", "r452" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r451", "r453" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r167", "r168", "r169", "r283", "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r61", "r62", "r63", "r236", "r237", "r239", "r240" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": { "auth_ref": [ "r369", "r371" ], "calculation": { "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.", "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount", "terseLabel": "Deemed dividend for down-round provision in warrants" } } }, "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantExercisePriceDecrease": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Warrant, Exercise Price, Decrease", "terseLabel": "Warrant exercise price (in Dollars per share)" } } }, "localname": "WarrantExercisePriceDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_WarrantExercisePriceIncrease": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Warrant, Exercise Price, Increase", "terseLabel": "Warrant exercise price (in Dollars per share)" } } }, "localname": "WarrantExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ScheduleofactivityrelatedtowarrantsTable", "http://usnuclearcorp.com/role/ScheduleofinformationaboutoptionsoutstandingandexercisableTable" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r226", "r232" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r224", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding - basic (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://usnuclearcorp.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6487483&loc=d3e32239-158577", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL109261905-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(5)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r523": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r524": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r525": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r526": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r527": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r528": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r529": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=126903467&loc=d3e32787-111569", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2459-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-07)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 85 0001213900-23-038626-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-038626-xbrl.zip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